



(19) Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) EP 1 574 520 A2

(12)

## EUROPEAN PATENT APPLICATION

(43) Date of publication:  
14.09.2005 Bulletin 2005/37

(51) Int Cl.7: C07K 14/47, C12N 15/12

(21) Application number: 05005504.5

(22) Date of filing: 02.02.2001

(84) Designated Contracting States:  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE TR

(30) Priority: 03.02.2000 US 496914  
27.04.2000 US 560875  
22.11.2000 US 721115

(62) Document number(s) of the earlier application(s) in  
accordance with Art. 76 EPC:  
01908837.6 / 1 254 269

(71) Applicant: Nuvolo, Inc.  
Sunnyvale, CA 94085 (US)

(72) Inventors:  
• Boyle, Bryan, J.  
San Francisco CA 94116 (US)  
• Yeung, George  
Mountain View CA 94043 (US)  
• Arterburn, Matthew, C.  
Pleasanton CA 94566 (US)

- Lui, Chenghua  
San Jose CA 95117 (US)
- Tang, Y., Tom  
San Jose CA 95118 (US)
- Godbole, Shubhada, D.  
Santa Clara CA 95051 (US)
- Kuo, Chiaoyun  
San Jose CA 95132 (US)
- Drmanac, Radoje, T.  
Palo Alto CA 94303 (US)
- Palencia, Sereando  
Santa Cruz CA 95060 (US)

(74) Representative: Forstmeyer, Dietmar et al  
Boeters & Lieck,  
Bereiteranger 15  
81541 München (DE)

### Remarks:

This application was filed on 14 - 03 - 2005 as a  
divisional application to the application mentioned  
under INID code 62.

### (54) Methods and materials relating to neuronal guidance molecule-like (NGM-like) polypeptides and polynucleotides

(57) The invention provides novel polynucleotides  
and polypeptides encoded by such polynucleotides and  
mutants or variants thereof that correspond to novel hu-  
man secreted NGM-like polypeptides. These polynucle-  
otides comprise nucleic acid sequences isolated from  
at least cDNA libraries prepared from adult spleen mR-  
NA (GIBCO) (Hyseq clone identification numbers

3073928 (SEQ ID NO: 1), and from infant brain mRNA  
(Columbia University) (Hyseq clone identification  
number 6346549) (SEQ ID NO: 18). Other aspects of  
the invention include vectors containing processes for  
producing novel human secreted NGM-like polypep-  
tides, and antibodies specific for such polypeptides.

**Description****1 TECHNICAL FIELD**

5 [0001] The present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with uses for these polynucleotides and proteins, for example in therapeutic, diagnostic and research methods. In particular, the invention relates to a novel neuronal guidance molecule-like (NGM-like) polypeptide.

**2 BACKGROUND ART**

10 [0002] Identified polynucleotide and polypeptide sequences have numerous applications in, for example, diagnostics, forensics, gene mapping; identification of mutations responsible for genetic disorders or other traits, to assess biodiversity, and to produce many other types of data and products dependent on DNA and amino acid sequences. Proteins are known to have biological activity, for example, by virtue of their secreted nature in the case of leader sequence cloning, by virtue of their cell or tissue source in the case of PCR-based techniques, or by virtue of structural similarity to other genes of known biological activity. It is to these polypeptides and the polynucleotides encoding them that the present invention is directed. In particular, this invention is directed to novel NGM-like polypeptides and polynucleotides.

15 [0003] In both vertebrate and invertebrate organisms, the ventral midline of the nervous system acts as an important intermediate target for axonal guidance (Brose et al, (1999) Cell 96, 795-806). The growth cones sense many specific 20 temporal and positional cues present in the midline and are attracted to it. Once there, different populations of axons take different routes, with some turning ipsilaterally while others, called commissural, cross the midline to deliver information to the other side. These divergent trajectories are governed by short-range guidance cues, both attractive and repulsive, that are expressed by midline cells and cells flanking the midline (Zou et al, (2000) Cell 102, 363-375). An interesting and puzzling aspect of commissural axons is that once they cross the midline they never cross back, 25 although some of them may grow for a considerable distance along the midline. What appears surprising is that these axons find the midline to be a favorable environment the first time around but not after they have crossed it.

30 [0004] This behavior is explained, in part, by spatial and temporal expression of Robo and Robo-like receptors and their ligands. Commissural axons express very low amounts of Robo receptors prior to crossing the midline. Upon crossing the midline, receptor(s) expression is upregulated and Slits, Semaphorins, neuronal leucine-rich repeat proteins (NLRRs), and other similar guidance proteins present in the midline region are able to interact with them. These 35 interactions now provide novel guidance cues to the migrating axons. Slits and Semaphorins when present in the midline, have been shown to provide repelling signals that stop the axons from recrossing the midline. Other cues are thought to provide positive guidance cues that would redirect the axons on the right path. Interestingly, both Slits and Semaphorins have been shown to be repellent for certain axons while they appear to be stimulants and chemoattractants for others.

40 [0005] Slits, and NLRRs belong to the leucine-rich repeat (LRR) family of proteins. Leucine-rich repeats are short 20-30 amino acid sequence motifs present in over 100 proteins and are involved in protein-protein interactions. LRR proteins are found in all the organisms from bacteria to plants to vertebrates and are involved in protein recognition across a wide range of functions including signal transduction, neuronal guidance, cell adhesion, development, recombination and transcription, and immune response. Slit proteins contain tandem arrays of leucine-rich repeats, a long 45 stretch of epidermal growth factor (EGF) repeats, an Agrin-Laminin-Perecan-Slit (ALPS) conserved spacer motif, and a cysteine knot dimerization motif. Slit proteins lack any transmembrane domains and are thought to be extracellular secreted proteins. However, recent studies have shown that the Slit protein does remain attached to the cell membrane and is eventually cleaved. NLRR proteins are homologous to Slit proteins and are implicated in neuronal cell adhesion and guidance (Taguchi et al, (1996) Molec. Brain Res. 35, 31-40), while Semaphorins contain a specific Sema domain that mediates protein-protein interactions.

45 [0006] Thus, neuronal guidance molecules (NGMs) and their receptors are crucial for the normal development and regulation of the nervous system. These are the molecular cues that guide the axons. The polypeptides and polynucleotides of the present invention could be useful in modulating neuronal growth and neuronal regenerative capacity, 50 treating neurodegenerative diseases like Alzheimer's and Parkinson's diseases, and diagnosing and mapping of genetic neuronal defects.

**3. SUMMARY OF THE INVENTION**

55 [0007] This invention is based on the discovery of novel NGM-like polypeptides, novel isolated polynucleotides encoding such polypeptides, including recombinant DNA molecules, cloned genes or degenerate variants thereof, especially naturally occurring variants such as allelic variants, antisense polynucleotide molecules, and antibodies that specifically recognize one or more epitopes present on such polypeptides, as well as hybridomas producing such

antibodies. Specifically, the polynucleotides of the present invention are based on NGM-like polynucleotides isolated from cDNA libraries prepared from adult spleen mRNA (GIBCO) (Hyseq clone identification numbers 3073928 (SEQ ID NO: 1), and from infant brain mRNA (Columbia University) (Hyseq clone identification number 6346549) (SEQ ID NO: 18).

5 [0008] The compositions of the present invention additionally include vectors such as expression vectors containing the polynucleotides of the invention, cells genetically engineered to contain such polynucleotides and cells genetically engineered to express such polynucleotides.

[0009] The compositions of the invention provide isolated polynucleotides that include, but are not limited to, a polynucleotide comprising the nucleotide sequence set forth in SEQ ID NO: 1-2, 4, 18-20, 22, or 31; or a fragment of SEQ ID NO: 1-2, 4, 18-20, 22, or 31; a polynucleotide comprising the full length protein coding sequence of SEQ ID NO: 1-2, 4, 18-20, 22, or 31 (for example, SEQ ID NO: 3 and 21); and a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of any of SEQ ID NO: 1-2, 4, 18-20, 22, or 31. The polynucleotides of the present invention also include, but are not limited to, a polynucleotide that hybridizes under stringent hybridization conditions to (a) the complement of any of the nucleotide sequences set forth in SEQ ID NO: 1-2, 4, 18-20, 22, or 31; (b) a nucleotide sequence encoding any of SEQ ID NO: 3, 5-13, 21, 23-27 or 28; a polynucleotide which is an allelic variant of any polynucleotides recited above having at least 70 % polynucleotide sequence identity to the polynucleotides; a polynucleotide which encodes a species homolog (e.g. orthologs) of any of the peptides recited above; or a polynucleotide that encodes a polypeptide comprising a specific domain or truncation of the polypeptide comprising SEQ ID NO: 3 and 21.

10 [0010] A collection as used in this application can be a collection of only one polynucleotide. The collection of sequence information or unique identifying information of each sequence can be provided on a nucleic acid array. In one embodiment, segments of sequence information are provided on a nucleic acid array to detect the polynucleotide that contains the segment. The array can be designed to detect full-match or mismatch to the polynucleotide that contains the segment. The collection can also be provided in a computer-readable format.

15 [0011] This invention further provides cloning or expression vectors comprising at least a fragment of the polynucleotides set forth above and host cells or organisms transformed with these expression vectors. Useful vectors include plasmids, cosmids, lambda phage derivatives, phagemids, and the like, that are well known in the art. Accordingly, the invention also provides a vector including a polynucleotide of the invention and a host cell containing the polynucleotide. In general, the vector contains an origin of replication functional in at least one organism, convenient restriction endonuclease sites, and a selectable marker for the host cell. Vectors according to the invention include expression vectors, replication vectors, probe generation vectors, and sequencing vectors. A host cell according to the invention can be a prokaryotic or eukaryotic cell and can be a unicellular organism or part of a multicellular organism.

20 [0012] The compositions of the present invention include polypeptides comprising, but not limited to, an isolated polypeptide selected from the group comprising the amino acid sequence of SEQ ID NO: 3, 5-13, 21, 23-27 or 28; or the corresponding full length or mature protein. Polypeptides of the invention also include polypeptides with biological activity that are encoded by (a) any of the polynucleotides having a nucleotide sequence set forth in SEQ ID NO: 1-2, 4, 18-20, 22, or 31; or (b) polynucleotides that hybridize to the complement of the polynucleotides of (a) under stringent hybridization conditions. Biologically or immunologically active variants of any of the protein sequences listed as SEQ ID NO: 3, 5-13, 21, 23-27 or 28 and substantial equivalents thereof that retain biological or immunological activity are also contemplated. The polypeptides of the invention may be wholly or partially chemically synthesized but are preferably produced by recombinant means using the genetically engineered cells (e.g. host cells) of the invention.

25 [0013] The invention also provides compositions comprising a polypeptide of the invention. Pharmaceutical compositions of the invention may comprise a polypeptide of the invention and an acceptable carrier, such as a hydrophilic, e.g., pharmaceutically acceptable, carrier.

30 [0014] The invention also relates to methods for producing a polypeptide of the invention comprising culturing host cells comprising an expression vector containing at least a fragment of a polynucleotide encoding the polypeptide of the invention in a suitable culture medium under conditions permitting expression of the desired polypeptide, and purifying the protein or peptide from the culture or from the host cells. Preferred embodiments include those in which the protein produced by such a process is a mature form of the protein.

35 [0015] Polynucleotides according to the invention have numerous applications in a variety of techniques known to those skilled in the art of molecular biology. These techniques include use as hybridization probes, use as oligomers, or primers, for PCR, use in an array, use in computer-readable media, use for chromosome and gene mapping, use in the recombinant production of protein, and use in generation of antisense DNA or RNA, their chemical analogs and the like. For example, when the expression of an mRNA is largely restricted to a particular cell or tissue type, polynucleotides of the invention can be used as hybridization probes to detect the presence of the particular cell or tissue mRNA in a sample using, e. g., *in situ* hybridization.

40 [0016] In other exemplary embodiments, the polynucleotides are used in diagnostics as expressed sequence tags for identifying expressed genes or, as well known in the art and exemplified by Vollrath et al., *Science* 258:52-59 (1992),

as expressed sequence tags for physical mapping of the human genome.

[0017] The polypeptides according to the invention can be used in a variety of conventional procedures and methods that are currently applied to other proteins. For example, a polypeptide of the invention can be used to generate an antibody that specifically binds the polypeptide. Such antibodies, particularly monoclonal antibodies, are useful for detecting or quantitating the polypeptide in tissue. The polypeptides of the invention can also be used as molecular weight markers, and as a food supplement.

[0018] Methods are also provided for preventing, treating, or ameliorating a medical condition which comprises the step of administering to a mammalian subject a therapeutically effective amount of a composition comprising a peptide of the present invention and a pharmaceutically acceptable carrier.

[0019] Thus, neuronal guidance molecules (NGMs) and their receptors are crucial for the normal development and regulation of the nervous system. These are the molecular cues that guide the axons. The polypeptides and polynucleotides of the present invention could be useful in modulating neuronal growth and neuronal regenerative capacity, treating neurodegenerative diseases like Alzheimer's and Parkinson's diseases, and diagnosing and mapping of genetic neuronal defects.

[0020] The methods of the invention also provide methods for the treatment of disorders as recited herein which comprise the administration of a therapeutically effective amount of a composition comprising a polynucleotide or polypeptide of the invention and a pharmaceutically acceptable carrier to a mammalian subject exhibiting symptoms or tendencies related to disorders as recited herein. In addition, the invention encompasses methods for treating diseases or disorders as recited herein comprising the step of administering a composition comprising compounds and other substances that modulate the overall activity of the target gene products and a pharmaceutically acceptable carrier. Compounds and other substances can effect such modulation either on the level of target gene/protein expression or target protein activity. Specifically, methods are provided for preventing, treating or ameliorating a medical condition, including viral diseases, which comprises administering to a mammalian subject, including but not limited to humans, a therapeutically effective amount of a composition comprising a polypeptide of the invention or a therapeutically effective amount of a composition comprising a binding partner of (e.g., antibody specifically reactive for) NGM-like polypeptides of the invention. The mechanics of the particular condition or pathology will dictate whether the polypeptides of the invention or binding partners (or inhibitors) of these would be beneficial to the individual in need of treatment.

[0021] According to this method, polypeptides of the invention can be administered to produce an *in vitro* or *in vivo* inhibition of cellular function. A polypeptide of the invention can be administered *in vivo* alone or as an adjunct to other therapies. Conversely, protein or other active ingredients of the present invention may be included in formulations of a particular agent to minimize side effects of such an agent.

[0022] The invention further provides methods for manufacturing medicaments useful in the above-described methods.

[0023] The present invention further relates to methods for detecting the presence of the polynucleotides or polypeptides of the invention in a sample (e.g., tissue or sample). Such methods can, for example, be utilized as part of prognostic and diagnostic evaluation of disorders as recited herein and for the identification of subjects exhibiting a predisposition to such conditions.

[0024] The invention provides a method for detecting a polypeptide of the invention in a sample comprising contacting the sample with a compound that binds to and forms a complex with the polypeptide under conditions and for a period sufficient to form the complex and detecting formation of the complex, so that if a complex is formed, the polypeptide is detected.

[0025] The invention also provides kits comprising polynucleotide probes and/or monoclonal antibodies, and optionally quantitative standards, for carrying out methods of the invention. Furthermore, the invention provides methods for evaluating the efficacy of drugs, and monitoring the progress of patients, involved in clinical trials for the treatment of disorders as recited above.

[0026] The invention also provides methods for the identification of compounds that modulate (i.e., increase or decrease) the expression or activity of the polynucleotides and/or polypeptides of the invention. Such methods can be utilized, for example, for the identification of compounds that can ameliorate symptoms of disorders as recited herein. Such methods can include, but are not limited to, assays for identifying compounds and other substances that interact with (e.g., bind to) the polypeptides of the invention.

[0027] The invention provides a method for identifying a compound that binds to the polypeptide of the present invention comprising contacting the compound with the polypeptide under conditions and for a time sufficient to form a polypeptide/compound complex and detecting the complex, so that if the polypeptide/compound complex is detected, a compound that binds to the polypeptide is identified.

[0028] Also provided is a method for identifying a compound that binds to the polypeptide comprising contacting the compound with the polypeptide in a cell for a time sufficient to form a polypeptide/compound complex wherein the complex drives expression of a reporter gene sequence in the cell and detecting the complex by detecting reporter

gene sequence expression so that if the polypeptide/compound complex is detected a compound that binds to the polypeptide is identified.

#### 4. BRIEF DESCRIPTION OF THE DRAWINGS

5

[0029]

Figure 1 shows the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID NO: 2 (i.e. SEQ ID NO: 3) NGM-like polypeptide and rat Slit SEQ ID NO: 14 (Brose et al, (1999) Cell 96, 795-806), indicating that the two sequences share 52% similarity over 185 amino acid residues and 35 % identity over the same 185 amino acid residues, wherein A=Alanine, C=Cysteine, D=Aspartic Acid, E= Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine, M=Methionine, N=Asparagine, P=Proline, Q=Glutamine, R=Arginine, S=Serine, T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine. Gaps are presented as dashes.

Figure 2 shows the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID NO: 2 (i.e. SEQ ID NO: 3) NGM-like polypeptide and rat Slit SEQ ID NO: 15 (Brose et al, (1999) Cell 96, 795-806), indicating that the two sequences share 53 % similarity over 179 amino acid residues and 33 % identity over the same 179 amino acid residues, wherein A=Alanine, C=Cysteine, D=Aspartic Acid, E= Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine, M=Methionine, N=Asparagine, P=Proline, Q=Glutamine, R=Arginine, S=Serine, T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine. Gaps are presented as dashes.

Figure 3 shows the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID NO: 2 (i.e. SEQ ID NO: 3) NGM-like polypeptide and Rat Slit homolog, SEQ ID NO: 16 (International Patent Application number WO99/55865), indicating that the two sequences share 50% similarity over 216 amino acid residues and 33 % identity over the same 216 amino acid residues, wherein A=Alanine, C=Cysteine, D=Aspartic Acid, E= Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine, M=Methionine, N=Asparagine, P=Proline, Q=Glutamine, R=Arginine, S=Serine, T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine. Gaps are presented as dashes.

Figure 4 shows the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID NO: 2 (i.e. SEQ ID NO: 3) NGM-like polypeptide and Rat Slit homolog, SEQ ID NO: 17 (International Patent Application number WO99/55865), indicating that the two sequences share 51 % similarity over 178 amino acid residues and 32 % identity over the same 178 amino acid residues, wherein A=Alanine, C=Cysteine, D=Aspartic Acid, E= Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine, M=Methionine, N=Asparagine, P=Proline, Q=Glutamine, R=Arginine, S=Serine, T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine. Gaps are presented as dashes.

Figure 5 shows the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID NO: 20 or 31 (i.e. SEQ ID NO: 21) NGM-like polypeptide and neuronal leucine-rich repeat protein-3 (NLRR-3), SEQ ID NO: 29, indicating that the two sequences share 46 % similarity over 511 amino acid residues and 27% identity over the same 511 amino acid residues, wherein A=Alanine, C=Cysteine, D=Aspartic Acid, E= Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine, M=Methionine, N=Asparagine, P=Proline, Q=Glutamine, R=Arginine, S=Serine, T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine. Gaps are presented as dashes.

Figure 6A and 6B show the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID NO: 20 or 31 (i.e. SEQ ID NO: 21) NGM-like polypeptide and human Tango-79 protein, SEQ ID NO: 30 (International Patent Application number WO9906427) indicating that the two sequences share 77 % similarity over 603 amino acid residues and 60% identity over the same 603 amino acid residues, wherein A=Alanine, C=Cysteine, D=Aspartic Acid, E= Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine, M=Methionine, N=Asparagine, P=Proline, Q=Glutamine, R=Arginine, S=Serine, T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine. Gaps are presented as dashes.

50

#### 5. DETAILED DESCRIPTION OF THE INVENTION

[0030] The NGM-like polypeptide of SEQ ID NO: 3 is an approximately 622-amino acid secreted protein with a predicted molecular mass of approximately 70 kDa unglycosylated. Protein database searches with the BLASTX algorithm (Altschul S.F. et al., J. Mol. Evol. 36:290-300 (1993) and Altschul S.F. et al., J. Mol. Biol. 21:403-10 (1990), herein incorporated by reference) indicate that SEQ ID NO: 3 is homologous to Slit proteins.

[0031] Figure 1 shows the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID NO: 2 (i.e. SEQ ID NO: 3) NGM-like polypeptide and rat Slit SEQ ID NO: 14 (Brose et al, (1999) Cell 96, 795-806), indicating

that the two sequences share 52% similarity over 185 amino acid residues and 35 % identity over the same 185 amino acid residues.

[0032] Figure 2 shows the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID NO: 2 (i.e. SEQ ID NO: 3) NGM-like polypeptide and rat Slit1 SEQ ID NO: 15 (Brose et al, (1999) Cell 96, 795-806), indicating that the two sequences share 53% similarity over 179 amino acid residues and 33 % identity over the same 179 amino acid residues.

[0033] Figure 3 shows the BLASTX amino acid sequence alignment between the protein encoded by SEQ 1D NO: 2 (i.e. SEQ ID NO: 3) NGM-like polypeptide and Rat Slit homolog, SEQ ID NO: 16 (International Patent Application number WO99/55865), indicating that the two sequences share 50 % similarity over 216 amino acid residues and 33 % identity over the same 216 amino acid residues.

[0034] Figure 4 shows the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID NO: 2 (i.e. SEQ ID NO: 3) NGM-like polypeptide and Rat Slit homolog, SEQ ID NO: 17 (International Patent Application number WO99/55865), indicating that the two sequences share 51 % similarity over 178 amino acid residues and 32 % identity over the same 178 amino acid residues.

[0035] A predicted approximately twenty five-residue signal peptide is encoded from approximately residue 1 through residue 25 of SEQ ID NO: 3 (SEQ 1D NO: 10). The extracellular portion is useful on its own. This can be confirmed by expression in mammalian cells and sequencing of the cleaved product. The signal peptide region was predicted using the Kyte-Doolittle hydrophobicity prediction algorithm (J. Mol Biol, 157, pp. 105-31 (1982), incorporated herein by reference). One of skill in the art will recognize that the actual cleavage site may be different than that predicted by the computer program.

[0036] A predicted approximately twenty-residue transmembrane region is encoded from approximately residue 168 to residue 187 of SEQ ID NO: 3 (SEQ ID NO: 11). A second predicted approximately twenty four-residue transmembrane region is encoded from approximately residue 527 to residue 550 of SEQ ID NO: 3 (SEQ ID NO: 12). The transmembrane portions may be useful on their own. This can be confirmed by expression in mammalian cells. The transmembrane peptide regions were predicted using the Kyte-Doolittle hydrophobicity prediction algorithm (J. Mol Biol, 157, pp. 105-31 (1982), incorporated herein by reference). One of skill in the art will recognize that the actual transmembrane regions may be different than those predicted by the computer program.

[0037] Using eMATRIX software package (Stanford University, Stanford, CA) (Wu et al., J. Comp. Biol., vol. 6, pp. 219-235 (1999), herein incorporated by reference), NGM-like polypeptide SEQ ID NO: 3, is expected to have five leucine-rich repeat signature domains as shown in the table. The domains corresponding to SEQ ID NO: 5-9 are as follows wherein A=Alanine, C=Cysteine, D=Aspartic Acid, E= Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine, M=Methionine, N=Asparagine, P=Proline, Q=Glutamine, R=Arginine, S=Serine, T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine:

SEQ ID NO	p-value	Signature ID NO	Name	Amino acid sequence encoded (start and end amino acid position)
5	8.435e-10	PR00019A	Leucine-rich repeat signature	LKILNLNFNNLTAL (327-340)
6	9.217e-10	PR00019A	Leucine-rich repeat signature	LRILDLSSNNNLLRI (182-195)
7	3.333e-09	PR00019A	Leucine-rich repeat signature	LKHLILSHNDLENL (278-291)
8	3.520e-09	PR00019B	Leucine-rich repeat signature	LKSLRRLSLSHNPI (227-240)
9	9.280e-09	PR00019B	Leucine-rich repeat signature	LKNLIYLKLDNRNI (299-312)

[0038] The NGM-like polypeptide of SEQ ID NO: 21 is an approximately 606-amino acid secreted protein with a predicted molecular mass of approximately 68 kDa unglycosylated. Protein database searches with the BLASTX algorithm (Altschul S.F. et al., J. Mol. Evol. 36:290-300 (1993) and Altschul S.F. et al., J. Mol. Biol. 21:403-10 (1990), herein incorporated by reference) indicate that SEQ ID NO: 3 is homologous to neuronal leucine-rich repeat-3 (NLRR-3) protein and Tango-79 protein.

[0039] Figure 5 shows the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID NO: 20 or 31 (i.e. SEQ ID NO: 21) NGM-like polypeptide and neuronal leucine-rich repeat protein-3 (NLRR-3), SEQ ID NO: 29, indicating that the two sequences share 46% similarity over 511 amino acid residues and 27% identity over the same 511 amino acid residues.

[0040] Figure 6A and 6B show the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID NO: 20 or 31 (i.e. SEQ ID NO: 21) NGM-like polypeptide and human Tango-79 protein, SEQ ID NO: 30 (International Patent Application number WO9906427) indicating that the two sequences share 77% similarity over 603 amino acid residues and 60% identity over the same 603 amino acid residues.

[0041] A predicted approximately twenty seven-residue signal peptide is encoded from approximately residue 1 through residue 27 of SEQ ID NO: 21 (SEQ ID NO: 26). The extracellular portion is useful on its own. This can be confirmed by expression in mammalian cells and sequencing of the cleaved product. The signal peptide region was predicted using the Neural Network SignalP V1.1 program (from Center for Biological Sequence Analysis, The Technical University of Denmark, incorporated herein by reference). One of skill in the art will recognize that the actual cleavage site may be different than that predicted by the computer program.

[0042] Using eMATRIX software package (Stanford University, Stanford, CA) (Wu et al., J. Comp. Biol., vol. 6, pp. 219-235 (1999), herein incorporated by reference), NGM-like polypeptide is expected to have a receptor interleukin-1 precursor domain, a leucine-rich repeat signature domain, and a receptor tyrosine kinase class III proteins domain as shown in the table. The domains corresponding to SEQ ID NO: 23-25 are as follows wherein A=Alanine, C=Cysteine, D=Aspartic Acid, E= Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine, M=Methionine, N=Asparagine, P=Proline, Q=Glutamine, R=Arginine, S=Serine, T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine:

SEQ ID NO	p-value	Signature ID NO	Name	Amino acid sequence encoded (start and end amino acid position)
23	5.871e-11	PD02870B	Receptor interleukin-1 precursor	LEIRFAQDQDQSGMYV CIASNAAGNDTFTASL TV (468-499)
24	8.043e-10	PR00019A	Leucine-rich repeat signature	LTHLNLSYNPISTI (275-287)
25	4.447e-09	BL00240B	Receptor tyrosine kinase class III proteins	LECSADGDPQPVISW VTPRRRFIT (430-452)

[0043] Thus, neuronal guidance molecules (NGMs) and their receptors are crucial for the normal development and regulation of the nervous system. These are the molecular cues that guide the axons. The polypeptides and polynucleotides of the present invention could be useful in modulating neuronal growth and neuronal regenerative capacity, treating neurodegenerative diseases like Alzheimer's and Parkinson's diseases, and diagnosing and mapping of genetic neuronal defects.

## 5.1 DEFINITIONS

[0044] It must be noted that as used herein and in the appended claims, the singular forms "a", "an" and "the" include plural references unless the context clearly dictates otherwise.

[0045] The term "active" refers to those forms of the polypeptide that retain the biologic and/or immunologic activities of any naturally occurring polypeptide. According to the invention, the terms "biologically active" or "biological activity" refer to a protein or peptide having structural, regulatory or biochemical functions of a naturally occurring molecule. Likewise "biologically active" or "biological activity" refers to the capability of the natural, recombinant or synthetic NGM-like peptide, or any peptide thereof, to induce a specific biological response in appropriate animals or cells and to bind with specific antibodies. The term "NGM-like biological activity" refers to biological activity that is similar to the biological activity of an NGM-like polypeptide. Preferably the biological activity of the polypeptide of SEQ ID NO: 3 is similar to the biological activity of a Slit protein. Preferably the biological activity of the polypeptide of SEQ ID NO: 21 is similar to the biological activity of a NLRR protein.

[0046] The term "activated cells" as used in this application are those cells which are engaged in extracellular or intracellular membrane trafficking, including the export of secretory or enzymatic molecules as part of a normal or disease process.

[0047] The terms "complementary" or "complementarity" refer to the natural binding of polynucleotides by base pairing. For example, the sequence 5'-AGT-3' binds to the complementary sequence 3'-TCA-5'. Complementarity between two single-stranded molecules may be "partial" such that only some of the nucleic acids bind or it may be "complete" such that total complementarity exists between the single stranded molecules. The degree of complementarity between the nucleic acid strands has significant effects on the efficiency and strength of the hybridization between the nucleic acid strands.

[0048] The term "embryonic stem cells (ES)" refers to a cell that can give rise to many differentiated cell types in an embryo or an adult, including the germ cells. The term "germ line stem cells (GSCs)" refers to stem cells derived from primordial stem cells that provide a steady and continuous source of germ cells for the production of gametes. The term "primordial germ cells (PGCs)" refers to a small population of cells set aside from other cell lineages particularly

from the yolk sac, mesenteries, or gonadal ridges during embryogenesis that have the potential to differentiate into germ cells and other cells. PGCs are the source from which GSCs and ES cells are derived. The PGCs, the GSCs and the ES cells are capable of self-renewal. Thus these cells not only populate the germ line and give rise to a plurality of terminally differentiated cells that comprise the adult specialized organs, but are able to regenerate themselves.

5 [0049] The term "expression modulating fragment," EMF, means a series of nucleotides that modulates the expression of an operably linked ORF or another EMF.

[0050] As used herein, a sequence is said to "modulate the expression of an operably linked sequence" when the expression of the sequence is altered by the presence of the EMF. EMFs include, but are not limited to, promoters, and promoter modulating sequences (inducible elements). One class of EMFs is nucleic acid fragments which induce 10 the expression of an operably linked ORF in response to a specific regulatory factor or physiological event.

[0051] The terms "nucleotide sequence" or "nucleic acid" or "polynucleotide" or "oligonucleotide" are used interchangeably and refer to a heteropolymer of nucleotides or the sequence of these nucleotides. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent 15 the sense or the antisense strand, to peptide nucleic acid (PNA) or to any DNA-like or RNA-like material. In the sequences, A is adenine, C is cytosine, G is guanine, and T is thymine, while N is A, G, C, or T (U). It is contemplated that where the polynucleotide is RNA, the T (thymine) in the sequence herein may be replaced with U (uracil). Generally, nucleic acid segments provided by this invention may be assembled from fragments of the genome and short oligonucleotide linkers, or from a series of oligonucleotides, or from individual nucleotides, to provide a synthetic nucleic 20 acid which is capable of being expressed in a recombinant transcriptional unit comprising regulatory elements derived from a microbial or viral operon, or a eukaryotic gene.

[0052] The terms "oligonucleotide fragment" or a "polynucleotide fragment", "portion," or "segment" or "probe" or "primer" are used interchangeably and refer to a sequence of nucleotide residues which are at least about 5 nucleotides, more preferably at least about 7 nucleotides, more preferably at least about 9 nucleotides, more preferably at least about 25 11 nucleotides and most preferably at least about 17 nucleotides. The fragment is preferably less than about 500 nucleotides, preferably less than about 200 nucleotides, more preferably less than about 100 nucleotides, more preferably less than about 50 nucleotides and most preferably less than 30 nucleotides. Preferably the probe is from about 6 nucleotides to about 200 nucleotides, preferably from about 15 to about 50 nucleotides, more preferably from about 17 to 30 nucleotides and most preferably from about 20 to 25 nucleotides. Preferably the fragments can be used in polymerase chain reaction (PCR), various hybridization procedures or microarray procedures to identify or amplify 30 identical or related parts of mRNA or DNA molecules. A fragment or segment may uniquely identify each polynucleotide sequence of the present invention. Preferably the fragment comprises a sequence substantially similar to a portion of SEQ ID NO: 1-2, 4, 18-20, 22, or 31.

[0053] Probes may, for example, be used to determine whether specific mRNA molecules are present in a cell or tissue or to isolate similar nucleic acid sequences from chromosomal DNA as described by Walsh et al. (Walsh, P.S. 35 et al., 1992, PCR Methods Appl 1:241-250). They may be labeled by nick translation, Klenow fill-in reaction, PCR, or other methods well known in the art. Probes of the present invention, their preparation and/or labeling are elaborated in Sambrook, J. et al., 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, NY; or Ausubel, F.M. et al., 1989, Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, both of which are incorporated herein by reference in their entirety.

[0054] The nucleic acid sequences of the present invention also include the sequence information from any of the 40 nucleic acid sequences of SEQ ID NO: 1-2, 4, 18-20, 22, or 31. The sequence information can be a segment of SEQ ID NO: 1-2, 4, 18-20, 22 or 31 that uniquely identifies or represents the sequence information of SEQ ID NO: 1-2, 4, 18-20, 22 or 31. One such segment can be a twenty-mer nucleic acid sequence because the probability that a twenty-mer is fully matched in the human genome is 1 in 300. In the human genome, there are three billion base pairs in one 45 set of chromosomes. Because  $4^{20}$  possible twenty-mers exist, there are 300 times more twenty-mers than there are base pairs in a set of human chromosome. Using the same analysis, the probability for a seventeen-mer to be fully matched in the human genome is approximately 1 in 5. When these segments are used in arrays for expression studies, fifteen-mer segments can be used. The probability that the fifteen-mer is fully matched in the expressed sequences is also approximately one in five because expressed sequences comprise less than approximately 5 % of the entire 50 genome sequence.

[0055] Similarly, when using sequence information for detecting a single mismatch, a segment can be a twenty-five mer. The probability that the twenty-five mer would appear in a human genome with a single mismatch is calculated by multiplying the probability for a full match ( $1+4^{25}$ ) times the increased probability for mismatch at each nucleotide position ( $3 \times 25$ ). The probability that an eighteen mer with a single mismatch can be detected in an array for expression 55 studies is approximately one in five. The probability that a twenty-mer with a single mismatch can be detected in a human genome is approximately one in five.

[0056] The term "open reading frame, " ORF, means a series of nucleotide triplets coding for amino acids without any termination codons and is a sequence translatable into protein.

[0057] The terms "operably linked" or "operably associated" refer to functionally related nucleic acid sequences. For example, a promoter is operably associated or operably linked with a coding sequence if the promoter controls the transcription of the coding sequence. While operably linked nucleic acid sequences can be contiguous and in the same reading frame, certain genetic elements e.g. repressor genes are not contiguously linked to the coding sequence but still control transcription/translation of the coding sequence.

[0058] The term "pluripotent" refers to the capability of a cell to differentiate into a number of differentiated cell types that are present in an adult organism. A pluripotent cell is restricted in its differentiation capability in comparison to a totipotent cell.

[0059] The terms "polypeptide" or "peptide" or "amino acid sequence" refer to an oligopeptide, peptide, polypeptide or protein sequence or fragment thereof and to naturally occurring or synthetic molecules. A polypeptide "fragment," "portion," or "segment" is a stretch of amino acid residues of at least about 5 amino acids, preferably at least about 7 amino acids, more preferably at least about 9 amino acids and most preferably at least about 17 or more amino acids. The peptide preferably is not greater than about 200 amino acids, more preferably less than 150 amino acids, and most preferably less than 100 amino acids. Preferably the peptide is from about 5 to about 200 amino acids. To be active, any polypeptide must have sufficient length to display biological and/or immunological activity.

[0060] The term "naturally occurring polypeptide" refers to polypeptides produced by cells that have not been genetically engineered and specifically contemplates various polypeptides arising from post-translational modifications of the polypeptide including, but not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation and acylation.

[0061] The term "translated protein coding portion" means a sequence which encodes for the full length protein which may include any leader sequence or a processing sequence.

[0062] The term "mature protein coding sequence" refers to a sequence which encodes a peptide or protein without any leader/signal sequence. The term "mature protein coding portion" refers to an amino acid sequence without any leader/signal sequence. It may also refer to a peptide sequence without the initial methionine residue. The peptide may have the leader sequences removed during processing in the cell or the protein may have been produced synthetically or using a polynucleotide only encoding for the mature protein coding sequence.

[0063] The term "derivative" refers to polypeptides chemically modified by such techniques as ubiquitination, labeling (e.g., with radionuclides or various enzymes), covalent polymer attachment such as pegylation (derivatization with polyethylene glycol) and insertion or substitution by chemical synthesis of amino acids such as ornithine, which do not normally occur in human proteins.

[0064] The term "variant"(or "analog") refers to any polypeptide differing from naturally occurring polypeptides by amino acid insertions, deletions, and substitutions, created using, e.g., recombinant DNA techniques. Guidance in determining which amino acid residues may be replaced, added or deleted without abolishing activities of interest, may be found by comparing the sequence of the particular polypeptide with that of homologous peptides and minimizing the number of amino acid sequence changes made in regions of high homology (conserved regions) or by replacing amino acids with consensus sequence.

[0065] Alternatively, recombinant variants encoding these same or similar polypeptides may be synthesized or selected by making use of the "redundancy" in the genetic code. Various codon substitutions, such as the silent changes which produce various restriction sites, may be introduced to optimize cloning into a plasmid or viral vector or expression in a particular prokaryotic or eukaryotic system. Mutations in the polynucleotide sequence may be reflected in the polypeptide or domains of other peptides added to the polypeptide to modify the properties of any part of the polypeptide, to change characteristics such as ligand-binding affinities, interchain affinities, or degradation/turnover rate.

[0066] Preferably, amino acid "substitutions" are the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, *i. e.*, conservative amino acid replacements. "Conservative" amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid. "Insertions" or "deletions" are preferably in the range of about 1 to 20 amino acids, more preferably 1 to 10 amino acids. The variation allowed may be experimentally determined by systematically making insertions, deletions, or substitutions of amino acids in a polypeptide molecule using recombinant DNA techniques and assaying the resulting recombinant variants for activity.

[0067] Alternatively, where alteration of function is desired, insertions, deletions or non-conservative alterations can be engineered to produce altered polypeptides. Such alterations can, for example, alter one or more of the biological functions or biochemical characteristics of the polypeptides of the invention. For example, such alterations may change polypeptide characteristics such as ligand-binding affinities, interchain affinities, or degradation/turnover rate. Further, such alterations can be selected so as to generate polypeptides that are better suited for expression, scale up and the

like in the host cells chosen for expression. For example, cysteine residues can be deleted or substituted with another amino acid residue in order to eliminate disulfide bridges.

[0068] The terms "purified" or "substantially purified" as used herein denotes that the indicated nucleic acid or polypeptide is present in the substantial absence of other biological macromolecules, e.g., polynucleotides, proteins, and the like. In one embodiment, the polynucleotide or polypeptide is purified such that it constitutes at least 95 % by weight, more preferably at least 99 % by weight, of the indicated biological macromolecules present (but water, buffers, and other small molecules, especially molecules having a molecular weight of less than 1000 daltons, can be present).

[0069] The term "isolated" as used herein refers to a nucleic acid or polypeptide separated from at least one other component (e.g., nucleic acid or polypeptide) present with the nucleic acid or polypeptide in its natural source. In one embodiment, the nucleic acid or polypeptide is found in the presence of (if anything) only a solvent, buffer, ion, or other components normally present in a solution of the same. The terms "isolated" and "purified" do not encompass nucleic acids or polypeptides present in their natural source.

[0070] The term "recombinant," when used herein to refer to a polypeptide or protein, means that a polypeptide or protein is derived from recombinant (e.g., microbial, insect, or mammalian) expression systems. "Microbial" refers to recombinant polypeptides or proteins made in bacterial or fungal (e.g., yeast) expression systems. As a product, "recombinant microbial" defines a polypeptide or protein essentially free of native endogenous substances and unaccompanied by associated native glycosylation. Polypeptides or proteins expressed in most bacterial cultures, e.g., *E. coli*, will be free of glycosylation modifications; polypeptides or proteins expressed in yeast will have a glycosylation pattern in general different from those expressed in mammalian cells.

[0071] The term "recombinant expression vehicle or vector" refers to a plasmid or phage or virus or vector, for expressing a polypeptide from a DNA (RNA) sequence. An expression vehicle can comprise a transcriptional unit comprising an assembly of (1) a genetic element or elements having a regulatory role in gene expression, for example, promoters or enhancers, (2) a structural or coding sequence which is transcribed into mRNA and translated into protein, and (3) appropriate transcription initiation and termination sequences. Structural units intended for use in yeast or eukaryotic expression systems preferably include a leader sequence enabling extracellular secretion of translated protein by a host cell. Alternatively, where recombinant protein is expressed without a leader or transport sequence, it may include an amino terminal methionine residue. This residue may or may not be subsequently cleaved from the expressed recombinant protein to provide a final product.

[0072] The term "recombinant expression system" means host cells which have stably integrated a recombinant transcriptional unit into chromosomal DNA or carry the recombinant transcriptional unit extrachromosomally. Recombinant expression systems as defined herein will express heterologous polypeptides or proteins upon induction of the regulatory elements linked to the DNA segment or synthetic gene to be expressed. This term also means host cells which have stably integrated a recombinant genetic element or elements having a regulatory role in gene expression, for example, promoters or enhancers. Recombinant expression systems as defined herein will express polypeptides or proteins endogenous to the cell upon induction of the regulatory elements linked to the endogenous DNA segment or gene to be expressed. The cells can be prokaryotic or eukaryotic.

[0073] The term "secreted" includes a protein that is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence when it is expressed in a suitable host cell. "Secreted" proteins include without limitation proteins secreted wholly (e.g., soluble proteins) or partially (e.g., receptors) from the cell in which they are expressed. "Secreted" proteins also include without limitation proteins that are transported across the membrane of the endoplasmic reticulum. "Secreted" proteins are also intended to include proteins containing non-typical signal sequences (e.g. Interleukin-1 Beta, see Krasney, P.A. and Young, P.R. (1992) Cytokine 4(2):134 -143) and factors released from damaged cells (e.g. Interleukin-1 Receptor Antagonist, see Arend, W.P. et. al. (1998) Annu. Rev. Immunol. 16:27-55)

[0074] Where desired, an expression vector may be designed to contain a "signal or leader sequence" which will direct the polypeptide through the membrane of a cell. Such a sequence may be naturally present on the polypeptides of the present invention or provided from heterologous protein sources by recombinant DNA techniques.

[0075] The term "stringent" is used to refer to conditions that are commonly understood in the art as stringent. Stringent conditions can include highly stringent conditions (i.e., hybridization to filter-bound DNA in 0.5 M NaHPO<sub>4</sub>, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°C, and washing in 0.1X SSC/0.1 % SDS at 68°C), and moderately stringent conditions (i.e., washing in 0.2X SSC/0.1% SDS at 42°C). Other exemplary hybridization conditions are described herein in the examples.

[0076] In instances of hybridization of deoxyoligonucleotides, additional exemplary stringent hybridization conditions include washing in 6X SSC/0.05% sodium pyrophosphate at 37°C (for 14-base oligonucleotides), 48°C (for 17-base oligonucleotides), 55°C (for 20-base oligonucleotides), and 60°C (for 23-base oligonucleotides).

[0077] As used herein, "substantially equivalent" or "substantially similar" can refer both to nucleotide and amino acid sequences, for example a mutant sequence, that varies from a reference sequence by one or more substitutions, deletions, or additions, the net effect of which does not result in an adverse functional dissimilarity between the reference

and subject sequences. Typically, such a substantially equivalent sequence varies from one of those listed herein by no more than about 35% (i.e., the number of individual residue substitutions, additions, and/or deletions in a substantially equivalent sequence, as compared to the corresponding reference sequence, divided by the total number of residues in the substantially equivalent sequence is about 0.35 or less). Such a sequence is said to have 65% sequence identity to the listed sequence. In one embodiment, a substantially equivalent, e.g., mutant, sequence of the invention varies from a listed sequence by no more than 30% (70% sequence identity); in a variation of this embodiment, by no more than 25% (75% sequence identity); and in a further variation of this embodiment, by no more than 20% (80% sequence identity) and in a further variation of this embodiment, by no more than 10% (90% sequence identity) and in a further variation of this embodiment, by no more than 5% (95% sequence identity). Substantially equivalent, e.g., mutant, amino acid sequences according to the invention preferably have at least 80% sequence identity with a listed amino acid sequence, more preferably at least 85% sequence identity, more preferably at least 90% sequence identity, more preferably at least 95% sequence identity, more preferably at least 98% sequence identity, and most preferably at least 99% sequence identity. Substantially equivalent nucleotide sequence of the invention can have lower percent sequence identities, taking into account, for example, the redundancy or degeneracy of the genetic code. Preferably, the nucleotide sequence has at least about 65% identity, more preferably at least about 75% identity, more preferably at least about 80% sequence identity, more preferably at least 85% sequence identity, more preferably at least 90% sequence identity, more preferably at least about 95% sequence identity, more preferably at least 98% sequence identity, and most preferably at least 99% sequence identity. For the purposes of the present invention, sequences having substantially equivalent biological activity and substantially equivalent expression characteristics are considered substantially equivalent. For the purposes of determining equivalence, truncation of the mature sequence (e.g., via a mutation which creates a spurious stop codon) should be disregarded. Sequence identity may be determined, e.g., using the Jotun Hein method (Hein, J. (1990) *Methods Enzymol.* 183:626-645). Identity between sequences can also be determined by other methods known in the art, e.g. by varying hybridization conditions.

[0078] The term "totipotent" refers to the capability of a cell to differentiate into all of the cell types of an adult organism.

[0079] The term "transformation" means introducing DNA into a suitable host cell so that the DNA is replicable, either as an extrachromosomal element, or by chromosomal integration. The term "transfection" refers to the taking up of an expression vector by a suitable host cell, whether or not any coding sequences are in fact expressed. The term "infection" refers to the introduction of nucleic acids into a suitable host cell by use of a virus or viral vector.

[0080] As used herein, an "uptake modulating fragment," UMF, means a series of nucleotides which mediate the uptake of a linked DNA fragment into a cell. UMFs can be readily identified using known UMFs as a target sequence or target motif with the computer-based systems described below. The presence and activity of a UMF can be confirmed by attaching the suspected UMF to a marker sequence. The resulting nucleic acid molecule is then incubated with an appropriate host under appropriate conditions and the uptake of the marker sequence is determined. As described above, a UMF will increase the frequency of uptake of a linked marker sequence.

[0081] Each of the above terms is meant to encompass all that is described for each, unless the context dictates otherwise.

## 5.2 NUCLEIC ACIDS OF THE INVENTION

[0082] The invention is based on the discovery of novel secreted NGM-like polypeptides, the polynucleotides encoding the NGM-like polypeptides and the use of these compositions for the diagnosis, treatment or prevention of cancers and other immunological disorders.

[0083] The isolated polynucleotides of the invention include, but are not limited to a polynucleotide comprising any of the nucleotide sequences of SEQ ID NO: 1-2, 4, 18-20, 22, or 31; a fragment of SEQ ID NO: 1-2, 4, 18-20, 22 or 31; a polynucleotide comprising the full length protein coding sequence of SEQ ID NO: 1-2, 4, 18-20, 22, or 31 (for example SEQ ID NO: 3); and a polynucleotide comprising the nucleotide sequence encoding the mature protein coding sequence of the polynucleotides of any one of SEQ ID NO: 1-2, 4, 18-20, 22, or 31. The polynucleotides of the present invention also include, but are not limited to, a polynucleotide that hybridizes under stringent conditions to (a) the complement of any of the nucleotide sequences of SEQ ID NO: 1-2, 4, 18-20, 22, or 31; (b) a polynucleotide encoding any one of the polypeptides of SEQ ID NO: 3, 5-13, 21, 23-27 or 28; (c) a polynucleotide which is an allelic variant of any polynucleotides recited above; (d) a polynucleotide which encodes a species homolog of any of the proteins recited above; or (e) a polynucleotide that encodes a polypeptide comprising a specific domain or truncation of the polypeptides of SEQ ID NO: 3, 5-13, 21, 23-27 or 28. Domains of interest may depend on the nature of the encoded polypeptide; e.g., domains in receptor-like polypeptides include ligand-binding, extracellular, transmembrane, or cytoplasmic domains, or combinations thereof; domains in immunoglobulin-like proteins include the variable immunoglobulin-like domains; domains in enzyme-like polypeptides include catalytic and substrate binding domains; and domains in ligand polypeptides include receptor-binding domains.

[0084] The polynucleotides of the invention include naturally occurring or wholly or partially synthetic DNA, e.g.,

cDNA and genomic DNA, and RNA, e.g., mRNA. The polynucleotides may include all of the coding region of the cDNA or may represent a portion of the coding region of the cDNA.

[0085] The present invention also provides genes corresponding to the cDNA sequences disclosed herein. The corresponding genes can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and/or amplification of genes in appropriate genomic libraries or other sources of genomic materials. Further 5' and 3' sequence can be obtained using methods known in the art. For example, full length cDNA or genomic DNA that corresponds to any of the polynucleotides of SEQ ID NO: 1-2, 4, 18-20, 22, or 31 can be obtained by screening appropriate cDNA or genomic DNA libraries under suitable hybridization conditions using any of the polynucleotides of SEQ ID NO: 1-2, 4, 18-20, 22, or 31 or a portion thereof as a probe. Alternatively, the polynucleotides of SEQ ID NO: 1-2, 4, 18-20, 22, or 31 may be used as the basis for suitable primer(s) that allow identification and/or amplification of genes in appropriate genomic DNA or cDNA libraries.

[0086] The nucleic acid sequences of the invention can be assembled from ESTs and sequences (including cDNA and genomic sequences) obtained from one or more public databases, such as dbEST, gbpri, and UniGene. The EST sequences can provide identifying sequence information, representative fragment or segment information, or novel segment information for the full-length gene.

[0087] The polynucleotides of the invention also provide polynucleotides including nucleotide sequences that are substantially equivalent to the polynucleotides recited above. Polynucleotides according to the invention can have, e.g., at least about 65 %, at least about 70 %, at least about 75%, at least about 80 %, 81%, 82 %, 83%, 84%, more typically at least about 85%, 86%, 87%, 88%, 89%, more typically at least about 90%, 91%, 92%, 93%, 94%, and even more typically at least about 95%, 96 %, 97%, 98%, 99 % sequence identity to a polynucleotide recited above.

[0088] Included within the scope of the nucleic acid sequences of the invention are nucleic acid sequence fragments that hybridize under stringent conditions to any of the nucleotide sequences of SEQ ID NO: 1-2, 4, 18-20, 22, or 31, or complements thereof, which fragment is greater than about 5 nucleotides, preferably 7 nucleotides, more preferably greater than 9 nucleotides and most preferably greater than 17 nucleotides. Fragments of, e.g. 15, 17, or 20 nucleotides or more that are selective for (i.e. specifically hybridize to) any one of the polynucleotides of the invention are contemplated. Probes capable of specifically hybridizing to a polynucleotide can differentiate polynucleotide sequences of the invention from other polynucleotide sequences in the same family of genes or can differentiate human genes from genes of other species, and are preferably based on unique nucleotide sequences.

[0089] The sequences falling within the scope of the present invention are not limited to these specific sequences, but also include allelic and species variations thereof. Allelic and species variations can be routinely determined by comparing the sequence provided in SEQ ID NO: 1-2, 4, 18-20, 22, or 31, a representative fragment thereof, or a nucleotide sequence at least 90% identical, preferably 95% identical, to SEQ ID NO: 1-2, 4, 18-20, 22, or 31 with a sequence from another isolate of the same species. Furthermore, to accommodate codon variability, the invention includes nucleic acid molecules coding for the same amino acid sequences as do the specific ORFs disclosed herein. In other words, in the coding region of an ORF, substitution of one codon for another codon that encodes the same amino acid is expressly contemplated.

[0090] The nearest neighbor result for the nucleic acids of the present invention, including SEQ ID NO: 1-2, 4, 18-20, 22, or 31, can be obtained by searching a database using an algorithm or a program. Preferably, a BLAST which stands for Basic Local alignment Search Tool is used to search for local sequence alignments (Altschul, S.F. J Mol. Evol. 36 290-300 (1993) and Altschul S.F. et al. J. Mol. Biol. 21:403-410 (1990))

[0091] Species homologs (or orthologs) of the disclosed polynucleotides and proteins are also provided by the present invention. Species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species.

[0092] The invention also encompasses allelic variants of the disclosed polynucleotides or proteins; that is, naturally-occurring alternative forms of the isolated polynucleotide which also encode proteins which are identical, homologous or related to that encoded by the polynucleotides.

[0093] The nucleic acid sequences of the invention are further directed to sequences which encode variants of the described nucleic acids. These amino acid sequence variants may be prepared by methods known in the art by introducing appropriate nucleotide changes into a native or variant polynucleotide. There are two variables in the construction of amino acid sequence variants: the location of the mutation and the nature of the mutation. Nucleic acids encoding the amino acid sequence variants are preferably constructed by mutating the polynucleotide to encode an amino acid sequence that does not occur in nature. These nucleic acid alterations can be made at sites that differ in the nucleic acids from different species (variable positions) or in highly conserved regions (constant regions). Sites at such locations will typically be modified in series, e.g., by substituting first with conservative choices (e.g., hydrophobic amino acid to a different hydrophobic amino acid) and then with more distant choices (e.g., hydrophobic amino acid to a charged amino acid), and then deletions or insertions may be made at the target site. Amino acid sequence deletions generally range from about 1 to 30 residues, preferably about 1 to 10 residues, and are typically contiguous. Amino

acid insertions include amino- and/or carboxyl-terminal fusions ranging in length from one to one hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Intrasequence insertions may range generally from about 1 to 10 amino residues, preferably from 1 to 5 residues. Examples of terminal insertions include the heterologous signal sequences necessary for secretion or for intracellular targeting in different host cells and sequences such as FLAG or poly-histidine sequences useful for purifying the expressed protein.

**[0094]** In a preferred method, polynucleotides encoding the novel amino acid sequences are changed via site-directed mutagenesis. This method uses oligonucleotide sequences to alter a polynucleotide to encode the desired amino acid variant, as well as sufficient adjacent nucleotides on both sides of the changed amino acid to form a stable duplex on either side of the site being changed. In general, the techniques of site-directed mutagenesis are well known to those of skill in the art and this technique is exemplified by publications such as, Edelman et al., *DNA* 2:183 (1983). A versatile and efficient method for producing site-specific changes in a polynucleotide sequence was published by Zoller and Smith, *Nucleic Acids Res.* 10:6487-6500 (1982). PCR may also be used to create amino acid sequence variants of the novel nucleic acids. When small amounts of template DNA are used as starting material, primer(s) that differs slightly in sequence from the corresponding region in the template DNA can generate the desired amino acid variant. PCR amplification results in a population of product DNA fragments that differ from the polynucleotide template encoding the polypeptide at the position specified by the primer. The product DNA fragments replace the corresponding region in the plasmid and this gives a polynucleotide encoding the desired amino acid variant.

**[0095]** A further technique for generating amino acid variants is the cassette mutagenesis technique described in Wells et al., *Gene* 34:315 (1985); and other mutagenesis techniques well known in the art, such as, for example, the techniques in Sambrook et al., *supra*, and *Current Protocols in Molecular Biology*, Ausubel et al. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be used in the practice of the invention for the cloning and expression of these novel nucleic acids. Such DNA sequences include those which are capable of hybridizing to the appropriate novel nucleic acid sequence under stringent conditions.

**[0096]** Polynucleotides encoding preferred polypeptide truncations of the invention can be used to generate polynucleotides encoding chimeric or fusion proteins comprising one or more domains of the invention and heterologous protein sequences.

**[0097]** The polynucleotides of the invention additionally include the complement of any of the polynucleotides recited above. The polynucleotide can be DNA (genomic, cDNA, amplified, or synthetic) or RNA. Methods and algorithms for obtaining such polynucleotides are well known to those of skill in the art and can include, for example, methods for determining hybridization conditions that can routinely isolate polynucleotides of the desired sequence identities.

**[0098]** In accordance with the invention, polynucleotide sequences comprising the mature protein coding sequences corresponding to any one of SEQ ID NO: 3, 5-13, 21, 23-27 or 28, or functional equivalents thereof, may be used to generate recombinant DNA molecules that direct the expression of that nucleic acid, or a functional equivalent thereof, in appropriate host cells. Also included are the cDNA inserts of any of the clones identified herein.

**[0099]** A polynucleotide according to the invention can be joined to any of a variety of other nucleotide sequences by well-established recombinant DNA techniques (see Sambrook J et al. (1989) *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, NY). Useful nucleotide sequences for joining to polynucleotides include an assortment of vectors, e.g., plasmids, cosmids, lambda phage derivatives, phagemids, and the like, that are well known in the art. Accordingly, the invention also provides a vector including a polynucleotide of the invention and a host cell containing the polynucleotide. In general, the vector contains an origin of replication functional in at least one organism, convenient restriction endonuclease sites, and a selectable marker for the host cell. Vectors according to the invention include expression vectors, replication vectors, probe generation vectors, and sequencing vectors. A host cell according to the invention can be a prokaryotic or eukaryotic cell and can be a unicellular organism or part of a multicellular organism.

**[0100]** The present invention further provides recombinant constructs comprising a nucleic acid having any of the nucleotide sequences of SEQ ID NO: 1-2, 4, 18-20, 22, or 31 or a fragment thereof or any other polynucleotides of the invention. In one embodiment, the recombinant constructs of the present invention comprise a vector, such as a plasmid or viral vector, into which a nucleic acid having any of the nucleotide sequences of SEQ ID NO: 1-2, 4, 18-20, 22, or 31 or a fragment thereof is inserted, in a forward or reverse orientation. In the case of a vector comprising one of the ORFs of the present invention, the vector may further comprise regulatory sequences, including for example, a promoter, operably linked to the ORF. Large numbers of suitable vectors and promoters are known to those of skill in the art and are commercially available for generating the recombinant constructs of the present invention. The following vectors are provided by way of example. Bacterial: pBs, phagescript, PsiX174, pBluescript SK, pBs KS, pNH8a, pNH16a, pNH18a, pNH46a (Stratagene); pTrc99A, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia). Eukaryotic: pWLneo, pSV2cat, pOG44, PXTI, pSG (Stratagene) pSVK3, pBPV, pMSG, pSVL (Pharmacia).

**[0101]** The isolated polynucleotide of the invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman et al., *Nucleic Acids Res.* 19,4485-4490 (1991), in order

to produce the protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, *Methods in Enzymology* 185, 537-566 (1990). As defined herein "operably linked" means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.

[0102] Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors or other vectors with selectable markers. Two appropriate vectors are pKK232-8 and pCM7. Particular named bacterial promoters include lacI, lacZ, T3, T7, gpt, lambda PR, and trc. Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art. Generally, recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the ampicillin resistance gene of *E. coli* and *S. cerevisiae* TRP1 gene, and a promoter derived from a highly expressed gene to direct transcription of a downstream structural sequence. Such promoters can be derived from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK), a-factor, acid phosphatase, or heat shock proteins, among others.

[0103] The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium. Optionally, the heterologous sequence can encode a fusion protein including an amino terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product. Useful expression vectors for bacterial use are constructed by inserting a structural DNA sequence encoding a desired protein together with suitable translation initiation and termination signals in operable reading phase with a functional promoter. The vector will comprise one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and to, if desirable, provide amplification within the host. Suitable prokaryotic hosts for transformation include *E. coli*, *Bacillus subtilis*, *Salmonella typhimurium* and various species within the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*, although others may also be employed as a matter of choice.

[0104] As a representative but non-limiting example, useful expression vectors for bacterial use can comprise a selectable marker and bacterial origin of replication derived from commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017). Such commercial vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and GEM 1 (Promega Biotech, Madison, WI, USA). These pBR322 "backbone" sections are combined with an appropriate promoter and the structural sequence to be expressed. Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is induced or derepressed by appropriate means (e.g., temperature shift or chemical induction) and cells are cultured for an additional period. Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification.

[0105] Polynucleotides of the invention can also be used to induce immune responses. For example, as described in Fan et al., *Nat. Biotech.* 17:870-872 (1999), incorporated herein by reference, nucleic acid sequences encoding a polypeptide may be used to generate antibodies against the encoded polypeptide following topical administration of naked plasmid DNA or following injection, and preferably intramuscular injection of the DNA. The nucleic acid sequences are preferably inserted in a recombinant expression vector and may be in the form of naked DNA.

### 5.3 ANTISENSE

[0106] Another aspect of the invention pertains to isolated antisense nucleic acid molecules that are hybridizable to or complementary to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1 - 2, 4, 18 - 20, 22, or 31, or fragments, analogs or derivatives thereof. An "antisense" nucleic acid comprises a nucleotide sequence that is complementary to a "sense" nucleic acid encoding a protein, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. In specific aspects, antisense nucleic acid molecules are provided that comprise a sequence complementary to at least about 10, 25, 50, 100, 250 or 500 nucleotides or an entire coding strand, or to only a portion thereof. Nucleic acid molecules encoding fragments, homologs, derivatives and analogs of a protein of any of SEQ ID NO: 1 - 2, 4, 18 - 20, 22, or 31 or antisense nucleic acids complementary to a nucleic acid sequence of SEQ ID NO: 1 - 2, 4, 18 - 20, 22, or 31 are additionally provided.

[0107] In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence of the invention. The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues. In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence of the invention. The term "noncoding region" refers to 5' and 3' sequences that flank the coding region that are not translated into amino acids (i.e., also referred to as 5' and 3' untranslated regions).

[0108] Given the coding strand sequences encoding a nucleic acid disclosed herein (e.g., SEQ ID NO: 1 - 2, 4, 18

- 20, 22, or 31, antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick or Hoogsteen base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of an mRNA, but more preferably is an oligonucleotide that is antisense to only a portion of the coding or noncoding region of an mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of an mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis or enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used.

[0108] Examples of modified nucleotides that can be used to generate the antisense nucleic acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl)uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiouracil, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

[0109] The antisense nucleic acid molecules of the invention are typically administered to a subject or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a protein according to the invention to thereby inhibit expression of the protein, e.g., by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule that binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, e.g., by linking the antisense nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens. The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

[0110] In yet another embodiment, the antisense nucleic acid molecule of the invention is an  $\alpha$ -anomeric nucleic acid molecule. An  $\alpha$ -anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual  $\alpha$ -units, the strands run parallel to each other (Gaultier *et al.* (1987) *Nucleic Acids Res* 15: 6625-6641). The antisense nucleic acid molecule can also comprise a 2'- $\alpha$ -methylribonucleotide (Inoue *et al.* (1987) *Nucleic Acids Res* 15: 6131-6148) or a chimeric RNA -DNA analogue (Inoue *et al.* (1987) *FEBS Lett* 215: 327-330).

#### 5.4 RIBOZYMES AND PNA MOIETIES

[0111] In still another embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity that are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes (described in Haselhoff and Gerlach (1988) *Nature* 334:585-591)) can be used to catalytically cleave mRNA transcripts to thereby inhibit translation of an mRNA. A ribozyme having specificity for a nucleic acid of the invention can be designed based upon the nucleotide sequence of a DNA disclosed herein (i.e., SEQ ID NO: 1 - 2, 4, 18 - 20, 22, or 31). For example, a derivative of Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a SECX-encoding mRNA. See, e.g., Cech *et al.* U.S. Pat. No. 4,987,071; and Cech *et al.* U.S. Pat. No. 5,116,742. Alternatively, SECX mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel *et al.*, (1993) *Science* 261:1411-1418.

[0112] Alternatively, gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region (e.g., promoter and/or enhancers) to form triple helical structures that prevent transcription of the gene in target cells. See generally, Helene. (1991) *Anticancer Drug Des.* 6: 569-84; Helene. *et al.* (1992) *Ann. N.Y. Acad. Sci.* 660:27-36; and Maher (1992) *Bioassays* 14: 807-15.

[0113] In various embodiments, the nucleic acids of the invention can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids (see Hyrup *et al.* (1996) *Bioorg Med Chem* 4: 5-23). As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic

5 acid mimics, e.g., DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup *et al.* (1996) above; Perry-O'Keefe *et al.* (1996) *PNAS* 93: 14670-675.

10 [0114] PNAs of the invention can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, e.g.; inducing transcription or translation arrest or inhibiting replication. PNAs of the invention can also be used, e.g., in the analysis of single base pair mutations in a gene by, e.g., PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, e.g., S1 nucleases (Hyrup B. (1996) above); or as probes or primers for DNA 15 sequence and hybridization (Hyrup *et al.* (1996), above; Perry-O'Keefe (1996), above).

[0115] In another embodiment, PNAs of the invention can be modified, e.g., to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras can be generated that may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes, e. 20 g., RNase H and DNA polymerases, to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup (1996) above). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup (1996) above and Finn *et al.* (1996) *Nucl Acids Res* 24: 3357-63. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry, 25 and modified nucleoside analogs, e.g., 5'-*(4-methoxytrityl)amino*-5'-deoxy-thymidine phosphoramidite, can be used between the PNA and the 5' end of DNA (Mag *et al.* (1989) *Nucl AcidRes* 17: 5973-88). PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment (Finn *et al.* (1996) above). Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment. See, Petersen *et al.* (1975) *Bioorg Med Chem Lett* 5: 1119-1124.

30 [0116] In other embodiments, the oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, e.g., Letsinger *et al.*, 1989, *Proc. Natl. Acad. Sci. U.S.A.* 86:6553-6556; Lemaitre *et al.*, 1987, *Proc. Natl. Acad. Sci.* 84:648-652; PCT Publication No. W088/09810) or the blood-brain barrier (see, e.g., PCT Publication No. W089/10134). In addition, oligonucleotides can be modified with hybridization triggered cleavage agents (See, e.g., Krol *et al.*, 1988, *BioTechniques* 6:958-976) or intercalating agents. (See, e.g., Zon, 1988, *Pharm. Res.* 5: 539-549). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, a hybridization triggered cross-linking agent, a transport agent, a hybridization-triggered cleavage agent, etc.

## 5.5 HOSTS

40 [0117] The present invention further provides host cells genetically engineered to contain the polynucleotides of the invention. For example, such host cells may contain nucleic acids of the invention introduced into the host cell using known transformation, transfection or infection methods. The present invention still further provides host cells genetically engineered to express the polynucleotides of the invention, wherein such polynucleotides are in operative association with a regulatory sequence heterologous to the host cell which drives expression of the polynucleotides in the cell.

45 [0118] Knowledge of NGM-like DNA sequences allows for modification of cells to permit, or increase, expression of NGM-like polypeptides. Cells can be modified (e.g., by homologous recombination) to provide increased NGM-like polypeptide expression by replacing, in whole or in part, the naturally occurring NGM-like promoter with all or part of a heterologous promoter so that the NGM-like polypeptide is expressed at higher levels. The heterologous promoter is inserted in such a manner that it is operatively linked to NGM-like encoding sequences. See, for example, PCT International Publication No. WO94/12650, PCT International Publication No. WO92/20808, and PCT International Publication No. WO91/09955. It is also contemplated that, in addition to heterologous promoter DNA, amplifiable marker DNA (e.g., ada, dhfr, and the multifunctional CAD gene which encodes carbamyl phosphate synthase, aspartate transcarbamylase, and dihydroorotase) and/or intron DNA may be inserted along with the heterologous promoter DNA. If linked to the NGM-like coding sequence, amplification of the marker DNA by standard selection methods results in co-amplification of the NGM-like coding sequences in the cells.

55 [0119] The host cell can be a higher eukaryotic host cell, such as a mammalian cell, a lower eukaryotic host cell,

such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the recombinant construct into the host cell can be effected by calcium phosphate transfection, DEAE, dextran-mediated transfection, or electroporation (Davis, L. et al., *Basic Methods in Molecular Biology* (1986)). The host cells containing one of the polynucleotides of the invention, can be used in conventional manners to produce the gene product encoded by the

5 isolated fragment (in the case of an ORF) or can be used to produce a heterologous protein under the control of the EMF.

[0120] Any host/vector system can be used to express one or more of the ORFs of the present invention. These include, but are not limited to, eukaryotic hosts such as HeLa cells, Cv-1 cell, COS cells, 293 cells, and Sf9 cells, as well as prokaryotic host such as *E. coli* and *B. subtilis*. The most preferred cells are those which do not normally express the particular polypeptide or protein or which expresses the polypeptide or protein at low natural level. Mature proteins can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook, et al., in *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor, New York (1989), the disclosure of which is hereby incorporated by reference.

10 [0121] Various mammalian cell culture systems can also be employed to express recombinant protein. Examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts, described by Gluzman, *Cell* 23:175 (1981). Other cell lines capable of expressing a compatible vector are, for example, the C127, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from *in vitro*

15 culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells. Mammalian expression vectors will comprise an origin of replication, a suitable promoter and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking nontranscribed sequences. DNA sequences derived from the SV40 viral genome, for example, SV40 origin, early promoter, enhancer, splice, and polyadenylation sites may be used to provide the required nontranscribed genetic 20 elements. Recombinant polypeptides and proteins produced in bacterial culture are usually isolated by initial extraction from cell pellets, followed by one or more salting-out, aqueous ion exchange or size exclusion chromatography steps. Protein refolding steps can be used, as necessary, in completing configuration of the mature protein. Finally, high 25 performance liquid chromatography (HPLC) can be employed for final purification steps. Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents.

[0122] Alternatively, it may be possible to produce the protein in lower eukaryotes such as yeast or insects or in 30 prokaryotes such as bacteria. Potentially suitable yeast strains include *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Kluyveromyces* strains, *Candida*, or any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial strains include *Escherichia coli*, *Bacillus subtilis*, *Salmonella typhimurium*, or any bacterial 35 strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional protein. Such covalent attachments may be accomplished using known chemical or enzymatic methods.

[0123] In another embodiment of the present invention, cells and tissues may be engineered to express an endogenous gene comprising the polynucleotides of the invention under the control of inducible regulatory elements, in which 40 case the regulatory sequences of the endogenous gene may be replaced by homologous recombination. As described herein, gene targeting can be used to replace a gene's existing regulatory region with a regulatory sequence isolated from a different gene or a novel regulatory sequence synthesized by genetic engineering methods. Such regulatory sequences may be comprised of promoters, enhancers, scaffold-attachment regions, negative regulatory elements, transcriptional initiation sites, regulatory protein binding sites or combinations of said sequences. Alternatively, sequences which affect the structure or stability of the RNA or protein produced may be replaced, removed, added, or otherwise modified by targeting. These sequence include polyadenylation signals, mRNA stability elements, splice sites, leader sequences for enhancing or modifying transport or secretion properties of the protein, or other sequences which alter or improve the function or stability of protein or RNA molecules.

[0124] The targeting event may be a simple insertion of the regulatory sequence, placing the gene under the control 45 of the new regulatory sequence, e.g., inserting a new promoter or enhancer or both upstream of a gene. Alternatively, the targeting event may be a simple deletion of a regulatory element, such as the deletion of a tissue-specific negative regulatory element. Alternatively, the targeting event may replace an existing element; for example, a tissue-specific enhancer can be replaced by an enhancer that has broader or different cell-type specificity than the naturally occurring 50 elements. Here, the naturally occurring sequences are deleted and new sequences are added. In all cases, the identification of the targeting event may be facilitated by the use of one or more selectable marker genes that are contiguous with the targeting DNA, allowing for the selection of cells in which the exogenous DNA has integrated into the host cell genome. The identification of the targeting event may also be facilitated by the use of one or more marker genes

exhibiting the property of negative selection, such that the negatively selectable marker is linked to the exogenous DNA, but configured such that the negatively selectable marker flanks the targeting sequence, and such that a correct homologous recombination event with sequences in the host cell genome does not result in the stable integration of the negatively selectable marker. Markers useful for this purpose include the Herpes Simplex Virus thymidine kinase (TK) gene or the bacterial xanthine-guanine phosphoribosyl-transferase (gpt) gene.

[0125] The gene targeting or gene activation techniques which can be used in accordance with this aspect of the invention are more particularly described in U.S. Patent No. 5,272,071 to Chappel; U.S. Patent No. 5,578,461 to Sherwin et al.; International Application No. PCT/US92/09627 (WO93/09222) by Selden et al.; and International Application No. PCT/US90/06436 (WO91/06667) by Skoultchi et al., each of which is incorporated by reference herein in its entirety.

## 5.6 POLYPEPTIDES OF THE INVENTION

[0126] The isolated polypeptides of the invention include, but are not limited to, a polypeptide comprising: the amino acid sequence set forth as any one of SEQ ID NO: 3, 5-13, 21, 23-27 or 28 or an amino acid sequence encoded by any one of the nucleotide sequences SEQ ED NO: 1-2, 4, 18-20, 22, or 31 or the corresponding full length or mature protein. Polypeptides of the invention also include polypeptides preferably with biological or immunological activity that are encoded by: (a) a polynucleotide having any one of the nucleotide sequences set forth in SEQ ID NO: 1-2, 4, 18-20, 22, or 31 or (b) polynucleotides encoding any one of the amino acid sequences set forth as SEQ ID NO: 3, 5-13, 21, 23-27 or 28 or (c) polynucleotides that hybridize to the complement of the polynucleotides of either (a) or (b) under stringent hybridization conditions. The invention also provides biologically active or immunologically active variants of any of the amino acid sequences set forth as SEQ ID NO: 3, 5-13, 21, 23-27 or 28 or the corresponding full length or mature protein; and "substantial equivalents" thereof (e.g., with at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, 86%, 87%, 88%, 89%, at least about 90%, 91%, 92%, 93%, 94%, typically at least about 95%, 96%, 97%, more typically at least about 98%, or most typically at least about 99% amino acid identity) that retain biological activity. Polypeptides encoded by allelic variants may have a similar, increased, or decreased activity compared to polypeptides comprising SEQ ID NO: 3, 5-13, 21, 23-27 or 28.

[0127] Fragments of the proteins of the present invention which are capable of exhibiting biological activity are also encompassed by the present invention. Fragments of the protein may be in linear form or they may be cyclized using known methods, for example, as described in H. U. Saragovi, et al., Bio/Technology 10, 773-778 (1992) and in R. S. McDowell, et al., J. Amer. Chem. Soc. 114, 9245-9253 (1992), both of which are incorporated herein by reference. Such fragments may be fused to carrier molecules such as immunoglobulins for many purposes, including increasing the valency of protein binding sites.

[0128] The present invention also provides both full-length and mature forms (for example, without a signal sequence or precursor sequence) of the disclosed proteins. The protein coding sequence is identified in the sequence listing by translation of the disclosed nucleotide sequences. The mature form of such protein may be obtained by expression of a full-length polynucleotide in a suitable mammalian cell or other host cell. The sequence of the mature form of the protein is also determinable from the amino acid sequence of the full-length form. Where proteins of the present invention are membrane bound, soluble forms of the proteins are also provided. In such forms, part or all of the regions causing the proteins to be membrane bound are deleted so that the proteins are fully secreted from the cell in which it is expressed.

[0129] Protein compositions of the present invention may further comprise an acceptable carrier, such as a hydrophilic, e.g., pharmaceutically acceptable, carrier.

[0130] The present invention further provides isolated polypeptides encoded by the nucleic acid fragments of the present invention or by degenerate variants of the nucleic acid fragments of the present invention. By "degenerate variant" is intended nucleotide fragments which differ from a nucleic acid fragment of the present invention (e.g., an ORF) by nucleotide sequence but, due to the degeneracy of the genetic code, encode an identical polypeptide sequence. Preferred nucleic acid fragments of the present invention are the ORFs that encode proteins.

[0131] A variety of methodologies known in the art can be utilized to obtain any one of the isolated polypeptides or proteins of the present invention. At the simplest level, the amino acid sequence can be synthesized using commercially available peptide synthesizers. The synthetically-constructed protein sequences, by virtue of sharing primary, secondary or tertiary structural and/or conformational characteristics with proteins may possess biological properties in common therewith, including protein activity. This technique is particularly useful in producing small peptides and fragments of larger polypeptides. Fragments are useful, for example, in generating antibodies against the native polypeptide. Thus, they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.

[0132] The polypeptides and proteins of the present invention can alternatively be purified from cells which have been altered to express the desired polypeptide or protein. As used herein, a cell is said to be altered to express a desired polypeptide or protein when the cell, through genetic manipulation, is made to produce a polypeptide or protein

which it normally does not produce or which the cell normally produces at a lower level. One skilled in the art can readily adapt procedures for introducing and expressing either recombinant or synthetic sequences into eukaryotic or prokaryotic cells in order to generate a cell which produces one of the polypeptides or proteins of the present invention.

[0133] The invention also relates to methods for producing a polypeptide comprising growing a culture of host cells of the invention in a suitable culture medium, and purifying the protein from the cells or the culture in which the cells are grown. For example, the methods of the invention include a process for producing a polypeptide in which a host cell containing a suitable expression vector that includes a polynucleotide of the invention is cultured under conditions that allow expression of the encoded polypeptide. The polypeptide can be recovered from the culture, conveniently from the culture medium, or from a lysate prepared from the host cells and further purified. Preferred embodiments include those in which the protein produced by such process is a full length or mature form of the protein.

[0134] In an alternative method, the polypeptide or protein is purified from bacterial cells which naturally produce the polypeptide or protein. One skilled in the art can readily follow known methods for isolating polypeptides and proteins in order to obtain one of the isolated polypeptides or proteins of the present invention. These include, but are not limited to, immunochromatography, HPLC, size-exclusion chromatography, ion-exchange chromatography, and immuno-affinity chromatography. See, e.g., Scopes, *Protein Purification: Principles and Practice*, Springer-Verlag (1994); Sambrook, et al., in *Molecular Cloning: A Laboratory Manual*; Ausubel et al., *Current Protocols in Molecular Biology*. Polypeptide fragments that retain biological/immunological activity include fragments comprising greater than about 100 amino acids, or greater than about 200 amino acids, and fragments that encode specific protein domains.

[0135] The purified polypeptides can be used in *in vitro* binding assays which are well known in the art to identify molecules which bind to the polypeptides. These molecules include but are not limited to, for e.g., small molecules, molecules from combinatorial libraries, antibodies or other proteins. The molecules identified in the binding assay are then tested for antagonist or agonist activity in *in vivo* tissue culture or animal models that are well known in the art. In brief, the molecules are titrated into a plurality of cell cultures or animals and then tested for either cell/animal death or prolonged survival of the animal/cells.

[0136] In addition, the peptides of the invention or molecules capable of binding to the peptides may be complexed with toxins, e.g., ricin or cholera, or with other compounds that are toxic to cells. The toxin-binding molecule complex is then targeted to a tumor or other cell by the specificity of the binding molecule for SEQ ID NO: 3, 5-13, 21, 23-27 or 28.

[0137] The protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a nucleotide sequence encoding the protein.

[0138] The proteins provided herein also include proteins characterized by amino acid sequences similar to those of purified proteins but into which modification are naturally provided or deliberately engineered. For example, modifications, in the peptide or DNA sequence, can be made by those skilled in the art using known techniques. Modifications of interest in the protein sequences may include the alteration, substitution, replacement, insertion or deletion of a selected amino acid residue in the coding sequence. For example, one or more of the cysteine residues may be deleted or replaced with another amino acid to alter the conformation of the molecule. Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art (see, e.g., U.S. Pat. No. 4,518,584). Preferably, such alteration, substitution, replacement, insertion or deletion retains the desired activity of the protein. Regions of the protein that are important for the protein function can be determined by various methods known in the art including the alanine-scanning method which involved systematic substitution of single or strings of amino acids with alanine, followed by testing the resulting alanine-containing variant for biological activity. This type of analysis determines the importance of the substituted amino acid(s) in biological activity. Regions of the protein that are important for protein function may be determined by the eMATRIX program.

[0139] Other fragments and derivatives of the sequences of proteins which would be expected to retain protein activity in whole or in part and are useful for screening or other immunological methodologies may also be easily made by those skilled in the art given the disclosures herein. Such modifications are encompassed by the present invention.

[0140] The protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, e.g., Invitrogen, San Diego, Calif., U.S.A. (the MaxBat™ kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference. As used herein, an insect cell capable of expressing a polynucleotide of the present invention is "transformed."

[0141] The protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein. The resulting expressed protein may then be purified from such culture (i. e., from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an affinity column containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl™ or Cibacrom blue 3GA Sepharose™; one or more steps involving hydrophobic interaction chromatography using such

resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography.

[0142] Alternatively, the protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX), or as a His tag. Kits for expression and purification of such fusion proteins are commercially available from New England Biolab (Beverly, Mass.), Pharmacia (Piscataway, N.J.) and Invitrogen, respectively. The protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope. One such epitope ("FLAG®") is commercially available from Kodak (New Haven, Conn.).

[0143] Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a substantially homogeneous isolated recombinant protein. The protein thus purified is substantially free of other mammalian proteins and is defined in accordance with the present invention as an "isolated protein."

[0144] The polypeptides of the invention include analogs (variants). The polypeptides of the invention include NGM-like analogs. This embraces fragments of NGM-like polypeptides of the invention, as well NGM-like polypeptides which comprise one or more amino acids deleted, inserted, or substituted. Also, analogs of the NGM-like polypeptides of the invention embrace fusions of the NGM-like polypeptides or modifications of the NGM-like polypeptides, wherein the NGM-like polypeptide or analog is fused to another moiety or moieties, e.g., targeting moiety or another therapeutic agent. Such analogs may exhibit improved properties such as activity and/or stability. Examples of moieties which may be fused to the NGM-like polypeptide or an analog include, for example, targeting moieties which provide for the delivery of polypeptide to neurons, e.g., antibodies to central nervous system, or antibodies to receptor and ligands expressed on neuronal cells. Other moieties which may be fused to NGM-like polypeptide include therapeutic agents which are used for treatment, for example anti-depressant drugs or other medications for neurological disorders. Also, NGM-like polypeptides may be fused to neuron growth modulators, and other chemokines for targeted delivery.

#### 25 5.6.1 DETERMINING POLYPEPTIDE AND POLYNUCLEOTIDE IDENTITY AND SIMILARITY

[0145] Preferred identity and/or similarity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in computer programs including, but are not limited to, the GCG program package, including GAP (Devereux, J., et al., Nucleic Acids Research 12(1):387 (1984); Genetics Computer Group, University of Wisconsin, Madison, WI), BLASTP, BLASTN, BLASTX, FASTA (Altschul, S.F. et al., J. Molec. Biol. 215:403-410 (1990), PSI-BLAST (Altschul S.F. et al., Nucleic Acids Res. vol. 25, pp. 3389-3402, herein incorporated by reference), the eMatrix software (Wu et al., J. Comp. Biol., vol. 6, pp. 219-235 (1999), herein incorporated by reference), emotif software (Nevill-Manning et al, ISMB-97, vol 4, pp. 202-209, herein incorporated by reference), the GeneAtlas software (Molecular Simulations Inc. (MSI), San Diego, CA) (Sanchez and Sali (1998) Proc. Natl. Acad. Sci., 95, 13597-13602; Kitson DH et al, (2000) "Remote homology detection using structural modeling - an evaluation" Submitted; Fischer and Eisenberg (1996) Protein Sci. 5, 947-955), Neural Network SignalP V1.1 program (from Center for Biological Sequence Analysis, The Technical University of Denmark) and the Kyte-Doolittle hydrophobicity prediction algorithm (J. Mol Biol, 157, pp. 105-31 (1982), incorporated herein by reference). The BLAST programs are publicly available from the National Center for Biotechnology Information (NCBI) and other sources (BLAST Manual, Altschul, S., et al. NCB NLM NIH Bethesda, MD 20894; Altschul, S., et al., J. Mol. Biol. 215:403-410 (1990).

#### 5.7 CHIMERIC AND FUSION PROTEINS

[0146] The invention also provides chimeric or fusion proteins. As used herein, a "chimeric protein" or "fusion protein" comprises a polypeptide of the invention operatively linked to another polypeptide. Within a fusion protein the polypeptide according to the invention can correspond to all or a portion of a protein according to the invention. In one embodiment, a fusion protein comprises at least one biologically active portion of a protein according to the invention. In another embodiment, a fusion protein comprises at least two biologically active portions of a protein according to the invention. Within the fusion protein, the term "operatively linked" is intended to indicate that the polypeptide according to the invention and the other polypeptide are fused in-frame to each other. The polypeptide can be fused to the N-terminus or C-terminus, or to the middle.

[0147] For example, in one embodiment a fusion protein comprises a polypeptide according to the invention operably linked to the extracellular domain of a second protein.

[0148] In another embodiment, the fusion protein is a GST-fusion protein in which the polypeptide sequences of the invention are fused to the C-terminus of the GST (i.e., glutathione S-transferase) sequences.

[0149] In another embodiment, the fusion protein is an immunoglobulin fusion protein in which the polypeptide sequences according to the invention comprise one or more domains fused to sequences derived from a member of the immunoglobulin protein family. The immunoglobulin fusion proteins of the invention can be incorporated into pharma-

ceutical compositions and administered to a subject to inhibit an interaction between a ligand and a protein of the invention on the surface of a cell, to thereby suppress signal transduction *in vivo*. The immunoglobulin fusion proteins can be used to affect the bioavailability of a cognate ligand. Inhibition of the ligand/protein interaction may be useful therapeutically for both the treatment of proliferative and differentiative disorders, e.g., cancer as well as modulating (e.g., promoting or inhibiting) cell survival. Moreover, the immunoglobulin fusion proteins of the invention can be used as immunogens to produce antibodies in a subject, to purify ligands, and in screening assays to identify molecules that inhibit the interaction of a polypeptide of the invention with a ligand.

[0150] A chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, e.g., by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive gene fragments that can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, Ausubel et al. (eds.) CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). A nucleic acid encoding a polypeptide of the invention can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the protein of the invention.

## 5.8 GENE THERAPY

[0151] Mutations in the polynucleotides of the invention gene may result in loss of normal function of the encoded protein. The invention thus provides gene therapy to restore normal activity of the polypeptides of the invention; or to treat disease states involving polypeptides of the invention. Delivery of a functional gene encoding polypeptides of the invention to appropriate cells is effected *ex vivo*, *in situ*, or *in vivo* by use of vectors, and more particularly viral vectors (e.g., adenovirus, adeno-associated virus, or a retrovirus), or *ex vivo* by use of physical DNA transfer methods (e.g., liposomes or chemical treatments). See, for example, Anderson, *Nature*, supplement to vol. 392, no. 6679, pp.25-20 (1998). For additional reviews of gene therapy technology see Friedmann, *Science*, 244: 1275-1281 (1989); Verma, *Scientific American*: 68-84 (1990); and Miller, *Nature*, 357: 455-460 (1992). Introduction of any one of the nucleotides of the present invention or a gene encoding the polypeptides of the present invention can also be accomplished with extrachromosomal substrates (transient expression) or artificial chromosomes (stable expression). Cells may also be cultured *ex vivo* in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced *in vivo* for therapeutic purposes. Alternatively, it is contemplated that in other human disease states, preventing the expression of or inhibiting the activity of polypeptides of the invention will be useful in treating the disease states. It is contemplated that antisense therapy or gene therapy could be applied to negatively regulate the expression of polypeptides of the invention.

[0152] Other methods inhibiting expression of a protein include the introduction of antisense molecules to the nucleic acids of the present invention, their complements, or their translated RNA sequences, by methods known in the art. Further, the polypeptides of the present invention can be inhibited by using targeted deletion methods, or the insertion of a negative regulatory element such as a silencer, which is tissue specific.

[0153] The present invention still further provides cells genetically engineered *in vivo* to express the polynucleotides of the invention, wherein such polynucleotides are in operative association with a regulatory sequence heterologous to the host cell which drives expression of the polynucleotides in the cell. These methods can be used to increase or decrease the expression of the polynucleotides of the present invention.

[0154] Knowledge of DNA sequences provided by the invention allows for modification of cells to permit, increase, or decrease, expression of endogenous polypeptide. Cells can be modified (e.g., by homologous recombination) to provide increased polypeptide expression by replacing, in whole or in part, the naturally occurring promoter with all or part of a heterologous promoter so that the cells express the protein at higher levels. The heterologous promoter is inserted in such a manner that it is operatively linked to the desired protein encoding sequences. See, for example, PCT International Publication No. WO 94/12650, PCT International Publication No. WO 92/20808, and PCT International Publication No. WO 91/09955. It is also contemplated that, in addition to heterologous promoter DNA, amplifiable marker DNA (e.g., ada, dhfr, and the multifunctional CAD gene which encodes carbamyl phosphate synthase, aspartate transcarbamylase, and dihydroorotase) and/or intron DNA may be inserted along with the heterologous promoter DNA. If linked to the desired protein coding sequence, amplification of the marker DNA by standard selection methods results in co-amplification of the desired protein coding sequences in the cells.

[0155] In another embodiment of the present invention, cells and tissues may be engineered to express an endogenous gene comprising the polynucleotides of the invention under the control of inducible regulatory elements, in which

case the regulatory sequences of the endogenous gene may be replaced by homologous recombination. As described herein, gene targeting can be used to replace a gene's existing regulatory region with a regulatory sequence isolated from a different gene or a novel regulatory sequence synthesized by genetic engineering methods. Such regulatory sequences may be comprised of promoters, enhancers, scaffold-attachment regions, negative regulatory elements, transcriptional initiation sites, regulatory protein binding sites or combinations of said sequences. Alternatively, sequences which affect the structure or stability of the RNA or protein produced may be replaced, removed, added, or otherwise modified by targeting. These sequences include polyadenylation signals, mRNA stability elements, splice sites, leader sequences for enhancing or modifying transport or secretion properties of the protein, or other sequences which alter or improve the function or stability of protein or RNA molecules.

[0156] The targeting event may be a simple insertion of the regulatory sequence, placing the gene under the control of the new regulatory sequence, e.g., inserting a new promoter or enhancer or both upstream of a gene. Alternatively, the targeting event may be a simple deletion of a regulatory element, such as the deletion of a tissue-specific negative regulatory element. Alternatively, the targeting event may replace an existing element; for example, a tissue-specific enhancer can be replaced by an enhancer that has broader or different cell-type specificity than the naturally occurring elements. Here, the naturally occurring sequences are deleted and new sequences are added. In all cases, the identification of the targeting event may be facilitated by the use of one or more selectable marker genes that are contiguous with the targeting DNA, allowing for the selection of cells in which the exogenous DNA has integrated into the cell genome. The identification of the targeting event may also be facilitated by the use of one or more marker genes exhibiting the property of negative selection, such that the negatively selectable marker is linked to the exogenous DNA, but configured such that the negatively selectable marker flanks the targeting sequence, and such that a correct homologous recombination event with sequences in the host cell genome does not result in the stable integration of the negatively selectable marker. Markers useful for this purpose include the Herpes Simplex Virus thymidine kinase (TK) gene or the bacterial xanthine-guanine phosphoribosyl-transferase (gpt) gene.

[0157] The gene targeting or gene activation techniques which can be used in accordance with this aspect of the invention are more particularly described in U.S. Patent No. 5,272,071 to Chappel; U.S. Patent No. 5,578,461 to Sherwin et al.; International Application No. PCT/US92/09627 (WO93/09222) by Selden et al.; and International Application No. PCT/US90/06436 (WO91/06667) by Skoultschi et al., each of which is incorporated by reference herein in its entirety.

## 5.9 TRANSGENIC ANIMALS

[0158] In preferred methods to determine biological functions of the polypeptides of the invention *in vivo*, one or more genes provided by the invention are either over expressed or inactivated in the germ line of animals using homologous recombination [Capecci, *Science* 244:1288-1292 (1989)]. Animals in which the gene is over expressed, under the regulatory control of exogenous or endogenous promoter elements, are known as transgenic animals. Animals in which an endogenous gene has been inactivated by homologous recombination are referred to as "knockout" animals. Knockout animals, preferably non-human mammals, can be prepared as described in U.S. Patent No. 5,557,032, incorporated herein by reference. Transgenic animals are useful to determine the roles polypeptides of the invention play in biological processes, and preferably in disease states. Transgenic animals are useful as model systems to identify compounds that modulate lipid metabolism. Transgenic animals, preferably non-human mammals, are produced using methods as described in U.S. Patent No. 5,489,743 and PCT Publication No. WO94/28122, incorporated herein by reference.

[0159] Transgenic animals can be prepared wherein all or part of a promoter of the polynucleotides of the invention is either activated or inactivated to alter the level of expression of the polypeptides of the invention. Inactivation can be carried out using homologous recombination methods described above. Activation can be achieved by supplementing or even replacing the homologous promoter to provide for increased protein expression. The homologous promoter can be supplemented by insertion of one or more heterologous enhancer elements known to confer promoter activation in a particular tissue.

[0160] The polynucleotides of the present invention also make possible the development, through, e.g., homologous recombination or knock out strategies; of animals that fail to express functional NGM-like polypeptide or that express a variant of NGM-like polypeptide. Such animals are useful as models for studying the *in vivo* activities of NGM-like polypeptides as well as for studying modulators of the NGM-like polypeptides.

## 5.10 USES AND BIOLOGICAL ACTIVITY OF HUMAN NGM-LIKE POLYPEPTIDES

[0161] The polynucleotides and proteins of the present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified herein. Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA). The mechanism underlying the particular condition or pathology will dictate whether the polypeptides of the invention, the

polynucleotides of the invention or modulators (activators or inhibitors) thereof would be beneficial to the subject in need of treatment. Thus, "therapeutic compositions of the invention" include compositions comprising isolated polynucleotides (including recombinant DNA molecules, cloned genes and degenerate variants thereof) or polypeptides of the invention (including full length protein, mature protein and truncations or domains thereof), or compounds and other substances that modulate the overall activity of the target gene products, either at the level of target gene/protein expression or target protein activity. Such modulators include polypeptides, analogs, (variants), including fragments and fusion proteins, antibodies and other binding proteins; chemical compounds that directly or indirectly activate or inhibit the polypeptides of the invention (identified, e.g., via drug screening assays as described herein); antisense polynucleotides and polynucleotides suitable for triple helix formation; and in particular antibodies or other binding partners that specifically recognize one or more epitopes of the polypeptides of the invention.

[0162] The polypeptides of the present invention may likewise be involved in cellular activation or in one of the other physiological pathways described herein.

#### 5.10.1 RESEARCH USES AND UTILITIES

[0163] The polynucleotides provided by the present invention can be used by the research community for various purposes. The polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; as a probe to "subtract-out" known sequences in the process of discovering other novel polynucleotides; for selecting and making oligomers for attachment to a "gene chip" or other support, including for examination of expression patterns; to raise anti-protein antibodies using DNA immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the polynucleotide can also be used in interaction trap assays (such as, for example, that described in Gyuris et al., *Cell* 75:791-803 (1993)) to identify polynucleotides encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction.

[0164] The polypeptides provided by the present invention can similarly be used in assays to determine biological activity, including in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues in which the corresponding polypeptide is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.

[0165] The polypeptides of the invention are also useful for making antibody substances that are specifically immunoreactive with NGM-like proteins. Antibodies and portions thereof (e.g., Fab fragments) which bind to the polypeptides of the invention can be used to identify the presence of such polypeptides in a sample. Such determinations are carried out using any suitable immunoassay format, and any polypeptide of the invention that is specifically bound by the antibody can be employed as a positive control.

[0166] Any or all of these research utilities are capable of being developed into reagent grade or kit format for commercialization as research products.

[0167] Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include without limitation "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E. F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S. L. and A. R. Kimmel eds., 1987.

#### 5.10.2 NUTRITIONAL USES

[0168] Polynucleotides and polypeptides of the present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate. In such cases the polypeptide or polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules. In the case of microorganisms, the polypeptide or polynucleotide of the invention can be added to the medium in or on which the microorganism is cultured.

[0169] Additionally, the polypeptides of the invention can be used as molecular weight markers, and as a food supplement. A polypeptide consisting of SEQ ID NO: 3, for example, has a molecular mass of approximately 70 kDa in its

unprocessed and unglycosylated state. Protein food supplements are well known and the formulation of suitable food supplements including polypeptides of the invention is within the level of skill in the food preparation art.

#### 5.10.3 CYTOKINE AND CELL PROLIFERATION/DIFFERENTIATION ACTIVITY

5

[0170] A polypeptide of the present invention may exhibit activity relating to cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations. A polynucleotide of the invention can encode a polypeptide exhibiting such attributes. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor-dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of therapeutic compositions of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+ (preB M+), 2E8, RB5, DA1, 123, T1165, HT2, CTLL2, TF-1, Mo7e, CMK, HUVEC, and Caco. Therapeutic compositions of the invention can be used in the following:

10

[0171] Assays for T-cell or thymocyte proliferation include without limitation those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, *In Vitro* assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Bertagnolli et al., J. Immunol. 145: 1706-1712, 1990; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Bertagnolli, et al., I. Immunol. 149: 3778-3783, 1992; Bowman et al., I. Immunol. 152:1756-1761, 1994.

15

[0172] Assays for cytokine production and/or proliferation of spleen cells, lymph node cells or thymocytes include, without limitation, those described in: Polyclonal T cell stimulation, Kruisbeek, A. M. and Shevach, E. M. In Current Protocols in Immunology. J. E. e.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human interleukin-γ, Schreiber, R. D. In Current Protocols in Immunology. J. E. e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994.

20

[0173] Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: Measurement of Human and Murine Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L. S. and Lipsky, P. E. In Current Protocols in Immunology. J. E. e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; deVries et al., J. Exp. Med. 173:1205-1211, 1991; Moreau et al., Nature 336:690-692, 1988; Greenberger et al., Proc. Natl. Acad. Sci. U.S.A. 80:2931-2938, 1983; Measurement of mouse and human interleukin 6-Nordan, R. In Current Protocols in Immunology. J. E. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto. 1991; Smith et al., Proc. Natl. Acad. Sci. U.S.A. 83:1857-1861, 1986; Measurement of human Interleukin 11-Bennett, F., Giannotti, J., Clark, S. C. and Turner, K. J. In Current Protocols in Immunology. J. E. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991; Measurement of mouse and human Interleukin 9-Ciarletta, A., Giannotti, J., Clark, S. C. and Turner, K. J. In Current Protocols in Immunology. J. E. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991.

25

[0174] Assays for T-cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, *In Vitro* assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger et al., Proc. Natl. Acad. Sci. USA 77:6091-6095, 1980; Weinberger et al., Eur. J. Immun. 11: 405-411, 1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988.

30

#### 5.10.4 STEM CELL GROWTH FACTOR ACTIVITY

35

[0175] A polypeptide of the present invention may exhibit stem cell growth factor activity and be involved in the proliferation, differentiation and survival of pluripotent and totipotent stem cells including primordial germ cells, embryonic stem cells, hematopoietic stem cells and/or germ line stem cells. Administration of the polypeptide of the invention to stem cells *in vivo* or *ex vivo* may maintain and expand cell populations in a totipotential or pluripotential state which would be useful for re-engineering damaged or diseased tissues, transplantation, manufacture of bio-pharmaceuticals and the development of bio-sensors. The ability to produce large quantities of human cells has important working applications for the production of human proteins which currently must be obtained from non-human sources or donors, implantation of cells to treat diseases such as Parkinson's, Alzheimer's and other neurodegenerative diseases; tissues for grafting such as bone marrow, skin, cartilage, tendons, bone, muscle (including cardiac muscle), blood vessels, cornea, neural cells, gastrointestinal cells and others; and organs for transplantation such as kidney, liver, pancreas (including islet cells), heart and lung.

40

[0176] It is contemplated that multiple different exogenous growth factors and/or cytokines may be administered in

combination with the polypeptide of the invention to achieve the desired effect, including any of the growth factors listed herein, other stem cell maintenance factors, and specifically including stem cell factor (SCF), leukemia inhibitory factor (LIF), Flt-3 ligand (Flt-3L), any of the interleukins, recombinant soluble IL-6 receptor fused to IL-6, macrophage inflammatory protein 1-alpha (MIP-1-alpha), G-CSF, GM-CSF, thrombopoietin (TPO), platelet factor 4 (PF-4), platelet-derived growth factor (PDGF), neural growth factors and basic fibroblast growth factor (bFGF).

[0177] Since totipotent stem cells can give rise to virtually any mature cell type, expansion of these cells in culture will facilitate the production of large quantities of mature cells. Techniques for culturing stem cells are known in the art and administration of polypeptides of the invention, optionally with other growth factors and/or cytokines, is expected to enhance the survival and proliferation of the stem cell populations. This can be accomplished by direct administration of the polypeptide of the invention to the culture medium. Alternatively, stroma cells transfected with a polynucleotide that encodes for the polypeptide of the invention can be used as a feeder layer for the stem cell populations in culture or *in vivo*. Stromal support cells for feeder layers may include embryonic bone marrow fibroblasts, bone marrow stromal cells, fetal liver cells, or cultured embryonic fibroblasts (see U.S. Patent No. 5,690,926).

[0178] Stem cells themselves can be transfected with a polynucleotide of the invention to induce autocrine expression of the polypeptide of the invention. This will allow for generation of undifferentiated totipotential/pluripotential stem cell lines that are useful as is or that can then be differentiated into the desired mature cell types. These stable cell lines can also serve as a source of undifferentiated totipotential/pluripotential mRNA to create cDNA libraries and templates for polymerase chain reaction experiments. These studies would allow for the isolation and identification of differentially expressed genes in stem cell populations that regulate stem cell proliferation and/or maintenance.

[0179] Expansion and maintenance of totipotent stem cell populations will be useful in the treatment of many pathological conditions. For example, polypeptides of the present invention may be used to manipulate stem cells in culture to give rise to neuroepithelial cells that can be used to augment or replace cells damaged by illness, autoimmune disease, accidental damage or genetic disorders. The polypeptide of the invention may be useful for inducing the proliferation of neural cells and for the regeneration of nerve and brain tissue, i.e. for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders which involve degeneration, death or trauma to neural cells or nerve tissue. In addition, the expanded stem cell populations can also be genetically altered for gene therapy purposes and to decrease host rejection of replacement tissues after grafting or implantation.

[0180] Expression of the polypeptide of the invention and its effect on stem cells can also be manipulated to achieve controlled differentiation of the stem cells into more differentiated cell types. A broadly applicable method of obtaining pure populations of a specific differentiated cell type from undifferentiated stem cell populations involves the use of a cell-type specific promoter driving a selectable marker. The selectable marker allows only cells of the desired type to survive. For example, stem cells can be induced to differentiate into cardiomyocytes (Wobus et al., *Differentiation*, 48: 173-182, (1991); Klug et al., *J. Clin. Invest.*, 98(1): 216-224, (1998)) or skeletal muscle cells (Browder, L. W. In: *Principles of Tissue Engineering* eds. Lanza et al., Academic Press (1997)). Alternatively, directed differentiation of stem cells can be accomplished by culturing the stem cells in the presence of a differentiation factor such as retinoic acid and an antagonist of the polypeptide of the invention which would inhibit the effects of endogenous stem cell factor activity and allow differentiation to proceed.

[0181] *In vitro* cultures of stem cells can be used to determine if the polypeptide of the invention exhibits stem cell growth factor activity. Stem cells are isolated from any one of various cell sources (including hematopoietic stem cells and embryonic stem cells) and cultured on a feeder layer, as described by Thompson et al. *Proc. Natl. Acad. Sci. U. S.A.*, 92: 7844-7848 (1995), in the presence of the polypeptide of the invention alone or in combination with other growth factors or cytokines. The ability of the polypeptide of the invention to induce stem cells proliferation is determined by colony formation on semi-solid support e.g. as described by Bernstein et al., *Blood*, 77: 2316-2321 (1991).

#### 5.10.5 HEMATOPOIESIS REGULATING ACTIVITY

[0182] A polypeptide of the present invention may be involved in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell disorders. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional circulating soluble factor activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all

of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either *in-vivo* or *ex-vivo* (i.e., in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy.

5 [0183] Therapeutic compositions of the invention can be used in the following:

[0184] Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.

[0185] Assays for embryonic stem cell differentiation (which will identify, among others, proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson et al. *Cellular Biology* 15:141-151, 1995; Keller et al., *Molecular and Cellular Biology* 13:473-486, 1993; McClanahan et al., *Blood* 81: 2903-2915, 1993.

[0186] Assays for stem cell survival and differentiation (which will identify, among others, proteins that regulate lympho-hematopoiesis) include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M. G. In *Culture of Hematopoietic Cells*. R. I. Freshney, et al. eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, N.Y. 1994; Hirayama et al., *Proc. Natl. Acad. Sci. USA* 89:5907-5911, 1992; Primitive hematopoietic colony forming cells with high proliferative potential, McNiece, I. K. and Briddell, R. A. In *Culture of Hematopoietic Cells*. R. I. Freshney, et al. eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, N.Y. 1994; Neben et al., *Experimental Hematology* 22:353-359, 1994; Cobblestone area forming cell assay, Ploemacher, R. E. In *Culture of Hematopoietic Cells*. R. I. Freshney, et al. eds. Vol pp. 1-21, Wiley-Liss, Inc., New York, N.Y. 1994; Long term bone marrow cultures in the presence of stromal cells,

10 Spooncer, E., Dexter, M. and Allen, T. In *Culture of Hematopoietic Cells*. R. I. Freshney, et al. eds. Vol pp. 163-179, Wiley-Liss, Inc., New York, N.Y. 1994; Long term culture initiating cell assay, Sutherland, H. J. In *Culture of Hematopoietic Cells*. R. I. Freshney, et al. eds. Vol pp. 139-162, Wiley-Liss, Inc., New York, N.Y. 1994.

#### 5.10.6 TISSUE GROWTH ACTIVITY

25 [0187] A polypeptide of the present invention also may be involved in bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as in wound healing and tissue repair and replacement, and in healing of burns, incisions and ulcers.

[0188] A polypeptide of the present invention which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals. Compositions of a polypeptide, antibody, binding partner, or other modulator of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. *De novo* bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.

[0189] A polypeptide of this invention may also be involved in attracting bone-forming cells, stimulating growth of bone-forming cells, or inducing differentiation of progenitors of bone-forming cells. Treatment of osteoporosis, osteoarthritis, bone degenerative disorders, or periodontal disease, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes may also be possible using the composition of the invention.

[0190] Another category of tissue regeneration activity that may involve the polypeptide of the present invention is tendon/ligament formation. Induction of tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue.

40 De *novo* tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors *ex vivo* for return *in vivo* to effect tissue repair. The compositions of the invention may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.

[0191] The compositions of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, i.e. for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, a composition may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous sys-

tem diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a composition of the invention.

5 [0192] Compositions of the invention may also be useful to promote better or faster closure of non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.

10 [0193] Compositions of the present invention may also be involved in the generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation of fibrotic scarring may allow normal tissue to regenerate. A polypeptide of the present invention may also exhibit angiogenic activity.

15 [0194] A composition of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.

[0195] A composition of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.

[0196] Therapeutic compositions of the invention can be used in the following:

20 [0197] Assays for tissue generation activity include, without limitation, those described in: International Patent Publication No. WO95/16035 (bone, cartilage, tendon); International Patent Publication No. WO95/05846 (nerve, neuronal); International Patent Publication No. WO91/07491 (skin, endothelium).

[0198] Assays for wound healing activity include, without limitation, those described in: Winter, Epidermal Wound Healing, pp. 71-112 (Maibach, H. I. and Rovee, D. T., eds.), Year Book Medical Publishers, Inc., Chicago, as modified by Eaglstein and Mertz, J. Invest. Dermatol 71:382-84 (1978).

#### 25 5.10.7 IMMUNE FUNCTION STIMULATING OR SUPPRESSING ACTIVITY

[0199] A polypeptide of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein. A polynucleotide of the invention can 30 encode a polypeptide exhibiting such activities. A protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SCID)), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral (e.g., HTV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases causes by viral, bacterial, fungal or 35 other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpes viruses, mycobacteria, Leishmania spp., malaria spp. and various fungal infections such as candidiasis. Of course, in this regard, proteins of the present invention may also be useful where a boost to the immune system generally may be desirable, i.e., in the treatment of cancer.

[0200] Autoimmune disorders which may be treated using a protein of the present invention include, for example, 40 connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitus, myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease. Such a protein (or antagonists thereof, including antibodies) of the present invention may also to be useful in the treatment of allergic reactions and conditions (e.g., anaphylaxis, serum sickness, drug reactions, food allergies, insect venom allergies, mastocytosis, allergic rhinitis, 45 hypersensitivity pneumonitis, urticaria, angioedema, eczema, atopic dermatitis, allergic contact dermatitis, erythema multiforme, Stevens-Johnson syndrome, allergic conjunctivitis, atopic keratoconjunctivitis, venereal keratoconjunctivitis, giant papillary conjunctivitis and contact allergies), such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for example, organ transplantation), may also be treatable using a protein (or antagonists thereof) of the present invention. The therapeutic effects of the 50 polypeptides or antagonists thereof on allergic reactions can be evaluated by in vivo animals models such as the cumulative contact enhancement test (Lastbom et al., Toxicology 125: 59-66, 1998), skin prick test (Hoffmann et al., Allergy 54: 446-54, 1999), guinea pig skin sensitization test (Vohr et al., Arch. Toxicol. 73: 501-9), and murine local lymph node assay (Kimber et al., J. Toxicol. Environ. Health 53: 563-79).

[0201] Using the proteins of the invention it may also be possible to modulate immune responses, in a number of 55 ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an immune response. The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppres-

sive agent. Tolerance, which involves inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.

5 [0202] Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such as, for example, B7)), e.g., preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune 10 reaction that destroys the transplant. The administration of a therapeutic composition of the invention may prevent cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, a lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these 15 blocking reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens.

20 [0203] The efficacy of particular therapeutic compositions in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins *in vivo* as described in Lenschow et al., *Science* 257:789-792 (1992) and Turka et al., *Proc. Natl. Acad. Sci USA*, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul ed., *Fundamental Immunology*, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of therapeutic compositions of the invention on the development of that disease.

25 [0204] Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms. Administration of reagents which block stimulation of T cells can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents 30 in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythematosus in MRL/lpr/lpr mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., *Fundamental Immunology*, Raven Press, New York, 1989, pp. 840-856).

35 [0205] Upregulation of an antigen function (e.g., a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response may be useful in cases of viral infection, including systemic viral diseases such as influenza, the common cold, and encephalitis.

40 [0206] Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells *in vitro* with viral antigen-pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the *in vitro* activated T cells into the patient. Another method of enhancing anti-viral immune responses would be to isolate infected 45 cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells *in vivo*.

50 [0207] A polypeptide of the present invention may provide the necessary stimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient mounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (e.g., a cytoplasmic-domain truncated portion) of an MHC class I alpha chain protein and  $\beta_2$  microglobulin protein or an MHC class II alpha chain protein and an MHC class II beta chain protein to thereby express MHC class I or MHC class II proteins on the cell surface. Expression of the appropriate class I or class II MHC in conjunction with a peptide having the activity of a B lymphocyte antigen (e.g., B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected tumor cell. Optionally, a gene 55 encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell

mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.

[0208] The activity of a protein of the invention may, among other means, be measured by the following methods:

[0209] Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Henmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Bowman et al., J. Virology 61: 1992-1998; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Brown et al., J. Immunol. 153:3079-3092, 1994.

[0210] Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Th1/Th2 profiles) include, without limitation, those described in: Maliszewski, J. Immunol. 144:3028-3033, 1990; and Assays for B cell function: In vitro antibody production, Mond, J. J. and Brunswick, M. In Current Protocols in Immunology. J. E. e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.

[0211] Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Th1 and CTL responses) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., J. Immunol. 149:3778-3783, 1992.

[0212] Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Experimental Medicine 173:549-559, 1991; Macatonia et al., Journal of Immunology 154: 5071-5079, 1995; Porgador et al., Journal of Experimental Medicine 182:255-260, 1995; Nair et al., Journal of Virology 67:4062-4069, 1993; Huang et al., Science 264:961-965, 1994; Macatonia et al., Journal of Experimental Medicine 169:1255-1264, 1989; Bhardwaj et al., Journal of Clinical Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640, 1990.

[0213] Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz et al., Cytometry 13:795-808, 1992; Gorczyca et al., Leukemia 7:659-670, 1993; Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991; Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al., Cytometry 14:891-897, 1993; Gorczyca et al., International Journal of Oncology 1:639-648, 1992.

[0214] Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., Blood 84:111-117, 1994; Fine et al., Cellular Immunology 155:111-122, 1994; Galy et al., Blood 85:2770-2778, 1995; Toki et al., Proc. Natl. Acad. Sci. USA 88:7548-7551, 1991.

#### 5.10.8 ACTIVIN/INHIBIN ACTIVITY

[0215] A polypeptide of the present invention may also exhibit activin- or inhibin-related activities. A polynucleotide of the invention may encode a polypeptide exhibiting such characteristics. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, a polypeptide of the present invention, alone or in heterodimers with a member of the inhibin family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively, the polypeptide of the invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary. See, for example, U.S. Pat. No. 4,798,885. A polypeptide of the invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as, but not limited to, cows, sheep and pigs.

[0216] The activity of a polypeptide of the invention may, among other means, be measured by the following methods.

[0217] Assays for activin/inhibin activity include, without limitation, those described in: Vale et al., Endocrinology 91: 562-572, 1972; Ling et al., Nature 321:779-782, 1986; Vale et al., Nature 321:776-779, 1986; Mason et al., Nature 318:659-663, 1985; Forage et al., Proc. Natl. Acad. Sci. USA 83:3091-3095, 1986.

## 5.10.9 CHEMOTACTIC/CHEMOKINETIC ACTIVITY

[0218] A polypeptide of the present invention may be involved in chemotactic or chemokinetic activity for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells. A polynucleotide of the invention can encode a polypeptide exhibiting such attributes. Chemotactic and chemokinetic receptor activation can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic compositions (e.g. proteins, antibodies, binding partners, or modulators of the invention) provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent.

[0219] A protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.

[0220] Therapeutic compositions of the invention can be used in the following:

[0221] Assays for chemotactic activity (which will identify proteins that induce or prevent chemotaxis) consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Marguiles, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta Chemokines 6.12.1-6.12.28; Taub et al. J. Clin. Invest. 95:1370-1376, 1995; Lind et al. APMIS 103:140-146, 1995; Muller et al Eur. J. Immunol. 25:1744-1748; Gruber et al. J. of Immunol. 152:5860-5867, 1994; Johnston et al. J. of Immunol. 153:1762-1768, 1994.

## 25 5.10.10 HEMOSTATIC AND THROMBOLYTIC ACTIVITY

[0222] A polypeptide of the invention may also be involved in hemostasis or thrombolysis or thrombosis. A polynucleotide of the invention can encode a polypeptide exhibiting such attributes. Compositions may be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A composition of the invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (e.g., stroke).

[0223] Therapeutic compositions of the invention can be used in the following:

[0224] Assay for hemostatic and thrombolytic activity include, without limitation, those described in: Linet et al., J. Clin. Pharmacol. 26:131-140, 1986; Burdick et al., Thrombosis Res. 45:413-419, 1987; Humphrey et al., Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins 35:467-474, 1988.

## 40 5.10.11 CANCER DIAGNOSIS AND THERAPY

[0225] Polypeptides of the invention may be involved in cancer cell generation, proliferation or metastasis. Detection of the presence or amount of polynucleotides or polypeptides of the invention may be useful for the diagnosis and/or prognosis of one or more types of cancer. For example, the presence or increased expression of a polynucleotide/polypeptide of the invention may indicate a hereditary risk of cancer, a precancerous condition, or an ongoing malignancy. Conversely, a defect in the gene or absence of the polypeptide may be associated with a cancer condition. Identification of single nucleotide polymorphisms associated with cancer or a predisposition to cancer may also be useful for diagnosis or prognosis.

[0226] Cancer treatments promote tumor regression by inhibiting tumor cell proliferation, inhibiting angiogenesis (growth of new blood vessels that is necessary to support tumor growth) and/or prohibiting metastasis by reducing tumor cell motility or invasiveness. Therapeutic compositions of the invention may be effective in adult and pediatric oncology including in solid phase tumors/malignancies, locally advanced tumors, human soft tissue sarcomas, metastatic cancer, including lymphatic metastases, blood cell malignancies including multiple myeloma, acute and chronic leukemias, and lymphomas, head and neck cancers including mouth cancer, larynx cancer and thyroid cancer, lung cancers including small cell carcinoma and non-small cell cancers, breast cancers including small cell carcinoma and ductal carcinoma, gastrointestinal cancers including esophageal cancer, stomach cancer, colon cancer, colorectal cancer and polyps associated with colorectal neoplasia, pancreatic cancers, liver cancer, urologic cancers including bladder cancer and prostate cancer, malignancies of the female genital tract including ovarian carcinoma, uterine (including endometrial) cancers, and solid tumor in the ovarian follicle, kidney cancers including renal cell carcinoma, brain can-

cers including intrinsic brain tumors, neuroblastoma, astrocytic brain tumors, gliomas, metastatic tumor cell invasion in the central nervous system, bone cancers including osteomas, skin cancers including malignant melanoma, tumor progression of human skin keratinocytes, squamous cell carcinoma, basal cell carcinoma, hemangiopericytoma and Karpesi's sarcoma.

5 [0227] Polypeptides, polynucleotides, or modulators of polypeptides of the invention (including inhibitors and stimulators of the biological activity of the polypeptide of the invention) may be administered to treat cancer. Therapeutic compositions can be administered in therapeutically effective dosages alone or in combination with adjuvant cancer therapy such as surgery, chemotherapy, radiotherapy, thermotherapy, and laser therapy, and may provide a beneficial effect, e.g. reducing tumor size, slowing rate of tumor growth, inhibiting metastasis, or otherwise improving overall  
10 clinical condition, without necessarily eradicating the cancer.

15 [0228] The composition can also be administered in therapeutically effective amounts as a portion of an anti-cancer cocktail. An anti-cancer cocktail is a mixture of the polypeptide or modulator of the invention with one or more anti-cancer drugs in addition to a pharmaceutically acceptable carrier for delivery. The use of anti-cancer cocktails as a cancer treatment is routine. Anti-cancer drugs that are well known in the art and can be used as a treatment in combination with the polypeptide or modulator of the invention include: Actinomycin D, Aminoglutethimide, Asparaginase, Bleomycin, Busulfan, Carboplatin, Carmustine, Chlorambucil, Cisplatin (cis-DDP), Cyclophosphamide, Cytarabine HCl (Cytosine arabinoside), Dacarbazine, Dactinomycin, Daunorubicin HCl, Doxorubicin HCl, Estramustine phosphate sodium, Etoposide (V16-213), Flouxuridine, 5-Fluorouracil (5-Fu), Flutamide, Hydroxyurea (hydroxycarbamide), Ifosamide, Interferon Alpha-2a, Interferon Alpha-2b, Leuprolide acetate (LHRH-releasing factor analog), Lomustine, Mechlorethamine HCl (nitrogen mustard), Melphalan, Mercaptopurine, Mesna, Methotrexate (MTX), Mitomycin, Mitoxantrone HCl, Octreotide, Plicamycin, Procarbazine HCl, Streptozocin, Tamoxifen citrate, Thioguanine, Thiotepa, Vinblastine sulfate, Vincristine sulfate, Amsacrine, Azacitidine, Hexamethylmelamine, Interleukin-2, Mitoguazone, Pentostatin, Se-mustine, Teniposide, and Vindesine sulfate.

20 [0229] In addition, therapeutic compositions of the invention may be used for prophylactic treatment of cancer. There  
25 are hereditary conditions and/or environmental situations (e.g. exposure to carcinogens) known in the art that predispose an individual to developing cancers. Under these circumstances, it may be beneficial to treat these individuals with therapeutically effective doses of the polypeptide of the invention to reduce the risk of developing cancers.

30 [0230] *In vitro* models can be used to determine the effective doses of the polypeptide of the invention as a potential cancer treatment. These *in vitro* models include proliferation assays of cultured tumor cells, growth of cultured tumor  
35 cells in soft agar (see Freshney, (1987) Culture of Animal Cells: A Manual of Basic Technique, Wiley-Liss, New York, NY Ch 18 and Ch 21), tumor systems in nude mice as described in Giovanella et al., J. Natl. Can. Inst., 52: 921-30 (1974), mobility and invasive potential of tumor cells in Boyden Chamber assays as described in Pilkington et al., Anticancer Res., 17: 4107-9 (1997), and angiogenesis assays such as induction of vascularization of the chick chorioallantoic membrane or induction of vascular endothelial cell migration as described in Ribatta et al., Intl. J. Dev. Biol., 40: 1189-97 (1999) and Li et al., Clin. Exp. Metastasis, 17:423-9 (1999), respectively. Suitable tumor cell lines are available, e.g. from American Type Tissue Culture Collection catalogs.

#### 5.10.12 RECEPTOR/LIGAND ACTIVITY

40 [0231] A polypeptide of the present invention may also demonstrate activity as receptor, receptor ligand or inhibitor or agonist of receptor/ligand interactions. A polynucleotide of the invention can encode a polypeptide exhibiting such characteristics. Examples of such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses. Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. A protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.

45 [0232] The activity of a polypeptide of the invention may, among other means, be measured by the following methods:

50 [0233] Suitable assays for receptor-ligand activity include without limitation those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 7.28, Measurement of Cellular Adhesion under static conditions 7.28.1-7.28.22), Takai et al., Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987; Bierer et al., J. Exp. Med. 168:1145-1156, 1988; Rosenstein et al., J. Exp. Med. 169:149-160 1989; Stoltenborg et al., J. Immunol. Methods 175:59-68, 1994; Stitt et al., Cell 80:661-670, 1995.

55 [0234] By way of example, the polypeptides of the invention may be used as a receptor for a ligand(s) thereby transmitting the biological activity of that ligand(s). Ligands may be identified through binding assays, affinity chromatography, dihybrid screening assays, BIAcore assays, gel overlay assays, or other methods known in the art.

[0235] Studies characterizing drugs or proteins as agonist, antagonist, partial agonist, or a partial antagonist require the use of other proteins as competing ligands. The polypeptides of the present invention or ligand(s) thereof may be labeled by being coupled to radioisotopes, colorimetric molecules or a toxin molecules by conventional methods. ("Guide to Protein Purification" Murray P. Deutscher (ed) Methods in Enzymology Vol. 182 (1990) Academic Press, Inc. San Diego). Examples of radioisotopes include, but are not limited to, tritium and carbon-14. Examples of colorimetric molecules include, but are not limited to, fluorescent molecules such as fluorescamine, or rhodamine or other colorimetric molecules. Examples of toxins include, but are not limited, to ricin.

#### 5.10.13 DRUG SCREENING

[0236] This invention is particularly useful for screening chemical compounds by using the novel polypeptides or binding fragments thereof in any of a variety of drug screening techniques. The polypeptides or fragments employed in such a test may either be free in solution, affixed to a solid support, borne on a cell surface or located intracellularly.

15 One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or a fragment thereof. Drugs are screened against such transformed cells in competitive binding assays. Such cells, either in viable or fixed form, can be used for standard binding assays. One may measure, for example, the formation of complexes between polypeptides of the invention or fragments and the agent being tested or examine the diminution in complex formation between the novel polypeptides and an appropriate cell line, which are well known in the art.

20 [0237] Sources for test compounds that may be screened for ability to bind to or modulate (i.e., increase or decrease) the activity of polypeptides of the invention include (1) inorganic and organic chemical libraries, (2) natural product libraries, and (3) combinatorial libraries comprised of either random or mimetic peptides, oligonucleotides or organic molecules.

25 [0238] Chemical libraries may be readily synthesized or purchased from a number of commercial sources, and may include structural analogs of known compounds or compounds that are identified as "hits" or "leads" via natural product screening.

30 [0239] The sources of natural product libraries are microorganisms (including bacteria and fungi), animals, plants or other vegetation, or marine organisms, and libraries of mixtures for screening may be created by: (1) fermentation and extraction of broths from soil, plant or marine microorganisms or (2) extraction of the organisms themselves. Natural product libraries include polyketides, non-ribosomal peptides, and (non-naturally occurring) variants thereof. For a review, see *Science* 282:63-68 (1998).

35 [0240] Combinatorial libraries are composed of large numbers of peptides, oligonucleotides or organic compounds and can be readily prepared by traditional automated synthesis methods, PCR, cloning or proprietary synthetic methods. Of particular interest are peptide and oligonucleotide combinatorial libraries. Still other libraries of interest include peptide, protein, peptidomimetic, multiparallel synthetic collection, recombinatorial, and polypeptide libraries. For a review of combinatorial chemistry and libraries created therefrom, see Myers, *Curr. Opin. Biotechnol.* 8:701-707 (1997). For reviews and examples of peptidomimetic libraries, see Al-Obeidi et al., *Mol. Biotechnol.* 9(3):205-23 (1998); Hruby et al., *Curr Opin Chem Biol.* 1(1):114-19 (1997); Dorner et al., *Bioorg Med Chem.* 4(5):709-15 (1996) (alkylated dipeptides).

40 [0241] Identification of modulators through use of the various libraries described herein permits modification of the candidate "hit" (or "lead") to optimize the capacity of the "hit" to bind a polypeptide of the invention. The molecules identified in the binding assay are then tested for antagonist or agonist activity in *in vivo* tissue culture or animal models that are well known in the art. In brief, the molecules are titrated into a plurality of cell cultures or animals and then tested for either cell/animal death or prolonged survival of the animal/cells.

45 [0242] The binding molecules thus identified may be complexed with toxins, e.g., ricin or cholera, or with other compounds that are toxic to cells such as radioisotopes. The toxin-binding molecule complex is then targeted to a tumor or other cell by the specificity of the binding molecule for a polypeptide of the invention. Alternatively, the binding molecules may be complexed with imaging agents for targeting and imaging purposes.

#### 50 5.10.14 ASSAY FOR RECEPTOR ACTIVITY

[0243] The invention also provides methods to detect specific binding of a polypeptide e.g. a ligand or a receptor. The art provides numerous assays particularly useful for identifying previously unknown binding partners for receptor polypeptides of the invention. For example, expression cloning using mammalian or bacterial cells, or dihybrid screening assays can be used to identify polynucleotides encoding binding partners. As another example, affinity chromatography with the appropriate immobilized polypeptide of the invention can be used to isolate polypeptides that recognize and bind polypeptides of the invention. There are a number of different libraries used for the identification of compounds, and in particular small molecule, that modulate (i. e., increase or decrease) biological activity of a polypep-

tide of the invention. Ligands for receptor polypeptides of the invention can also be identified by adding exogenous ligands, or cocktails of ligands to two cell populations that are genetically identical except for the expression of the receptor of the invention: one cell population expresses the receptor of the invention whereas the other does not. The response of the two cell populations to the addition of ligand(s) are then compared. Alternatively, an expression library can be co-expressed with the polypeptide of the invention in cells and assayed for an autocrine response to identify potential ligand(s). As still another example, BIAcore assays, gel overlay assays, or other methods known in the art can be used to identify binding partner polypeptides, including, (1) organic and inorganic chemical libraries, (2) natural product libraries, and (3) combinatorial libraries comprised of random peptides, oligonucleotides or organic molecules.

[0244] The role of downstream intracellular signaling molecules in the signaling cascade of the polypeptide of the invention can be determined. For example, a chimeric protein in which the cytoplasmic domain of the polypeptide of the invention is fused to the extracellular portion of a protein, whose ligand has been identified, is produced in a host cell. The cell is then incubated with the ligand specific for the extracellular portion of the chimeric protein, thereby activating the chimeric receptor. Known downstream proteins involved in intracellular signaling can then be assayed for expected modifications i.e. phosphorylation. Other methods known to those in the art can also be used to identify signaling molecules involved in receptor activity.

#### 5.10.15 ANTI-INFLAMMATORY ACTIVITY

[0245] Compositions of the present invention may also exhibit anti-inflammatory activity. The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response. Compositions with such activities can be used to treat inflammatory conditions including chronic or acute conditions, including without limitation intimation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting from over production of cytokines such as TNF or IL-1. Compositions of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material. Compositions of this invention may be utilized to prevent or treat conditions such as, but not limited to, sepsis, acute pancreatitis, endotoxin shock, cytokine induced shock, rheumatoid arthritis, chronic inflammatory arthritis, pancreatic cell damage from diabetes mellitus type 1, graft versus host disease, inflammatory bowel disease, inflammation associated with pulmonary disease, other autoimmune disease or inflammatory disease, an antiproliferative agent such as for acute or chronic myelogenous leukemia or in the prevention of premature labor secondary to intrauterine infections.

#### 5.10.16 LEUKEMIAS

[0246] Leukemias and related disorders may be treated or prevented by administration of a therapeutic that promotes or inhibits function of the polynucleotides and/or polypeptides of the invention. Such leukemias and related disorders include but are not limited to acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia, chronic leukemia, chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia (for a review of such disorders, see Fishman et al., 1985, Medicine, 2d Ed., J.B. Lippincott Co., Philadelphia).

#### 5.10.17 NERVOUS SYSTEM DISORDERS

[0247] Nervous system disorders, involving cell types which can be tested for efficacy of intervention with compounds that modulate the activity of the polynucleotides and/or polypeptides of the invention, and which can be treated upon thus observing an indication of therapeutic utility, include but are not limited to nervous system injuries, and diseases or disorders which result in either a disconnection of axons, a diminution or degeneration of neurons, or demyelination. Nervous system lesions which may be treated in a patient (including human and non-human mammalian patients) according to the invention include but are not limited to the following lesions of either the central (including spinal cord, brain) or peripheral nervous systems:

- 55 (i) traumatic lesions, including lesions caused by physical injury or associated with surgery, for example, lesions which sever a portion of the nervous system, or compression injuries;
- (ii) ischemic lesions, in which a lack of oxygen in a portion of the nervous system results in neuronal injury or death, including cerebral infarction or ischemia, or spinal cord infarction or ischemia;

- (iii) infectious lesions, in which a portion of the nervous system is destroyed or injured as a result of infection, for example, by an abscess or associated with infection by human immunodeficiency virus, herpes zoster, or herpes simplex virus or with Lyme disease, tuberculosis, syphilis;
- 5 (iv) degenerative lesions, in which a portion of the nervous system is destroyed or injured as a result of a degenerative process including but not limited to degeneration associated with Parkinson's disease, Alzheimer's disease, Huntington's chorea, or amyotrophic lateral sclerosis;
- (v) lesions associated with nutritional diseases or disorders, in which a portion of the nervous system is destroyed or injured by a nutritional disorder or disorder of metabolism including but not limited to, vitamin B12 deficiency, folic acid deficiency, Wernicke disease, tobacco-alcohol amblyopia, Marchiafava-Bignami disease (primary degeneration of the corpus callosum), and alcoholic cerebellar degeneration;
- 10 (vi) neurological lesions associated with systemic diseases including but not limited to diabetes (diabetic neuropathy, Bell's palsy), systemic lupus erythematosus, carcinoma, or sarcoidosis;
- (vii) lesions caused by toxic substances including alcohol, lead, or particular neurotoxins; and
- 15 (viii) demyelinated lesions in which a portion of the nervous system is destroyed or injured by a demyelinating disease including but not limited to multiple sclerosis, human immunodeficiency virus-associated myelopathy, transverse myelopathy or various etiologies, progressive multifocal leukoencephalopathy, and central pontine myelinolysis.

**[0248]** Therapeutics which are useful according to the invention for treatment of a nervous system disorder may be selected by testing for biological activity in promoting the survival or differentiation of neurons. For example, and not by way of limitation, therapeutics which elicit any of the following effects may be useful according to the invention:

- (i) increased survival time of neurons in culture;
- (ii) increased sprouting of neurons in culture or *in vivo*;
- 25 (iii) increased production of a neuron-associated molecule in culture or *in vivo*, e.g., choline acetyltransferase or acetylcholinesterase with respect to motor neurons; or
- (iv) decreased symptoms of neuron dysfunction *in vivo*.

**[0249]** Such effects may be measured by any method known in the art. In preferred, non-limiting embodiments, increased survival of neurons may be measured by the method set forth in Arakawa et al. (1990, *J. Neurosci.* 10: 3507-3515); increased sprouting of neurons may be detected by methods set forth in Pestronk et al. (1980, *Exp. Neurol.* 70:65-82) or Brown et al. (1981, *Ann. Rev. Neurosci.* 4:17-42); increased production of neuron-associated molecules may be measured by bioassay, enzymatic assay, antibody binding, Northern blot assay, etc., depending on the molecule to be measured; and motor neuron dysfunction may be measured by assessing the physical manifestation of motor neuron disorder, e.g., weakness, motor neuron conduction velocity, or functional disability.

**[0250]** In specific embodiments, motor neuron disorders that may be treated according to the invention include but are not limited to disorders such as infarction, infection, exposure to toxin, trauma, surgical damage, degenerative disease or malignancy that may affect motor neurons as well as other components of the nervous system, as well as disorders that selectively affect neurons such as amyotrophic lateral sclerosis, and including but not limited to progressive spinal muscular atrophy, progressive bulbar palsy, primary lateral sclerosis, infantile and juvenile muscular atrophy, progressive bulbar paralysis of childhood (Fazio-Londe syndrome), poliomyelitis and the post polio syndrome, and Hereditary Motorsensory Neuropathy (Charcot-Marie-Tooth Disease).

#### 5.10.18 OTHER ACTIVITIES

**[0251]** A polypeptide of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or circadian cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional factors or component(s); effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic lineages; hormonal or endocrine activity; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or

complement); and the ability to act as an antigen in a vaccine composition to raise an immune response against such protein or another material or entity which is cross-reactive with such protein.

#### 5.10.19 IDENTIFICATION OF POLYMORPHISMS

5 [0252] The demonstration of polymorphisms makes possible the identification of such polymorphisms in human subjects and the pharmacogenetic use of this information for diagnosis and treatment. Such polymorphisms may be associated with, e.g., differential predisposition or susceptibility to various disease states (such as disorders involving inflammation or immune response) or a differential response to drug administration, and this genetic information can  
10 be used to tailor preventive or therapeutic treatment appropriately. For example, the existence of a polymorphism associated with a predisposition to inflammation or autoimmune disease makes possible the diagnosis of this condition in humans by identifying the presence of the polymorphism.

15 [0253] Polymorphisms can be identified in a variety of ways known in the art which all generally involve obtaining a sample from a patient, analyzing DNA from the sample, optionally involving isolation or amplification of the DNA, and identifying the presence of the polymorphism in the DNA. For example, PCR may be used to amplify an appropriate fragment of genomic DNA which may then be sequenced. Alternatively, the DNA may be subjected to allele-specific oligonucleotide hybridization (in which appropriate oligonucleotides are hybridized to the DNA under conditions permitting detection of a single base mismatch) or to a single nucleotide extension assay (in which an oligonucleotide that hybridizes immediately adjacent to the position of the polymorphism is extended with one or more labeled nucleotides).  
20 In addition, traditional restriction fragment length polymorphism analysis (using restriction enzymes that provide differential digestion of the genomic DNA depending on the presence or absence of the polymorphism) may be performed. Arrays with nucleotide sequences of the present invention can be used to detect polymorphisms. The array can comprise modified nucleotide sequences of the present invention in order to detect the nucleotide sequences of the present invention. In the alternative, any one of the nucleotide sequences of the present invention can be placed on the array  
25 to detect changes from those sequences.

25 [0254] Alternatively a polymorphism resulting in a change in the amino acid sequence could also be detected by detecting a corresponding change in amino acid sequence of the protein, e.g., by an antibody specific to the variant sequence.

#### 30 5.10.20 ARTHRITIS AND INFLAMMATION

35 [0255] The immunosuppressive effects of the compositions of the invention against rheumatoid arthritis is determined in an experimental animal model system. The experimental model system is adjuvant induced arthritis in rats, and the protocol is described by J. Holoshitz, et al., 1983, *Science*, 219:56, or by B. Waksman et al., 1963, *Int. Arch. Allergy Appl. Immunol.*, 23:129. Induction of the disease can be caused by a single injection, generally intradermally, of a suspension of killed *Mycobacterium tuberculosis* in complete Freund's adjuvant (CFA). The route of injection can vary, but rats may be injected at the base of the tail with an adjuvant mixture. The polypeptide is administered in phosphate buffered solution (PBS) at a dose of about 1-5 mg/kg. The control consists of administering PBS only.

40 [0256] The procedure for testing the effects of the test compound would consist of intradermally injecting killed *Mycobacterium tuberculosis* in CFA followed by immediately administering the test compound and subsequent treatment every other day until day 24. At 14, 15, 18, 20, 22, and 24 days after injection of *Mycobacterium* CFA, an overall arthritis score may be obtained as described by J. Holoskitz above. An analysis of the data would reveal that the test compound would have a dramatic affect on the swelling of the joints as measured by a decrease of the arthritis score.

#### 45 5.11 THERAPEUTIC METHODS

50 [0257] The compositions (including polypeptide fragments, analogs, variants and antibodies or other binding partners or modulators including antisense polynucleotides) of the invention have numerous applications in a variety of therapeutic methods. Examples of therapeutic applications include, but are not limited to, those exemplified herein.

#### 5.11.1 EXAMPLE

55 [0258] One embodiment of the invention is the administration of an effective amount of the NGM-like polypeptides or other composition of the invention to individuals affected by a disease or disorder that can be modulated by regulating the peptides of the invention. While the mode of administration is not particularly important, parenteral administration is preferred. An exemplary mode of administration is to deliver an intravenous bolus. The dosage of NGM-like polypeptides or other composition of the invention will normally be determined by the prescribing physician. It is to be expected that the dosage will vary according to the age, weight, condition and response of the individual patient. Typically, the

amount of polypeptide administered per dose will be in the range of about 0.01 $\mu$ g/kg to 100 mg/kg of body weight, with the preferred dose being about 0.1 $\mu$ g/kg to 10 mg/kg of patient body weight. For parenteral administration, NGM-like polypeptides of the invention will be formulated in an injectable form combined with a pharmaceutically acceptable parenteral vehicle. Such vehicles are well known in the art and examples include water, saline, Ringer's solution, dextrose solution, and solutions consisting of small amounts of the human serum albumin. The vehicle may contain minor amounts of additives that maintain the isotonicity and stability of the polypeptide or other active ingredient. The preparation of such solutions is within the skill of the art.

## 5.12 PHARMACEUTICAL FORMULATIONS AND ROUTES OF ADMINISTRATION

[0259] A protein or other composition of the present invention (from whatever source derived, including without limitation from recombinant and non-recombinant sources and including antibodies and other binding partners of the polypeptides of the invention) may be administered to a patient in need, by itself, or in pharmaceutical compositions where it is mixed with suitable carriers or excipient(s) at doses to treat or ameliorate a variety of disorders. Such a composition may optionally contain (in addition to protein or other active ingredient and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient (s). The characteristics of the carrier will depend on the route of administration. The pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IFN, TNF0, TNF1, TNF2, G-CSF, Meg-CSF, thrombopoietin, stem cell factor, and erythropoietin. In further compositions, proteins of the invention may be combined with other agents beneficial to the treatment of the disease or disorder in question. These agents include various growth factors such as epidermal growth factor (EGF), platelet-derived growth factor (PDGF), transforming growth factors (TGF- $\alpha$  and TGF- $\beta$ ), insulin-like growth factor (IGF), as well as cytokines described herein.

[0260] The pharmaceutical composition may further contain other agents which either enhance the activity of the protein or other active ingredient or complement its activity or use in treatment. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with protein or other active ingredient of the invention, or to minimize side effects. Conversely, protein or other active ingredient of the present invention may be included in formulations of the particular clotting factor, cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent to minimize side effects of the clotting factor, cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent (such as IL-1Ra, IL-1 Hy1, IL-1 Hy2, anti-TNF, corticosteroids, immunosuppressive agents). A protein of the present invention may be active in multimers (e.g., heterodimers or homodimers) or complexes with itself or other proteins. As a result, pharmaceutical compositions of the invention may comprise a protein of the invention in such multimeric or complexed form.

[0261] As an alternative to being included in a pharmaceutical composition of the invention including a first protein, a second protein or a therapeutic agent may be concurrently administered with the first protein (e.g., at the same time, or at differing times provided that therapeutic concentrations of the combination of agents is achieved at the treatment site). Techniques for formulation and administration of the compounds of the instant application may be found in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, PA, latest edition. A therapeutically effective dose further refers to that amount of the compound sufficient to result in amelioration of symptoms, e.g., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. When applied to an individual active ingredient, administered alone, a therapeutically effective dose refers to that ingredient alone. When applied to a combination, a therapeutically effective dose refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.

[0262] In practicing the method of treatment or use of the present invention, a therapeutically effective amount of protein or other active ingredient of the present invention is administered to a mammal having a condition to be treated. Protein or other active ingredient of the present invention may be administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors. When co-administered with one or more cytokines, lymphokines or other hematopoietic factors, protein or other active ingredient of the present invention may be administered either simultaneously with the cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering protein or other active ingredient of the present invention in combination with cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors.

## 5.12.1 ROUTES OF ADMINISTRATION

[0263] Suitable routes of administration may, for example, include oral, rectal, transmucosal, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal,

5 direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections. Administration of protein or other active ingredient of the present invention used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, topical application or cutaneous, subcutaneous, intraperitoneal, parenteral or intravenous injection. Intravenous administration to the patient is preferred.

10 [0264] Alternately, one may administer the compound in a local rather than systemic manner, for example, via injection of the compound directly into a arthritic joints or in fibrotic tissue, often in a depot or sustained release formulation. In order to prevent the scarring process frequently occurring as complication of glaucoma surgery, the compounds may be administered topically, for example, as eye drops. Furthermore, one may administer the drug in a targeted drug delivery system, for example, in a liposome coated with a specific antibody, targeting, for example, arthritic or fibrotic tissue. The liposomes will be targeted to and taken up selectively by the afflicted tissue.

15 [0265] The polypeptides of the invention are administered by any route that delivers an effective dosage to the desired site of action. The determination of a suitable route of administration and an effective dosage for a particular indication is within the level of skill in the art. Preferably for wound treatment, one administers the therapeutic compound directly to the site. Suitable dosage ranges for the polypeptides of the invention can be extrapolated from these dosages or 20 from similar studies in appropriate animal models. Dosages can then be adjusted as necessary by the clinician to provide maximal therapeutic benefit.

## 5.12.2 COMPOSITIONS/FORMULATIONS

25 [0266] Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. These pharmaceutical compositions may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

30 Proper formulation is dependent upon the route of administration chosen. When a therapeutically effective amount of protein or other active ingredient of the present invention is administered orally, protein or other active ingredient of the present invention will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95 % protein or other active ingredient of the present 35 invention, and preferably from about 25 to 90 % protein or other active ingredient of the present invention. When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene 40 glycol, propylene glycol or polyethylene glycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of protein or other active ingredient of the present invention, and preferably from about 1 to 50% protein or other active ingredient of the present invention.

45 [0267] When a therapeutically effective amount of protein or other active ingredient of the present invention is administered by intravenous, cutaneous, or subcutaneous injection, protein or other active ingredient of the present invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein or other active ingredient solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to protein or other active ingredient of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The pharmaceutical composition of the present 50 invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art. For injection, the agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

55 [0268] For oral administration, the compounds can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. Pharmaceutical preparations for oral use can be obtained solid excipient, optionally grinding

a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

[0269] Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration. For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

[0270] For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch. The compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampules or in multidose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

[0271] Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

[0272] The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides. In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

[0273] A pharmaceutical carrier for the hydrophobic compounds of the invention is a co-solvent system comprising benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase. The co-solvent system may be the VPD co-solvent system. VPD is a solution of 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant polysorbate 80, and 65% w/v polyethylene glycol 300, made up to volume in absolute ethanol. The VPD co-solvent system (VPD:5W) consists of VPD diluted 1:1 with a 5% dextrose in water solution. This co-solvent system dissolves hydrophobic compounds well, and itself produces low toxicity upon systemic administration. Naturally, the proportions of a co-solvent system may be varied considerably without destroying its solubility and toxicity characteristics. Furthermore, the identity of the co-solvent components may be varied: for example, other low-toxicity nonpolar surfactants may be used instead of polysorbate 80; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g. polyvinyl pyrrolidone; and other sugars or polysaccharides may substitute for dextrose. Alternatively, other delivery systems for hydrophobic pharmaceutical compounds may be employed. Liposomes and emulsions are well known examples of delivery vehicles or carriers for hydrophobic drugs. Certain organic solvents such as dimethylsulfoxide also may be employed, although usually at the cost of greater toxicity. Additionally, the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various types of sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical

nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein or other active ingredient stabilization may be employed.

**[0274]** The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols. Many of the active ingredients of the invention may be provided as salts with pharmaceutically compatible counter ions. Such pharmaceutically acceptable base addition salts are those salts which retain the biological effectiveness and properties of the free acids and which are obtained by reaction with inorganic or organic bases such as sodium hydroxide, magnesium hydroxide, ammonia, trialkylamine, dialkylamine, monoalkylamine, dibasic amino acids, sodium acetate, potassium benzoate, triethanol amine and the like.

**[0275]** The pharmaceutical composition of the invention may be in the form of a complex of the protein(s) or other active ingredient of present invention along with protein or peptide antigens. The protein and/or peptide antigen will deliver a stimulatory signal to both B and T lymphocytes. B lymphocytes will respond to antigen through their surface immunoglobulin receptor. T lymphocytes will respond to antigen through the T cell receptor (TCR) following presentation of the antigen by MHC proteins. MHC and structurally related proteins including those encoded by class I and class II MHC genes on host cells will serve to present the peptide antigen(s) to T lymphocytes. The antigen components could also be supplied as purified MHC-peptide complexes alone or with co-stimulatory molecules that can directly signal T cells. Alternatively antibodies able to bind surface immunoglobulin and other molecules on B cells as well as antibodies able to bind the TCR and other molecules on T cells can be combined with the pharmaceutical composition of the invention.

**[0276]** The pharmaceutical composition of the invention may be in the form of a liposome in which protein of the present invention is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithins, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Patent Nos. 4,235,871; 4,501,728; 4,837,028; and 4,737,323, all of which are incorporated herein by reference.

**[0277]** The amount of protein or other active ingredient of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of protein or other active ingredient of the present invention with which to treat each individual patient. Initially, the attending physician will administer low doses of protein or other active ingredient of the present invention and observe the patient's response. Larger doses of protein or other active ingredient of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.01  $\mu$ g to about 100 mg (preferably about 0.1  $\mu$ g to about 10 mg, more preferably about 0.1  $\mu$ g to about 1 mg) of protein or other active ingredient of the present invention per kg body weight. For compositions of the present invention which are useful for bone, cartilage, tendon or ligament regeneration, the therapeutic method includes administering the composition topically, systematically, or locally as an implant or device. When administered, the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage or tissue damage. Topical administration may be suitable for wound healing and tissue repair. Therapeutically useful agents other than a protein or other active ingredient of the invention which may also optionally be included in the composition as described above, may alternatively or additionally, be administered simultaneously or sequentially with the composition in the methods of the invention. Preferably for bone and/or cartilage formation, the composition would include a matrix capable of delivering the protein-containing or other active ingredient-containing composition to the site of bone and/or cartilage damage, providing a structure for the developing bone and cartilage and optimally capable of being resorbed into the body. Such matrices may be formed of materials presently in use for other implanted medical applications.

**[0278]** The choice of matrix material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance, and interface properties. The particular application of the compositions will define the appropriate formulation. Potential matrices for the compositions may be biodegradable and chemically defined calcium sulfate, tricalcium phosphate, hydroxyapatite, polylactic acid, polyglycolic acid and polyanhydrides. Other potential materials are biodegradable and biologically well-defined, such as bone or dermal collagen. Further matrices are comprised of pure proteins or extracellular matrix components. Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxyapatite, bioglass, aluminates, or other ceramics. Matrices may be comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalcium

phosphate. The bioceramics may be altered in composition, such as in calcium-aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability. Presently preferred is a 50:50 (mole weight) co-polymer of lactic acid and glycolic acid in the form of porous particles having diameters ranging from 150 to 800 microns. In some applications, it will be useful to utilize a sequestering agent, such as carboxymethyl cellulose or autologous

5 blood clot, to prevent the protein compositions from disassociating from the matrix.

[0279] A preferred family of sequestering agents is cellulosic materials such as alkylcelluloses (including hydroxy-alkylcelluloses), including methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl-methylcellulose, and carboxymethylcellulose, the most preferred being cationic salts of carboxymethylcellulose (CMC). Other preferred sequestering agents include hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxo-10 yethylene oxide, carboxyvinyl polymer and poly(vinyl alcohol). The amount of sequestering agent useful herein is 0.5-20 wt %, preferably 1-10 wt % based on total formulation weight, which represents the amount necessary to prevent desorption of the protein from the polymer matrix and to provide appropriate handling of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells. In further compositions, proteins or other active ingredient of

15 the invention may be combined with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in question. These agents include various growth factors such as epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factors (TGF- $\alpha$  and TGF- $\beta$ ), and insulin-like growth factor (IGF).

[0280] The therapeutic compositions are also presently valuable for veterinary applications. Particularly domestic animals and thoroughbred horses, in addition to humans, are desired patients for such treatment with proteins or other 20 active ingredient of the present invention. The dosage regimen of a protein-containing pharmaceutical composition to be used in tissue regeneration will be determined by the attending physician considering various factors which modify the action of the proteins, e.g., amount of tissue weight desired to be formed, the site of damage, the condition of the damaged tissue, the size of a wound, type of damaged tissue (e.g., bone), the patient's age, sex, and diet, the severity 25 of any infection, time of administration and other clinical factors. The dosage may vary with the type of matrix used in the reconstitution and with inclusion of other proteins in the pharmaceutical composition. For example, the addition of other known growth factors, such as IGF I (insulin like growth factor I), to the final composition, may also effect the dosage. Progress can be monitored by periodic assessment of tissue/bone growth and/or repair, for example, X-rays, histomorphometric determinations and tetracycline labeling.

[0281] Polynucleotides of the present invention can also be used for gene therapy. Such polynucleotides can be 30 introduced either in vivo or ex vivo into cells for expression in a mammalian subject. Polynucleotides of the invention may also be administered by other known methods for introduction of nucleic acid into a cell or organism (including, without limitation, in the form of viral vectors or naked DNA). Cells may also be cultured ex vivo in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced in vivo for therapeutic purposes.

### 35 5.12.3 EFFECTIVE DOSAGE

[0282] Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active 40 ingredients are contained in an effective amount to achieve its intended purpose. More specifically, a therapeutically effective amount means an amount effective to prevent development of or to alleviate the existing symptoms of the subject being treated. Determination of the effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from appropriate in vitro assays. For example, a dose can be formulated in animal models to achieve a circulating concentration range that can be used to more accurately 45 determine useful doses in humans. For example, a dose can be formulated in animal models to achieve a circulating concentration range that includes the  $IC_{50}$  as determined in cell culture (i.e., the concentration of the test compound which achieves a half-maximal inhibition of the protein's biological activity). Such information can be used to more accurately determine useful doses in humans.

[0283] A therapeutically effective dose refers to that amount of the compound that results in amelioration of symptoms 50 or a prolongation of survival in a patient. Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the  $LD_{50}$  (the dose lethal to 50% of the population) and the  $ED_{50}$  (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio between  $LD_{50}$  and  $ED_{50}$ . Compounds which exhibit high therapeutic indices are preferred. The data obtained from these cell culture 55 assays and animal studies can be used in formulating a range of dosage for use in human. The dosage of such compounds lies preferably within a range of circulating concentrations that include the  $ED_{50}$  with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the

patient's condition. See, e.g., Fingl et al., 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 p.l. Dosage amount and interval may be adjusted individually to provide plasma levels of the active moiety which are sufficient to maintain the desired effects, or minimal effective concentration (MEC). The MEC will vary for each compound but can be estimated from *in vitro* data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. However, HPLC assays or bioassays can be used to determine plasma concentrations.

[0284] Dosage intervals can also be determined using MEC value. Compounds should be administered using a regimen which maintains plasma levels above the MEC for 10-90% of the time, preferably between 30-90% and most preferably between 50-90%. In cases of local administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration.

[0285] An exemplary dosage regimen for polypeptides or other compositions of the invention will be in the range of about 0.01  $\mu$ g/kg to 100 mg/kg of body weight daily, with the preferred dose being about 0.1  $\mu$ g/kg to 25 mg/kg of patient body weight daily, varying in adults and children. Dosing may be once daily, or equivalent doses may be delivered at longer or shorter intervals.

[0286] The amount of composition administered will, of course, be dependent on the subject being treated, on the subject's age and weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician.

#### 5.12.4 PACKAGING

[0287] The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may, for example, comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. Compositions comprising a compound of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.

#### 5.13 ANTIBODIES

[0288] Also included in the invention are antibodies to proteins, or fragments of proteins of the invention. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, i.e., molecules that contain an antigen-binding site that specifically binds (immunoreacts with) an antigen. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain,  $F_{ab}$ ,  $F_{ab_2}$  and  $F_{(ab)_2}$  fragments, and an  $F_{ab}$  expression library. In general, an antibody molecule obtained from humans relates to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature of the heavy chain present in the molecule. Certain classes have subclasses as well, such as IgG<sub>1</sub>, IgG<sub>2</sub>, and others. Furthermore, in humans, the light chain may be a kappa chain or a lambda chain. Reference herein to antibodies includes a reference to all such classes, subclasses and types of human antibody species.

[0289] An isolated related protein of the invention may be intended to serve as an antigen, or a portion or fragment thereof, and additionally can be used as an immunogen to generate antibodies that immunospecifically bind the antigen, using standard techniques for polyclonal and monoclonal antibody preparation. The full-length protein can be used or, alternatively, the invention provides antigenic peptide fragments of the antigen for use as immunogens. An antigenic peptide fragment comprises at least 6 amino acid residues of the amino acid sequence of the full length protein, such as an amino acid sequence shown in SEQ ID NO: 3, 5 - 13, 21, 23 - 27, or 28, and encompasses an epitope thereof such that an antibody raised against the peptide forms a specific immune complex with the full length protein or with any fragment that contains the epitope. Preferably, the antigenic peptide comprises at least 10 amino acid residues, or at least 15 amino acid residues, or at least 20 amino acid residues, or at least 30 amino acid residues. Preferred epitopes encompassed by the antigenic peptide are regions of the protein that are located on its surface; commonly these are hydrophilic regions.

[0290] In certain embodiments of the invention, at least one epitope encompassed by the antigenic peptide is a region of NGM-like protein that is located on the surface of the protein, e.g., a hydrophilic region. A hydrophobicity analysis of the human related protein sequence will indicate which regions of a related protein are particularly hydrophilic and, therefore, are likely to encode surface residues useful for targeting antibody production. As a means for targeting antibody production, hydropathy plots showing regions of hydrophilicity and hydrophobicity may be generated by any method well known in the art, including, for example, the Kyte Doolittle or the Hopp Woods methods, either with or without Fourier transformation. See, e.g., Hopp and Woods, 1981, *Proc. Nat. Acad. Sci. USA* 78: 3824-3828; Kyte and Doolittle 1982, *J. Mol. Biol.* 157: 105-142, each of which is incorporated herein by reference in its entirety. Antibodies that are specific for one or more domains within an antigenic protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.

[0291] A protein of the invention, or a derivative, fragment, analog, homolog or ortholog thereof, may be utilized as

an immunogen in the generation of antibodies that immunospecifically bind these protein components.

[0292] The term "specific for" indicates that the variable regions of the antibodies of the invention recognize and bind polypeptides of the invention exclusively (i. e., able to distinguish the polypeptide of the invention from other similar polypeptides despite sequence identity, homology, or similarity found in the family of polypeptides), but may also interact with other proteins (for example, *S. aureus* protein A or other antibodies in ELISA techniques) through interactions with sequences outside the variable region of the antibodies, and in particular, in the constant region of the molecule. Screening assays to determine binding specificity of an antibody of the invention are well known and routinely practiced in the art. For a comprehensive discussion of such assays, see Harlow et al. (Eds), *Antibodies A Laboratory Manual*; Cold Spring Harbor Laboratory; Cold Spring Harbor, NY (1988), Chapter 6. Antibodies that recognize and bind fragments of the polypeptides of the invention are also contemplated, provided that the antibodies are first and foremost specific for, as defined above, full-length polypeptides of the invention. As with antibodies that are specific for full length polypeptides of the invention, antibodies of the invention that recognize fragments are those which can distinguish polypeptides from the same family of polypeptides despite inherent sequence identity, homology, or similarity found in the family of proteins.

[0293] Antibodies of the invention are useful for, for example, therapeutic purposes (by modulating activity of a polypeptide of the invention), diagnostic purposes to detect or quantitate a polypeptide of the invention, as well as purification of a polypeptide of the invention. Kits comprising an antibody of the invention for any of the purposes described herein are also comprehended. In general, a kit of the invention also includes a control antigen for which the antibody is immunospecific. The invention further provides a hybridoma that produces an antibody according to the invention. Antibodies of the invention are useful for detection and/or purification of the polypeptides of the invention.

[0294] Monoclonal antibodies binding to the protein of the invention may be useful diagnostic agents for the immunodetection of the protein. Neutralizing monoclonal antibodies binding to the protein may also be useful therapeutics for both conditions associated with the protein and also in the treatment of some forms of cancer where abnormal expression of the protein is involved. In the case of cancerous cells or leukemic cells, neutralizing monoclonal antibodies against the protein may be useful in detecting and preventing the metastatic spread of the cancerous cells, which may be mediated by the protein.

[0295] The labeled antibodies of the present invention can be used for *in vitro*, *in vivo*, and *in situ* assays to identify cells or tissues in which a fragment of the polypeptide of interest is expressed. The antibodies may also be used directly in therapies or other diagnostics. The present invention further provides the above-described antibodies immobilized on a solid support. Examples of such solid supports include plastics such as polycarbonate, complex carbohydrates such as agarose and Sepharose®, acrylic resins and such as polyacrylamide and latex beads. Techniques for coupling antibodies to such solid supports are well known in the art (Weir, D.M. et al., "Handbook of Experimental Immunology" 4th Ed., Blackwell Scientific Publications, Oxford, England, Chapter 10 (1986); Jacoby, W.D. et al., *Meth. Enzym.* 34 Academic Press, N.Y. (1974)). The immobilized antibodies of the present invention can be used for *in vitro*, *in vivo*, and *in situ* assays as well as for immuno-affinity purification of the proteins of the present invention.

[0296] Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies directed against a protein of the invention, or against derivatives, fragments, analogs homologs or orthologs thereof (see, for example, *Antibodies: A Laboratory Manual*, Harlow E. and Lane D, 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, incorporated herein by reference). Some of these antibodies are discussed below.

### 5.13.1 POLYCLONAL ANTIBODIES

[0297] For the production of polyclonal antibodies, various suitable host animals (e.g., rabbit, goat, mouse or other mammal) may be immunized by one or more injections with the native protein, a synthetic variant thereof, or a derivative of the foregoing. An appropriate immunogenic preparation can contain, for example, the naturally occurring immunogenic protein, a chemically synthesized polypeptide representing the immunogenic protein, or a recombinantly expressed immunogenic protein. Furthermore, the protein may be conjugated to a second protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. The preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund's (complete and incomplete), mineral gels (e.g., aluminum hydroxide), surface-active substances (e.g., lysol-ecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), adjuvants usable in humans such as Bacille Calmette-Guerin and *Corynebacterium parvum*, or similar immunostimulatory agents. Additional examples of adjuvants that can be employed include MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).

[0298] The polyclonal antibody molecules directed against the immunogenic protein can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific

antigen which is the target of the immunoglobulin sought, or an epitope thereof, may be immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. Purification of immunoglobulins is discussed, for example, by D. Wilkinson (The Scientist, published by The Scientist, Inc., Philadelphia PA, Vol. 14, No. 8 (April 17, 2000), pp. 25-28).

5

### 5.13.2 MONOCLONAL ANTIBODIES

**[0299]** The term "monoclonal antibody" (MAb) or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one molecular species of antibody molecule consisting of a unique light chain gene product and a unique heavy chain gene product. In particular, the complementarity determining regions (CDRs) of the monoclonal antibody are identical in all the molecules of the population. MAbs thus contain an antigen-binding site capable of immunoreacting with a particular epitope of the antigen characterized by a unique binding affinity for it.

**[0300]** Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized in vitro.

**[0301]** The immunizing agent will typically include the protein antigen, a fragment thereof or a fusion protein thereof. Generally, either peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

**[0302]** Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63).

**[0303]** The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem., 107:220 (1980). Preferably, antibodies having a high degree of specificity and a high binding affinity for the target antigen are isolated.

**[0304]** After the desired hybridoma cells are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells can be grown in vivo as ascites in a mammal.

**[0305]** The monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

**[0306]** The monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U. S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Patent No. 4,816,567; Morrison, Nature

368, 812-13 (1994)) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.

5

### 5.13.3 HUMANIZED ANTIBODIES

[0307] The antibodies directed against the protein antigens of the invention can further comprise humanized antibodies or human antibodies. These antibodies are suitable for administration to humans without engendering an immune response by the human against the administered immunoglobulin. Humanized forms of antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')<sub>2</sub> or other antigen-binding subsequences of antibodies) that are principally comprised of the sequence of a human immunoglobulin, and contain minimal sequence derived from a non-human immunoglobulin. Humanization can be performed following the method of Winter and co-workers (Jones et al., *Nature*, 321:522-525 (1986); Riechmann et al., *Nature*, 332:323-327 (1988); Verhoeven et al., *Science*, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. (See also U.S. Patent No. 5,225,539). In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies can also comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., 1986; Riechmann et al., 1988; and Presta, *Curr. Op. Struct. Biol.*, 2:593-596 (1992)).

25

### 5.13.4 HUMAN ANTIBODIES

[0308] Fully human antibodies relate to antibody molecules in which essentially the entire sequences of both the light chain and the heavy chain, including the CDRs, arise from human genes. Such antibodies are termed "human antibodies", or "fully human antibodies" herein. Human monoclonal antibodies can be prepared by the trioma technique; the human B-cell hybridoma technique (see Kozbor, et al., 1983 *Immunol Today* 4: 72) and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole, et al., 1985 In: *MONOCLONAL ANTIBODIES AND CANCER THERAPY*, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the present invention and may be produced by using human hybridomas (see Cote, et al., 1983. *Proc Natl Acad Sci USA* 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus in vitro (see Cole, et al., 1985 In: *MONOCLONAL ANTIBODIES AND CANCER THERAPY*, Alan R. Liss, Inc., pp. 77-96).

30

[0309] In addition, human antibodies can also be produced using additional techniques, including phage display libraries (Hoogenboom and Winter, *J. Mol. Biol.*, 227:381 (1991); Marks et al., *J. Mol. Biol.*, 222:581 (1991)). Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in Marks et al. *Bio/Technology* 10, 779-783 (1992)); Lonberg et al. (*Nature* 368 856-859 (1994)); Morrison (*Nature* 368, 812-13 (1994)); Fishwild et al., (*Nature Biotechnology* 14, 845-51 (1996)); Neuberger (*Nature Biotechnology* 14, 826 (1996)); and Lonberg and Huszar (*Intern. Rev. Immunol.* 13 65-93 (1995)).

35

[0310] Human antibodies may additionally be produced using transgenic nonhuman animals that are modified so as to produce fully human antibodies rather than the animal's endogenous antibodies in response to challenge by an antigen. (See PCT publication WO94/02602). The endogenous genes encoding the heavy and light immunoglobulin chains in the nonhuman host have been incapacitated, and active loci encoding human heavy and light chain immunoglobulins are inserted into the host's genome. The human genes are incorporated, for example, using yeast artificial chromosomes containing the requisite human DNA segments. An animal which provides all the desired modifications is then obtained as progeny by crossbreeding intermediate transgenic animals containing fewer than the full complement of the modifications. The preferred embodiment of such a nonhuman animal is a mouse, and is termed the Xenomouse™ as disclosed in PCT publications WO 96/33735 and WO 96/34096. This animal produces B cells that secrete fully human immunoglobulins. The antibodies can be obtained directly from the animal after immunization with an immunogen of interest, as, for example, a preparation of a polyclonal antibody, or alternatively from immortalized B cells derived from the animal, such as hybridomas producing monoclonal antibodies. Additionally, the genes encoding

the immunoglobulins with human variable regions can be recovered and expressed to obtain the antibodies directly, or can be further modified to obtain analogs of antibodies such as, for example, single chain Fv molecules.

[0311] An example of a method of producing a nonhuman host, exemplified as a mouse, lacking expression of an endogenous immunoglobulin heavy chain is disclosed in U.S. Patent No. 5,939,598. It can be obtained by a method including deleting the J segment genes from at least one endogenous heavy chain locus in an embryonic stem cell to prevent rearrangement of the locus and to prevent formation of a transcript of a rearranged immunoglobulin heavy chain locus, the deletion being effected by a targeting vector containing a gene encoding a selectable marker; and producing from the embryonic stem cell a transgenic mouse whose somatic and germ cells contain the gene encoding the selectable marker.

[0312] A method for producing an antibody of interest, such as a human antibody, is disclosed in U.S. Patent No. 5,916,771. It includes introducing an expression vector that contains a nucleotide sequence encoding a heavy chain into one mammalian host cell in culture, introducing an expression vector containing a nucleotide sequence encoding a light chain into another mammalian host cell, and fusing the two cells to form a hybrid cell. The hybrid cell expresses an antibody containing the heavy chain and the light chain.

[0313] In a further improvement on this procedure, a method for identifying a clinically relevant epitope on an immunogen, and a correlative method for selecting an antibody that binds immunospecifically to the relevant epitope with high affinity, are disclosed in PCT publication WO 99/53049.

#### 5.13.5 FAB FRAGMENTS AND SINGLE CHAIN ANTIBODIES

[0314] According to the invention, techniques can be adapted for the production of single-chain antibodies specific to an antigenic protein of the invention (see e.g., U.S. Patent No. 4,946,778). In addition, methods can be adapted for the construction of  $F_{ab}$  expression libraries (see e.g., Huse, et al., 1989 *Science* 246: 1275-1281) to allow rapid and effective identification of monoclonal  $F_{ab}$  fragments with the desired specificity for a protein or derivatives, fragments, analogs or homologs thereof. Antibody fragments that contain the idiotypes to a protein antigen may be produced by techniques known in the art including, but not limited to: (i) an  $F_{(ab')2}$  fragment produced by pepsin digestion of an antibody molecule; (ii) an  $F_{ab}$  fragment generated by reducing the disulfide bridges of an  $F_{(ab')2}$  fragment; (iii) an  $F_{ab}$  fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv)  $F_v$  fragments.

#### 5.13.6 BISPECIFIC ANTIBODIES

[0315] Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for an antigenic protein of the invention. The second binding target is any other antigen, and advantageously is a cell-surface protein or receptor or receptor subunit.

[0316] Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, *Nature*, 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker et al., 1991 *EMBO J.*, 10:3655-3659.

[0317] Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are cotransfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh et al., *Methods in Enzymology*, 121:210 (1986).

[0318] According to another approach described in WO 96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers that are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 region of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.

[0319] Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g.  $F(ab')_2$  bispecific

antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al., Science 229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate  $F(ab')_2$  fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and

5 prevent intermolecular disulfide formation. The  $Fab'$  fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the  $Fab'$ -TNB derivatives is then reconverted to the  $Fab'$ -thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other  $Fab'$ -TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

10 [0320] Additionally,  $Fab'$  fragments can be directly recovered from *E. coli* and chemically coupled to form bispecific antibodies: Shalaby et al., J. Exp. Med. 175:217-225 (1992) describe the production of a fully humanized bispecific antibody  $F(ab')_2$  molecule. Each  $Fab'$  fragment was separately secreted from *E. coli* and subjected to directed chemical coupling *in vitro* to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.

15 [0321] Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., J. Immunol. 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the  $Fab'$  portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for 20 the production of antibody homodimers. The "diabody" technology described by Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain ( $V_H$ ) connected to a light-chain variable domain ( $V_L$ ) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the  $V_H$  and  $V_L$  domains of one 25 fragment are forced to pair with the complementary  $V_L$  and  $V_H$  domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber et al., J. Immunol. 152:5368 (1994).

30 [0322] Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al., J. Immunol. 147:60 (1991).

35 [0323] Exemplary bispecific antibodies can bind to two different epitopes, at least one of which originates in the protein antigen of the invention. Alternatively, an anti-antigenic arm of an immunoglobulin molecule can be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (Fc R), such as Fc RI (CD64), Fc RII (CD32) and Fc RIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular antigen. Bispecific antibodies can also be used to direct cytotoxic agents to cells which express a particular antigen. These antibodies possess an antigen-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the protein antigen described herein and further binds tissue factor (TF).

### 5.13.7 HETEROCONJUGATE ANTIBODIES

40 [0324] Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Patent No. 4,676,980), and for treatment of HIV infection (WO 91/00360; WO 92/200373; EP 03089). It is contemplated that the antibodies can be prepared *in vitro* using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins can be constructed using 45 a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptopbutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.

### 5.13.8 EFFECTOR FUNCTION ENGINEERING

50 [0325] It can be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, e.g., the effectiveness of the antibody in treating cancer. For example, cysteine residue(s) can be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated can have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., J. Exp. Med., 176: 1191-1195 (1992) and Shopes, J. Immunol., 148: 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity can also be prepared using heterobifunctional cross-linkers as described in Wolff et al. Cancer Research, 53: 2560-2565 (1993). Alternatively, an antibody 55 can be engineered that has dual Fc regions and can thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al., Anti-Cancer Drug Design, 3: 219-230 (1989).

## 5.13.9 IMMUNOCONJUGATES

[0326] The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).

[0327] Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, *Phytolaca americana* proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the trichothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include <sup>212</sup>Bi, <sup>131</sup>I, <sup>131</sup>In, <sup>90</sup>Y, and <sup>186</sup>Re.

[0328] Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al., *Science*, 238: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026.

[0329] In another embodiment, the antibody can be conjugated to a "receptor" (such streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (e.g., avidin) that is in turn conjugated to a cytotoxic agent.

## 5.14 COMPUTER READABLE SEQUENCES

[0330] In one application of this embodiment, a nucleotide sequence of the present invention can be recorded on computer readable media. As used herein, "computer readable media" refers to any medium which can be read and accessed directly by a computer. Such media include, but are not limited to: magnetic storage media, such as floppy discs, hard disc storage medium, and magnetic tape; optical storage media such as CD-ROM; electrical storage media such as RAM and ROM; and hybrids of these categories such as magnetic/optical storage media. A skilled artisan can readily appreciate how any of the presently known computer readable mediums can be used to create a manufacture comprising computer readable medium having recorded thereon a nucleotide sequence of the present invention. As used herein, "recorded" refers to a process for storing information on computer readable medium. A skilled artisan can readily adopt any of the presently known methods for recording information on computer readable medium to generate manufactures comprising the nucleotide sequence information of the present invention.

[0331] A variety of data storage structures are available to a skilled artisan for creating a computer readable medium having recorded thereon a nucleotide sequence of the present invention. The choice of the data storage structure will generally be based on the means chosen to access the stored information. In addition, a variety of data processor programs and formats can be used to store the nucleotide sequence information of the present invention on computer readable medium. The sequence information can be represented in a word processing text file, formatted in commercially-available software such as WordPerfect and Microsoft Word, or represented in the form of an ASCII file, stored in a database application, such as DB2, Sybase, Oracle, or the like. A skilled artisan can readily adapt any number of data processor structuring formats (e.g. text file or database) in order to obtain computer readable medium having recorded thereon the nucleotide sequence information of the present invention.

[0332] By providing any of the nucleotide sequences SEQ ID NO: 1-2, 4, 18-20, 22, or 31 or a representative fragment thereof; or a nucleotide sequence at least 95 % identical to any of the nucleotide sequences of SEQ ID NO: 1-2, 4, 18-20, 22, or 31 in computer readable form, a skilled artisan can routinely access the sequence information for a variety of purposes. Computer software is publicly available which allows a skilled artisan to access sequence information provided in a computer readable medium. The examples which follow demonstrate how software which implements the BLAST (Altschul et al., *J. Mol. Biol.* 215:403-410 (1990)) and BLAZE (Brutlag et al., *Comp. Chem.* 17:203-207 (1993)) search algorithms on a Sybase system is used to identify open reading frames (ORFs) within a nucleic acid sequence. Such ORFs may be protein encoding fragments and may be useful in producing commercially important proteins such as enzymes used in fermentation reactions and in the production of commercially useful metabolites.

[0333] As used herein, "a computer-based system" refers to the hardware means, software means, and data storage means used to analyze the nucleotide sequence information of the present invention. The minimum hardware means

of the computer-based systems of the present invention comprises a central processing unit (CPU), input means, output means, and data storage means. A skilled artisan can readily appreciate that any one of the currently available computer-based systems are suitable for use in the present invention. As stated above, the computer-based systems of the present invention comprise a data storage means having stored therein a nucleotide sequence of the present invention and the necessary hardware means and software means for supporting and implementing a search means. As used herein, "data storage means" refers to memory which can store nucleotide sequence information of the present invention, or a memory access means which can access manufactures having recorded thereon the nucleotide sequence information of the present invention.

[0334] As used herein, "search means" refers to one or more programs which are implemented on the computer-based system to compare a target sequence or target structural motif with the sequence information stored within the data storage means. Search means are used to identify fragments or regions of a known sequence which match a particular target sequence or target motif. A variety of known algorithms are disclosed publicly and a variety of commercially available software for conducting search means are and can be used in the computer-based systems of the present invention. Examples of such software includes, but is not limited to, Smith-Waterman, MacPattern (EMBL), BLASTN and BLASTA (NPOLYPEPTIDEIA). A skilled artisan can readily recognize that any one of the available algorithms or implementing software packages for conducting homology searches can be adapted for use in the present computer-based systems. As used herein, a "target sequence" can be any nucleic acid or amino acid sequence of six or more nucleotides or two or more amino acids. A skilled artisan can readily recognize that the longer a target sequence is, the less likely a target sequence will be present as a random occurrence in the database. The most preferred sequence length of a target sequence is from about 10 to 100 amino acids, or from about 30 to 300 nucleotide residues. However, it is well recognized that searches for commercially important fragments, such as sequence fragments involved in gene expression and protein processing, may be of shorter length.

[0335] As used herein, "a target structural motif," or "target motif," refers to any rationally selected sequence or combination of sequences in which the sequence(s) are chosen based on a three-dimensional configuration which is formed upon the folding of the target motif. There are a variety of target motifs known in the art. Protein target motifs include, but are not limited to, enzyme active sites and signal sequences. Nucleic acid target motifs include, but are not limited to, promoter sequences, hairpin structures and inducible expression elements (protein binding sequences).

### 5.15 TRIPLE HELIX FORMATION

[0336] In addition, the fragments of the present invention, as broadly described, can be used to control gene expression through triple helix formation or antisense DNA or RNA, both of which methods are based on the binding of a polynucleotide sequence to DNA or RNA. Polynucleotides suitable for use in these methods are usually 20 to 40 bases in length and are designed to be complementary to a region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 15241:456 (1988); and Dervan et al., Science 251:1360 (1991)) or to the mRNA itself (antisense - Olmno, J. Neurochem. 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988)). Triple helix-formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques have been demonstrated to be effective in model systems. Information contained in the sequences of the present invention is necessary for the design of an antisense or triple helix oligonucleotide.

### 5.16 DIAGNOSTIC ASSAYS AND KITS

[0337] The present invention further provides methods to identify the presence or expression of one of the ORFs of the present invention, or homolog thereof, in a test sample, using a nucleic acid probe or antibodies of the present invention, optionally conjugated or otherwise associated with a suitable label.

[0338] In general, methods for detecting a polynucleotide of the invention can comprise contacting a sample with a compound that binds to and forms a complex with the polynucleotide for a period sufficient to form the complex, and detecting the complex, so that if a complex is detected, a polynucleotide of the invention is detected in the sample. Such methods can also comprise contacting a sample under stringent hybridization conditions with nucleic acid primers that anneal to a polynucleotide of the invention under such conditions, and amplifying annealed polynucleotides, so that if a polynucleotide is amplified, a polynucleotide of the invention is detected in the sample.

[0339] In general, methods for detecting a polypeptide of the invention can comprise contacting a sample with a compound that binds to and forms a complex with the polypeptide for a period sufficient to form the complex, and detecting the complex, so that if a complex is detected, a polypeptide of the invention is detected in the sample.

[0340] In detail, such methods comprise incubating a test sample with one or more of the antibodies or one or more of the nucleic acid probes of the present invention and assaying for binding of the nucleic acid probes or antibodies to components within the test sample.

[0341] Conditions for incubating a nucleic acid probe or antibody with a test sample vary. Incubation conditions depend on the format employed in the assay, the detection methods employed, and the type and nature of the nucleic acid probe or antibody used in the assay. One skilled in the art will recognize that any one of the commonly available hybridization, amplification or immunological assay formats can readily be adapted to employ the nucleic acid probes or antibodies of the present invention. Examples of such assays can be found in Chard, T., An Introduction to Radioimmunoassay and Related Techniques, Elsevier Science Publishers, Amsterdam, The Netherlands (1986); Bullock, G.R. et al., Techniques in Immunocytochemistry, Academic Press, Orlando, FL Vol. 1 (1982), Vol. 2 (1983), Vol. 3 (1985); Tijssen, P., Practice and Theory of immunoassays: Laboratory Techniques in Biochemistry and Molecular Biology, Elsevier Science Publishers, Amsterdam, The Netherlands (1985). The test samples of the present invention include cells, protein or membrane extracts of cells, or biological fluids such as sputum, blood, serum, plasma, or urine. The test sample used in the above-described method will vary based on the assay format, nature of the detection method and the tissues, cells or extracts used as the sample to be assayed. Methods for preparing protein extracts or membrane extracts of cells are well known in the art and can be readily be adapted in order to obtain a sample which is compatible with the system utilized.

[0342] In another embodiment of the present invention, kits are provided which contain the necessary reagents to carry out the assays of the present invention. Specifically, the invention provides a compartment kit to receive, in close confinement, one or more containers which comprises: (a) a first container comprising one of the probes or antibodies of the present invention; and (b) one or more other containers comprising one or more of the following: wash reagents, reagents capable of detecting presence of a bound probe or antibody.

[0343] In detail, a compartment kit includes any kit in which reagents are contained in separate containers. Such containers include small glass containers, plastic containers or strips of plastic or paper. Such containers allows one to efficiently transfer reagents from one compartment to another compartment such that the samples and reagents are not cross-contaminated, and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another. Such containers will include a container which will accept the test sample, a container which contains the antibodies used in the assay, containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, etc.), and containers which contain the reagents used to detect the bound antibody or probe. Types of detection reagents include labeled nucleic acid probes, labeled secondary antibodies, or in the alternative, if the primary antibody is labeled, the enzymatic, or antibody binding reagents which are capable of reacting with the labeled antibody. One skilled in the art will readily recognize that the disclosed probes and antibodies of the present invention can be readily incorporated into one of the established kit formats which are well known in the art.

### 5.17 MEDICAL IMAGING

[0344] The novel polypeptides and binding partners of the invention are useful in medical imaging of sites expressing the molecules of the invention (e.g., where the polypeptide of the invention is involved in the immune response, for imaging sites of inflammation or infection). See, e.g., Kunkel et al., U.S. Pat. NO. 5,413,778. Such methods involve chemical attachment of a labeling or imaging agent, administration of the labeled polypeptide to a subject in a pharmaceutically acceptable carrier, and imaging the labeled polypeptide *in vivo* at the target site.

### 5.18 SCREENING ASSAYS

[0345] Using the isolated proteins and polynucleotides of the invention, the present invention further provides methods of obtaining and identifying agents which bind to a polypeptide encoded by an ORF corresponding to any of the nucleotide sequences set forth in SEQ ID NO: 1-2, 4, 18-20, 22, or 31, or bind to a specific domain of the polypeptide encoded by the nucleic acid. In detail, said method comprises the steps of:

- (a) contacting an agent with an isolated protein encoded by an ORF of the present invention, or nucleic acid of the invention; and
- (b) determining whether the agent binds to said protein or said nucleic acid.

[0346] In general, therefore, such methods for identifying compounds that bind to a polynucleotide of the invention can comprise contacting a compound with a polynucleotide of the invention for a time sufficient to form a polynucleotide/compound complex, and detecting the complex, so that if a polynucleotide/compound complex is detected, a compound that binds to a polynucleotide of the invention is identified.

[0347] Likewise, in general, therefore, such methods for identifying compounds that bind to a polypeptide of the invention can comprise contacting a compound with a polypeptide of the invention for a time sufficient to form a polypeptide/compound complex, and detecting the complex, so that if a polypeptide/compound complex is detected, a compound that binds to a polynucleotide of the invention is identified.

[0348] Methods for identifying compounds that bind to a polypeptide of the invention can also comprise contacting a compound with a polypeptide of the invention in a cell for a time sufficient to form a polypeptide/compound complex, wherein the complex drives expression of a receptor gene sequence in the cell, and detecting the complex by detecting reporter gene sequence expression, so that if a polypeptide/compound complex is detected, a compound that binds a polypeptide of the invention is identified.

[0349] Compounds identified via such methods can include compounds which modulate the activity of a polypeptide of the invention (that is, increase or decrease its activity, relative to activity observed in the absence of the compound). Alternatively, compounds identified via such methods can include compounds which modulate the expression of a polynucleotide of the invention (that is, increase or decrease expression relative to expression levels observed in the absence of the compound). Compounds, such as compounds identified via the methods of the invention, can be tested using standard assays well known to those of skill in the art for their ability to modulate activity/expression.

[0350] The agents screened in the above assay can be, but are not limited to, peptides, carbohydrates, vitamin derivatives, or other pharmaceutical agents. The agents can be selected and screened at random or rationally selected or designed using protein modeling techniques.

[0351] For random screening, agents such as peptides, carbohydrates, pharmaceutical agents and the like are selected at random and are assayed for their ability to bind to the protein encoded by the ORF of the present invention. Alternatively, agents may be rationally selected or designed. As used herein, an agent is said to be "rationally selected or designed" when the agent is chosen based on the configuration of the particular protein. For example, one skilled in the art can readily adapt currently available procedures to generate peptides, pharmaceutical agents and the like, capable of binding to a specific peptide sequence, in order to generate rationally designed antipeptide peptides, for example see Hurby et al., *Application of Synthetic Peptides: Antisense Peptides*, In *Synthetic Peptides, A User's Guide*, W.H. Freeman, NY (1992), pp. 289-307, and Kaspczak et al., *Biochemistry* 28:9230-8 (1989), or pharmaceutical agents, or the like.

[0352] In addition to the foregoing, one class of agents of the present invention, as broadly described, can be used to control gene expression through binding to one of the ORFs or EMFs of the present invention. As described above, such agents can be randomly screened or rationally designed/selected. Targeting the ORF or EMF allows a skilled artisan to design sequence specific or element specific agents, modulating the expression of either a single ORF or multiple ORFs which rely on the same EMF for expression control. One class of DNA binding agents are agents which contain base residues which hybridize or form a triple helix formation by binding to DNA or RNA. Such agents can be based on the classic phosphodiester, ribonucleic acid backbone, or can be a variety of sulfhydryl or polymeric derivatives which have base attachment capacity.

[0353] Agents suitable for use in these methods usually contain 20 to 40 bases and are designed to be complementary to a region of the gene involved in transcription (triple helix - see Lee et al., *Nucl. Acids Res.* 6:3073 (1979); Cooney et al., *Science* 241:456 (1988); and Dervan et al., *Science* 251:1360 (1991)) or to the mRNA itself (antisense - Okano, *J. Neurochem.* 56:560 (1991); *Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression*, CRC Press, Boca Raton, FL (1988)). Triple helix-formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques have been demonstrated to be effective in model systems. Information contained in the sequences of the present invention is necessary for the design of an antisense or triple helix oligonucleotide and other DNA binding agents.

[0354] Agents which bind to a protein encoded by one of the ORFs of the present invention can be used as a diagnostic agent. Agents which bind to a protein encoded by one of the ORFs of the present invention can be formulated using known techniques to generate a pharmaceutical composition.

## 5.19 USE OF NUCLEIC ACIDS AS PROBES

[0355] Another aspect of the subject invention is to provide for polypeptide-specific nucleic acid hybridization probes capable of hybridizing with naturally occurring nucleotide sequences. The hybridization probes of the subject invention may be derived from any of the nucleotide sequences SEQ ID NO: 1-2, 4, 18-20, 22, or 31. Because the corresponding gene is only expressed in a limited number of tissues, a hybridization probe derived from any of the nucleotide sequences SEQ ID NO: 1-2, 4, 18-20, 22, or 31 can be used as an indicator of the presence of RNA of cell type of such a tissue in a sample.

[0356] Any suitable hybridization technique can be employed, such as, for example, *in situ* hybridization. PCR as described in US Patents Nos. 4,683,195 and 4,965,188 provides additional uses for oligonucleotides based upon the nucleotide sequences. Such probes used in PCR may be of recombinant origin, may be chemically synthesized, or a mixture of both. The probe will comprise a discrete nucleotide sequence for the detection of identical sequences or a degenerate pool of possible sequences for identification of closely related genomic sequences.

[0357] Other means for producing specific hybridization probes for nucleic acids include the cloning of nucleic acid sequences into vectors for the production of mRNA probes. Such vectors are known in the art and are commercially

available and may be used to synthesize RNA probes *in vitro* by means of the addition of the appropriate RNA polymerase as T7 or SP6 RNA polymerase and the appropriate radioactively labeled nucleotides. The nucleotide sequences may be used to construct hybridization probes for mapping their respective genomic sequences. The nucleotide sequence provided herein may be mapped to a chromosome or specific regions of a chromosome using well known 5 genetic and/or chromosomal mapping techniques. These techniques include *in situ* hybridization, linkage analysis against known chromosomal markers, hybridization screening with libraries or flow-sorted chromosomal preparations specific to known chromosomes, and the like. The technique of fluorescent *in situ* hybridization of chromosome spreads has been described, among other places, in Verma et al (1988) *Human Chromosomes: A Manual of Basic Techniques*, Pergamon Press, New York NY.

10 [0358] Fluorescent *in situ* hybridization of chromosomal preparations and other physical chromosome mapping techniques may be correlated with additional genetic map data. Examples of genetic map data can be found in the 1994 Genome Issue of *Science* (265:1981f). Correlation between the location of a nucleic acid on a physical chromosomal map and a specific disease (or predisposition to a specific disease) may help delimit the region of DNA associated with that genetic disease. The nucleotide sequences of the subject invention may be used to detect differences in gene 15 sequences between normal, carrier or affected individuals.

## 5.20 PREPARATION OF SUPPORT BOUND OLIGONUCLEOTIDES

20 [0359] Oligonucleotides, i.e., small nucleic acid segments, may be readily prepared by, for example, directly synthesizing the oligonucleotide by chemical means, as is commonly practiced using an automated oligonucleotide synthesizer.

25 [0360] Support bound oligonucleotides may be prepared by any of the methods known to those of skill in the art using any suitable support such as glass, polystyrene or Teflon. One strategy is to precisely spot oligonucleotides synthesized by standard synthesizers. Immobilization can be achieved using passive adsorption (Inouye & Hondo, 1990 *J. Clin Microbiol* 28(6) 1462-72); using UV light (Nagata et al., 1985; Dahlen et al., 1987; Morrissey & Collins, *Mol. Cell Probes* 1989 3(2) 189-207) or by covalent binding of base modified DNA (Keller et al., 1988; 1989); all references being specifically incorporated herein.

30 [0361] Another strategy that may be employed is the use of the strong biotin-streptavidin interaction as a linker. For example, Broude et al. (1994) *Proc. Natl. Acad. Sci USA* 91(8) 3072-6 describe the use of biotinylated probes, although these are duplex probes, that are immobilized on streptavidin-coated magnetic beads. Streptavidin-coated beads may be purchased from Dynal, Oslo. Of course, this same linking chemistry is applicable to coating any surface with streptavidin. Biotinylated probes may be purchased from various sources, such as, e.g., Operon Technologies (Alameda, CA).

35 [0362] Nunc Laboratories (Naperville, IL) is also selling suitable material that could be used. Nunc Laboratories have developed a method by which DNA can be covalently bound to the microwell surface termed CovaLink NH. CovaLink NH is a polystyrene surface grafted with secondary amino groups (> NH) that serve as bridge-heads for further covalent coupling. CovaLink Modules may be purchased from Nunc Laboratories. DNA molecules may be bound to CovaLink exclusively at the 5'-end by a phosphoramidate bond, allowing immobilization of more than 1 pmol of DNA (Rasmussen et al., (1991) *Anal Biochem* 198(1) 138-42).

40 [0363] The use of CovaLink NH strips for covalent binding of DNA molecules at the 5'-end has been described (Rasmussen et al., 1991). In this technology, a phosphoramidate bond is employed (Chu et al., 1983 *Nucleic Acids* 11 (18) 6513-29). This is beneficial as immobilization using only a single covalent bond is preferred. The phosphoramidate bond joins the DNA to the CovaLink NH secondary amino groups that are positioned at the end of spacer arms covalently grafted onto the polystyrene surface through a 2 nm long spacer arm. To link an oligonucleotide to CovaLink NH via an phosphoramidate bond, the oligonucleotide terminus must have a 5'-end phosphate group. It is, perhaps, even 45 possible for biotin to be covalently bound to CovaLink and then streptavidin used to bind the probes.

45 [0364] More specifically, the linkage method includes dissolving DNA in water (7.5 ng/ul) and denaturing for 10 min. at 95°C and cooling on ice for 10 min. Ice-cold 0.1 M 1-methylimidazole, pH 7.0 (1-MeIm<sub>7</sub>), is then added to a final concentration of 10 mM 1-MeIm<sub>7</sub>. A ss DNA solution is then dispensed into CovaLink NH strips (75 ul/well) standing on ice.

50 [0365] Carbodiimide 0.2 M 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide(EDC), dissolved in 10 mM 1-MeIm<sub>7</sub>, is made fresh and 25 ul added per well. The strips are incubated for 5 hours at 50°C. After incubation the strips are washed using, e.g., Nunc-Immuno Wash; first the wells are washed 3 times, then they are soaked with washing solution for 5 min., and finally they are washed 3 times (where in the washing solution is 0.4 N NaOH, 0.25% SDS heated to 50°C).

55 [0366] It is contemplated that a further suitable method for use with the present invention is that described in PCT Patent Application WO 90/03382 (Southern & Maskos), incorporated herein by reference. This method of preparing an oligonucleotide bound to a support involves attaching a nucleoside 3'-reagent through the phosphate group by a covalent phosphodiester link to aliphatic hydroxyl groups carried by the support. The oligonucleotide is then synthesized

on the supported nucleoside and protecting groups removed from the synthetic oligonucleotide chain under standard conditions that do not cleave the oligonucleotide from the support. Suitable reagents include nucleoside phosphoramidite and nucleoside hydrogen phosphorate.

[0367] An on-chip strategy for the preparation of DNA probe for the preparation of DNA probe arrays may be employed. For example, addressable laser-activated photodeprotection may be employed in the chemical synthesis of oligonucleotides directly on a glass surface, as described by Fodor *et al.* (1991) *Science* 251(4995) 767-73, incorporated herein by reference. Probes may also be immobilized on nylon supports as described by Van Ness *et al.* (1991) *Nucleic Acids Res.* 19(12) 3345-50; or linked to Teflon using the method of Duncan & Cavalier (1988) *Anal Biochem* 169(1) 104-8; all references being specifically incorporated herein.

[0368] To link an oligonucleotide to a nylon support, as described by Van Ness *et al.* (1991), requires activation of the nylon surface via alkylation and selective activation of the 5'-amine of oligonucleotides with cyanuric chloride.

[0369] One particular way to prepare support bound oligonucleotides is to utilize the light-generated synthesis described by Pease *et al.*, (1994) *Proc. Natl. Acad. Sci USA* 91(11) 5022-6. These authors used current photolithographic techniques to generate arrays of immobilized oligonucleotide probes (DNA chips). These methods, in which light is used to direct the synthesis of oligonucleotide probes in high-density, miniaturized arrays, utilize photolabile 5'-protectedN-acyl-deoxymucleoside phosphoramidites, surface linker chemistry and versatile combinatorial synthesis strategies. A matrix of 256 spatially defined oligonucleotide probes may be generated in this manner.

## 5.21 PREPARATION OF NUCLEIC ACID FRAGMENTS

[0370] The nucleic acids may be obtained from any appropriate source, such as cDNAs, genomic DNA, chromosomal DNA, microdissected chromosome bands, cosmid or YAC inserts, and RNA, including mRNA without any amplification steps. For example, Sambrook *et al.* (1989) describes three protocols for the isolation of high molecular weight DNA from mammalian cells (p. 9.14-9.23).

[0371] DNA fragments may be prepared as clones in M13, plasmid or lambda vectors and/or prepared directly from genomic DNA or cDNA by PCR or other amplification methods. Samples may be prepared or dispensed in multiwell plates. About 100-1000 ng of DNA samples may be prepared in 2-500 ml of final volume.

[0372] The nucleic acids would then be fragmented by any of the methods known to those of skill in the art including, for example, using restriction enzymes as described at 9.24-9.28 of Sambrook *et al.* (1989), shearing by ultrasound and NaOH treatment.

[0373] Low pressure shearing is also appropriate, as described by Schriefer *et al.* (1990) *Nucleic Acids Res.* 18(24) 7455-6. In this method, DNA samples are passed through a small French pressure cell at a variety of low to intermediate pressures. A lever device allows controlled application of low to intermediate pressures to the cell. The results of these studies indicate that low-pressure shearing is a useful alternative to sonic and enzymatic DNA fragmentation methods.

[0374] One particularly suitable way for fragmenting DNA is contemplated to be that using the two base recognition endonuclease, CviJI, described by Fitzgerald *et al.* (1992) *Nucleic Acids Res.* 20(14) 3753-62. These authors described an approach for the rapid fragmentation and fractionation of DNA into particular sizes that they contemplated to be suitable for shotgun cloning and sequencing.

[0375] The restriction endonuclease CviJI normally cleaves the recognition sequence PuGCPy between the G and C to leave blunt ends. Atypical reaction conditions, which alter the specificity of this enzyme (CviJI\*\*), yield a quasi-random distribution of DNA fragments from the small molecule pUC19 (2688 base pairs). Fitzgerald *et al.* (1992) quantitatively evaluated the randomness of this fragmentation strategy, using a CviJI\*\* digest of pUC19 that was size fractionated by a rapid gel filtration method and directly ligated, without end repair, to a lac Z minus M13 cloning vector. Sequence analysis of 76 clones showed that CviJI\*\* restricts pyGCPy and PuGCPu, in addition to PuGCPy sites, and that new sequence data is accumulated at a rate consistent with random fragmentation.

[0376] As reported in the literature, advantages of this approach compared to sonication and agarose gel fractionation include: smaller amounts of DNA are required (0.2-0.5 ug instead of 2-5 ug); and fewer steps are involved (no pre-ligation, end repair, chemical extraction, or agarose gel electrophoresis and elution are needed).

[0377] Irrespective of the manner in which the nucleic acid fragments are obtained or prepared, it is important to denature the DNA to give single stranded pieces available for hybridization. This is achieved by incubating the DNA solution for 2-5 minutes at 80-90°C. The solution is then cooled quickly to 2°C to prevent renaturation of the DNA fragments before they are contacted with the chip. Phosphate groups must also be removed from genomic DNA by methods known in the art.

## 5.22 PREPARATION OF DNA ARRAYS

[0378] Arrays may be prepared by spotting DNA samples on a support such as a nylon membrane. Spotting may be performed by using arrays of metal pins (the positions of which correspond to an array of wells in a microtiter plate)

to repeated transfer of about 20 nl of a DNA solution to a nylon membrane. By offset printing, a density of dots higher than the density of the wells is achieved. One to 25 dots may be accommodated in 1 mm<sup>2</sup>, depending on the type of label used. By avoiding spotting in some preselected number of rows and columns, separate subsets (subarrays) may be formed. Samples in one subarray may be the same genomic segment of DNA (or the same gene) from different individuals, or may be different, overlapped genomic clones. Each of the subarrays may represent replica spotting of the same samples. In one example, a selected gene segment may be amplified from 64 patients. For each patient, the amplified gene segment may be in one 96-well plate (all 96 wells containing the same sample). A plate for each of the 64 patients is prepared. By using a 96-pin device, all samples may be spotted on one 8 x 12 cm membrane. Subarrays may contain 64 samples, one from each patient. Where the 96 subarrays are identical, the dot span may be 1 mm<sup>2</sup> and there may be a 1 mm space between subarrays.

[0379] Another approach is to use membranes or plates (available from NUNC, Naperville, Illinois) which may be partitioned by physical spacers e.g. a plastic grid molded over the membrane, the grid being similar to the sort of membrane applied to the bottom of multiwell plates, or hydrophobic strips. A fixed physical spacer is not preferred for imaging by exposure to flat phosphor-storage screens or x-ray films.

[0380] The present invention is illustrated in the following examples. Upon consideration of the present disclosure, one of skill in the art will appreciate that many other embodiments and variations may be made in the scope of the present invention. Accordingly, it is intended that the broader aspects of the present invention not be limited to the disclosure of the following examples. The present invention is not to be limited in scope by the exemplified embodiments which are intended as illustrations of single aspects of the invention, and compositions and methods which are functionally equivalent are within the scope of the invention. Indeed, numerous modifications and variations in the practice of the invention are expected to occur to those skilled in the art upon consideration of the present preferred embodiments. Consequently, the only limitations which should be placed upon the scope of the invention are those which appear in the appended claims.

[0381] All references cited within the body of the instant specification are hereby incorporated by reference in their entirety.

## 6.0 EXAMPLES

### EXAMPLE 1

#### Isolation and characterization of SEQ ID NO: 1 and 18 from cDNA Libraries

[0382] A plurality of novel nucleic acids were obtained from cDNA libraries prepared from adult spleen mRNA (GIBCO) (Hyseq clone identification numbers 3073928 (SEQ ID NO: 1), and from infant brain mRNA (Columbia University) (Hyseq clone identification number 6346549) (SEQ ID NO: 18) using standard PCR, sequencing by hybridization sequence signature analysis, and Sanger sequencing techniques. The inserts of the library were amplified with PCR using primers specific for vector sequences flanking the inserts. These samples were spotted onto nylon membranes and interrogated with oligonucleotide probes to give sequence signatures. The clones were clustered into groups of similar or identical sequences, and single representative clones were selected from each group for gel sequencing. The 5' sequence of the amplified inserts was then deduced using the reverse M13 sequencing primer in a typical Sanger sequencing protocol. PCR products were purified and subjected to fluorescent dye terminator cycle sequencing. Single-pass gel sequencing was done using a 377 Applied Biosystems (ABI) sequencer. The inserts were identified as novel sequences not previously obtained from these libraries and not previously reported in public databases. The sequences were designated as SEQ ID NO: 1 (from adult spleen mRNA) and SEQ ID NO: 18 (from infant brain mRNA).

[0383] Tissue expression patterns for SEQ ID NO: 1 and 18 were determined by blasting the sequences against the Hyseq's EST nucleic acid databases. SEQ ID NO: 1 was found to be expressed in adult spleen tissue, while expression of SEQ ID NO: 18 was detected in infant and adult brain tissues. One skilled in art may realize that the nucleic acids of the SEQ ID NO: 1 and 18 may be expressed in other tissues as well.

### EXAMPLE 2

#### ASSEMBLAGE OF SEQ ID NO: 19

[0384] The nucleic acid of the present invention, designated as SEQ ID NO: 19 was assembled using SEQ ID NO: 18 as a seed. Then a recursive algorithm was used to extend the seed into an extended assemblage, by pulling additional sequences from different databases (i.e., Hyseq's database containing EST sequences, dbEST version 114, gb pri 114, and UniGene version 101) that belong to this assemblage. The algorithm terminated when there was no additional sequences from the above databases that would extend the assemblage. Inclusion of component sequences

into the assemblage was based on a BLASTN hit to the extending assemblage with BLAST score greater than 300 and percent identity greater than 95 %.

[0385] The nearest neighbor result for the assembled contigs were obtained by a FASTA version 3 search against Genpept release 114, using FASTXY algorithm. FASTXY is an improved version of FASTA alignment which allows in-codon frame shifts. The nearest neighbor result showed the closest homologue for each assemblage from Genpept (and contains the translated amino acid sequences for which the assemblage encodes). The nearest neighbor result is set forth below:

SEQ ID NO:	Accession No.	Description	Smith-Waterman Score	% Identity
19	M86826	Homo sapiens insulin-like growth factor binding protein complex	281	39.706

[0386] A polypeptide was predicted to be encoded by SEQ ID NO: 19 as set forth below. The polypeptide was predicted using a software program called FASTY (available from <http://fasta.bioch.virginia.edu>) which selects a polypeptide based on a comparison of translated novel polynucleotide to known polypeptides (W.R. Pearson, Methods in Enzymology, 183: 63-98 (1990), herein incorporated by reference).

20	Predicted beginning nucleotide location	Predicted end nucleotide location	AMINO ACID ENCODED BY SEQ ID NO: 2 (A=Alanine, C=Cysteine, D=Aspartic Acid, E=Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine, M=Methionine, N=Asparagine, P=Proline, Q=Glutamine, R=Arginine, S=Serine, T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine, X=Unknown, *=Stop Codon, / =possible nucleotide deletion, \ =possible nucleotide insertion)
45	489	19	ILDLSKNRLKSVNPEEFISYPLLEEIDLSDNIIANVE PGAFNNLFLNRLSRLKGNRLKLVPLGVFTGLSNL TKLDISENKIVILLDYMFQDLHNLKSLEVGDNDL VYISHRAFGSGLLSLEQLTLEKCNLTAVPTEALSHL RPRAKLGAKHGQDGVQS (SEQ ID NO: 28)

### EXAMPLE 3

#### ASSEMBLAGE OF SEQ ID NO: 2 and 3

[0387] Assembly of novel nucleotide sequence of SEQ ID NO: 2 was accomplished by using an EST sequence SEQ ID NO: 1 as seed. The seed was extended by gel sequencing (377 Applied Biosystems (ABI) sequencer) using primers to extend the 3' end (primer extension). The seed was also extended towards the 5' end by Rapid Amplification of cDNA Ends (RACE). mRNA from various tissues were obtained from the following vendors: trachea and pituitary gland from Clontech; heart, fetal heart, placenta, brain, small intestine, fetal lung, uterus, and fetal brain from Invitrogen. Tissue mRNAs were pooled together and used for the RACE. The nested PCR products were subsequently cloned

and sequenced using 377 Applied Biosystems (ABI) sequencer.

[0388] A polypeptide (SEQ ID NO: 3) was predicted to be encoded by SEQ ID NO: 2 as set forth below. The polypeptide was predicted using a software program called BLASTX which selects a polypeptide based on a comparison of translated novel polynucleotide to known polynucleotides. The initial methionine starts at position 186 of SEQ ID NO:

5 2 and the putative stop codon, TAA, begins at position 2052 of the nucleotide sequence.

[0389] The NGM-like polypeptide of SEQ ID NO: 3 is an approximately 622-amino acid secreted protein with a predicted molecular mass of approximately 70 kDa unglycosylated. Protein database searches with the BLASTX algorithm (Altschul S.F. et al., J. Mol. Evol. 36:290-300 (1993) and Altschul S.F. et al., J. Mol. Biol. 21:403-10 (1990), herein incorporated by reference) indicate that SEQ ID NO: 3 is homologous to Slit proteins.

10 [0390] Figure 1 shows the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID NO: 2 (i.e. SEQ ID NO: 3) NGM-like polypeptide and rat Slit1 SEQ ID NO: 14 (Brose et al., (1999) Cell 96, 795-806), indicating that the two sequences share 52% similarity over 185 amino acid residues and 35 % identity over the same 185 amino acid residues.

15 [0391] Figure 2 shows the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID NO: 2 (i.e. SEQ ID NO: 3) NGM-like polypeptide and rat Slit1 SEQ ID NO: 15 (Brose et al., (1999) Cell 96, 795-806), indicating that the two sequences share 53% similarity over 179 amino acid residues and 33 % identity over the same 179 amino acid residues.

20 [0392] Figure 3 shows the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID NO: 2 (i.e. SEQ ID NO: 3) NGM-like polypeptide and Rat Slit homolog, SEQ ID NO: 16 (International Patent Application number WO99/55865), indicating that the two sequences share 50% similarity over 216 amino acid residues and 33% identity over the same 216 amino acid residues.

25 [0393] Figure 4 shows the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID NO: 2 (i.e. SEQ ID NO: 3) NGM-like polypeptide and Rat Slit homolog, SEQ ID NO: 17 (International Patent Application number WO99/55865), indicating that the two sequences share 51 % similarity over 178 amino acid residues and 32 % identity over the same 178 amino acid residues.

30 [0394] A predicted approximately twenty five-residue signal peptide is encoded from approximately residue 1 through residue 25 of SEQ ID NO: 3 (SEQ ID NO: 10). The extracellular portion is useful on its own. This can be confirmed by expression in mammalian cells and sequencing of the cleaved product. The signal peptide region was predicted using the Kyte-Doolittle hydrophobicity prediction algorithm (J. Mol Biol, 157, pp. 105-31 (1982), incorporated herein by reference). One of skill in the art will recognize that the actual cleavage site may be different than that predicted by the computer program.

35 [0395] A predicted approximately twenty-residue transmembrane region is encoded from approximately residue 168 to residue 187 of SEQ ID NO: 3 (SEQ ID NO: 11). A second predicted approximately twenty four-residue transmembrane region is encoded from approximately residue 527 to residue 550 of SEQ ID NO: 3 (SEQ ID NO: 12). The transmembrane portions may be useful on their own. This can be confirmed by expression in mammalian cells. The transmembrane peptide regions were predicted using the Kyte-Doolittle hydrophobicity prediction algorithm (J. Mol Biol, 157, pp. 105-31 (1982), incorporated herein by reference). One of skill in the art will recognize that the actual transmembrane regions may be different than those predicted by the computer program.

40 [0396] Using eMATRIX software package (Stanford University, Stanford, CA) (Wu et al., J. Comp. Biol., vol. 6, pp. 219-235 (1999), herein incorporated by reference), NGM-like polypeptide SEQ ID NO: 3, is expected to have five leucine-rich repeat signature domains as shown in the table. The domains corresponding to SEQ ID NO: 5-9 are as follows wherein A=Alanine, C=Cysteine, D=Aspartic Acid, E= Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine, M=Methionine, N=Asparagine, P=Proline, Q=Glutamine, R=Arginine, S=Serine, T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine:

45

SEQ	p-value	Signature	Name	Amino acid sequence
-----	---------	-----------	------	---------------------

50

55

ID NO		ID NO		encoded (start and end amino acid position)
5	8.435e-10	PR00019A	Leucine-rich repeat signature	LKILNLSFNNLTAL (327-340)
10	9.217e-10	PR00019A	Leucine-rich repeat signature	LRILDLSNNNILRI (182-195)
15	3.333e-09	PR00019A	Leucine-rich repeat signature	LKHLILSHNDLENL (278-291)
20	3.520e-09	PR00019B	Leucine-rich repeat signature	LKSLRRLSLSHNPI (227-240)
	9.280e-09	PR00019B	Leucine-rich repeat signature	LKNLIYLKLDRNRI (299-312)

25 [0397] In order to determine the chromosomal location of SEQ ID NO: 2, the entire nucleic acid sequence was first blasted against the human genome sequence database available at NCBI web site, <http://www.ncbi.nlm.nih.gov>. If the search results in an almost identical hit over a substantial segment of the query sequence, then the sequence is considered to map to same location in the human genome as the homologous sequences. Sequences homologous to SEQ ID NO: 2 were found on human chromosome 5.

30 [0398] SEQ ID NO: 2 was determined to be present in the following tissues: adrenal gland (Clontech) (Hyseq library name ADR002), adult heart (GIBCO) (Hyseq library name AHR001), adult kidney (GIBCO) (Hyseq library name AKD001) and (Invitrogen) (Hyseq library name AKT002), adult lung (GIBCO) (Hyseq library name ALG001), adult ovary (Invitrogen) (Hyseq library name AOV001), adult cervix (BioChain) (Hyseq library name CVX001), endothelial cells (Stratagene) (Hyseq library name EDT001), fetal brain (Clontech) (Hyseq library name FBR001), fetal kidney (Clontech) (Hyseq library names FKD001 and FKD002), fetal lung (Clontech) (Hyseq library name FLG001), fetal liver-spleen (Columbia University) (Hyseq library names FLS002 and FLS003), fetal muscle (Invitrogen) (Hyseq library name FMS001), infant brain (Columbia University) (Hyseq library name IB2002), lung tumor (Invitrogen) (Hyseq library name LGT002), lymphocytes (ATCC) (Hyseq library name LPC001), leukocyte (GIBCO) (Hyseq library name LUC001), melanoma from cell line ATCC #CRL 1424 (Clontech) (Hyseq library name MBL004), retinoic acid induced neuronal cells (Stratagene) (Hyseq library name NTR001), pituitary gland (Clontech) (Hyseq library name PIT004), placenta (Clontech) (Hyseq library name PLA003), prostate (Clontech) (Hyseq library name PRT001), small intestine (Clontech) (Hyseq library name SIN001), spinal cord (Clontech) (Hyseq library name SPC001), stomach (Clontech) (Hyseq library name STO001), thyroid gland (Clontech) (Hyseq library name THR001), and uterus (Clontech) (Hyseq library name UTR001). The tissue expression information was determined using the tissue source of the ESTs that comprise SEQ ID NO: 2 and the tissue sources of the other ESTs of the cluster to which those ESTs belong. Clusters were made 45 depending on the sequence signature of each sequence as described in Example 1.

#### EXAMPLE 4

##### ASSEMBLAGE OF SEQ ID NO: 20, 21 and 28

50 [0399] Assembly of the novel nucleotide sequences of SEQ ID NO: 20 and 28 were accomplished using the EST sequence SEQ ID NO: 18 as a seed. The seed was extended by gel sequencing (377 Applied Biosystems (ABI) sequencer) using primers to extend the 3' end (primer extension). The seed was also extended by searching for homologous sequences using BLAST algorithm and the human genomic sequence database available at NCBI website, <http://www.ncbi.nlm.nih.gov>. The sequence of SEQ ID NO: 31 has been further extended from the 5' and 3' ends than SEQ ID NO: 20.

55 [0400] A polypeptide (SEQ ID NO: 21) was predicted to be encoded by SEQ ID NO: 20 as set forth below. The polypeptide was predicted using a software program called BLASTX which selects a polypeptide based on a compar-

ison of translated novel polynucleotide to known polynucleotides. The initial methionine starts at position 1 of SEQ ID NO: 2 and the putative stop codon, TGA, begins at position 1819 of the nucleotide sequence. SEQ ID NO: 21 was also predicted to be encoded by SEQ ID NO: 31 based on the polypeptide prediction made using SEQ ID NO: 20. The initial methionine starts at position 485 and the putative stop codon, TGA, begins at position 2305 of the nucleotide sequence.

5 [0401] The NGM-like polypeptide of SEQ ID NO: 21 is an approximately 606-amino acid secreted protein with a predicted molecular mass of approximately 68 kDa unglycosylated. Protein database searches with the BLASTX algorithm (Altschul S.F. et al., J. Mol. Evol. 36:290-300 (1993) and Altschul S.F. et al., J. Mol. Biol. 21:403-10 (1990), herein incorporated by reference) indicate that SEQ ID NO: 3 is homologous to neuronal leucine-rich repeat-3 (NLRR-3) protein and Tango-79 protein.

10 [0402] Figure 5 shows the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID NO: 20 or 31 (i.e. SEQ ID NO: 21) NGM-like polypeptide and neuronal leucine-rich repeat protein-3 (NLRR-3), SEQ ID NO: 29, indicating that the two sequences share 46% similarity over 511 amino acid residues and 27% identity over the same 511 amino acid residues.

15 [0403] Figure 6A and 6B show the BLASTX amino acid sequence alignment between the protein encoded by SEQ ID NO: 20 or 31 (i.e. SEQ ID NO: 21) NGM-like polypeptide and human Tango-79 protein, SEQ ID NO: 30 (International Patent Application number WO9906427) indicating that the two sequences share 77% similarity over 603 amino acid residues and 60% identity over the same 603 amino acid residues.

20 [0404] A predicted approximately twenty seven-residue signal peptide is encoded from approximately residue 1 through residue 27 of SEQ ID NO: 21 (SEQ ID NO: 26). The extracellular portion is useful on its own. This can be confirmed by expression in mammalian cells and sequencing of the cleaved product. The signal peptide region was predicted using the Neural Network SignalP V1.1 program (from Center for Biological Sequence Analysis, The Technical University of Denmark, incorporated herein by reference). One of skill in the art will recognize that the actual cleavage site may be different than that predicted by the computer program.

25 [0405] Using eMATRIX software package (Stanford University, Stanford, CA) (Wu et al., J. Comp. Biol., vol. 6, pp. 219-235 (1999), herein incorporated by reference), NGM-like polypeptide is expected to have a receptor interleukin-1 precursor domain, a leucine-rich repeat signature domain, and a receptor tyrosine kinase class III proteins domain as shown in the table. The domains corresponding to SEQ ID NO: 23-25 are as follows wherein A=Alanine, C=Cysteine, D=Aspartic Acid, E= Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine, M=Methionine, N=Asparagine, P=Proline, Q=Glutamine, R=Arginine, S=Serine, T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine:

SEQ ID NO	p-value	Signature ID NO	Name	Amino acid sequence encoded (start and end amino acid position)
23	5.871e-11	PD02870B	Receptor interleukin-1 precursor	LEIRFAQDQDSGMVYV CIASNAAGNDTFTASL TV (468-499)
24	8.043e-10	PR00019A	Leucine-rich repeat signature	LTHLNLSYNPISTI (275-287)
25	4.447e-09	BL00240B	Receptor tyrosine kinase class III proteins	LECSADGDPQPVISW VTPRRRFIT (430-452)

50

[0406] In order to determine the chromosomal location of SEQ ID NO: 20, the entire nucleic acid sequence was first blasted against the human genome sequence database available at NCBI web site, <http://www.ncbi.nlm.nih.gov>. If the search results in an almost identical hit over a substantial segment of the query sequence, then the sequence is considered to map to same location in the human genome as the homologous sequences. Sequences homologous to SEQ ID NO: 20 were found on human chromosome 9.

55 [0407] SEQ ID NO: 20 or 31 were determined to be present in the following tissues: fetal brain (Clontech) (Hyseq library name FBR006), fetal muscle (Invitrogen) (Hyseq library name FMS001), fetal brain (Clontech) (Hyseq library

name HFB001), infant brain (Columbia University) (Hyseq library names IB2002 and IB2003), lymphocytes (ATCC) (Hyseq library name LPC001), neuronal cells (Stratagene) (Hyseq library name NTU001), and pituitary gland (Clontech) (Hyseq library name PIT004). The tissue expression information was determined using the tissue source of the ESTs that comprise SEQ ID NO: 20 or 31 and the tissue sources of the other ESTs of the cluster to which those ESTs belong.

5 Clusters were made depending on the sequence signature of each sequence as described in Example 1.

## EXAMPLE 5

A. Expression of SEQ ID NO: 3 and 21 in cells

10 [0408] Chinese Hamster Ovary (CHO) cells or other suitable cell types are grown in DMEM (ATCC) and 10% fetal bovine serum (FBS) (Gibco) to 70% confluence. Prior to transfection the media is changed to DMEM and 0.5% FCS. Cells are transfected with cDNAs for SEQ ID NO: 2, 4, 20, 22, or 31 or with pBGal vector by the FuGENE-6 transfection reagent (Boehringer). In summary, 4  $\mu$ l of FuGENE-6 is diluted in 100  $\mu$ l of DMEM and incubated for 5 minutes. Then, this is added to 1  $\mu$ g of DNA and incubated for 15 minutes before adding it to a 35 mm dish of CHO cells. The CHO cells are incubated at 37°C with 5 % CO<sub>2</sub>. After 24 hours, media and cell lysates are collected, centrifuged and dialyzed against assay buffer (15 mM Tris pH 7.6, 134 mM NaCl, 5 mM glucose, 3 mM CaCl<sub>2</sub> and MgCl<sub>2</sub>).

B. Expression Study Using SEQ ID NO: 1-2, 4, 18-20, 22, or 31

20 [0409] The expression of SEQ ID NO: 1-2, 4, 18-20, 22, or 31 in various tissues is analyzed using a semi-quantitative polymerase chain reaction-based technique. Human cDNA libraries are used as sources of expressed genes from tissues of interest (adult bladder, adult brain, adult heart, adult kidney, adult lymph node, adult liver, adult lung, adult ovary, adult placenta, adult rectum, adult spleen, adult testis, bone marrow, thymus, thyroid gland, fetal kidney, fetal 25 liver, fetal liver-spleen, fetal skin, fetal brain, fetal leukocyte and macrophage). Gene-specific primers are used to amplify portions of SEQ ID NO: 1-2, 4, 18-20, 22, or 31 sequence from the samples. Amplified products are separated on an agarose gel, transferred and chemically linked to a nylon filter. The filter is then hybridized with a radioactively labeled (<sup>33</sup>P-dCTP) double-stranded probe generated from SEQ ID NO: 1-2, 4, 18-20, 22, or 31 using a Klenow polymerase, random-prime method. The filters are washed (high stringency) and used to expose a phosphorimaging screen 30 for several hours. Bands indicate the presence of cDNA including SEQ ID NO: 1-2, 4, 18-20, 22, or 31 sequences in a specific library, and thus mRNA expression in the corresponding cell type or tissue.

35

40

45

50

55

**SEQUENCE LISTING**

<110> Hysaq, Inc.  
Boyle, Bryan J  
Yeung, George  
Arterburn, Matthew C  
Palencia, Servando  
Liu, Chenghua  
Tang, Y. Tom  
Godbole, Shubhada D  
Kuo, Chiaoyun  
Drmanac, Radoje T  
Palencia, Sevando

<120> METHODS AND MATERIALS RELATING TO NEURONAL GUIDANCE MOLECULE-LIKE (NGM-LIKE) POLYPEPTIDES AND POLYNUCLEOTIDES

<130> Hys-35/ 21272-038

<140> NOT YET ASSIGNED

<141> 2000-02-02

<150> 09/721,115

<151> 2000-11-22

<150> US 09/560,875

<151> 2000-04-27

<150> US 09/496,914

<151> 2000-02-03

<160> 31

<170> PatentIn version 3.0

<210> 1

<211> 474

<212> DNA

<213> *Homo sapiens*

<220>

<221> misc\_feature

<222> (1) .. (474)

<223> n = A, T,

```
<400> 1
ntttcatag atagctatga tagagaggcc ctgaaaatacc gcgtcgacac cacgcgtcg 60
accacgcgtg cgaataattt aacaaaagta ccatcatatg cctttaaattt acttaaaagt 120
gttagaagac tttctttgtc ggataatcct atgaaagcaa tacagccctt tgcatttaaa 180
ggacttgcgg atttggaaata cctccctcg aaaaattcaa gaatttaggaa tgttactagg 240
gatgggttta gaggaattaa taatcttaaa catttgatct taagtctaaa tgatcttag 300
aattttaaattt ctgacacattt cattttggta aagaacttaa tttaccttaa gtttagataga 360
aacagaatac tttagcattga taatgataca tttgaaaata tgggagcatc tttgaagatc 420
cttaatctgt catttaataa acttacagcc ttgcattcca aggggccctaa gccc 474
```

5 <210> 2  
 <211> 2204  
 <212> DNA  
 <213> Homo sapiens  
  
 10 <220>  
 <221> CDS  
 <222> (186)..(2054)  
  
 15 <400> 2  
 cagtggtaac aacgcagagt agcgggggg gtggaggtca gcagtgccac agaacaaaact 60  
 ggagttaaga aatgtcggttc ttcagattt aaaaagaaaaac ctttactgaa tcagctgagt 120  
 gttaataata cgaatttcct tttcttgcca attctgtatc gaacagaaaa tccaagaaca 180  
 gggat atg tgt gga tta cag ttt tct ctg cct tgc cta cga ctg ttt ctg 230  
     Met Cys Gly Leu Gln Phe Ser Leu Pro Cys Leu Arg Leu Phe Leu  
     1           5           10           15  
  
 20 gtt gtt acc tgt tat ctt tta tta ctc cac aaa gaa ata ctt gga 278  
   Val Val Thr Cys Tyr Leu Leu Leu Leu His Lys Glu Ile Leu Gly  
   20           25           30  
  
 25 tgt tcg tct gtt tgt cag ctc tgc act ggg aga caa att aac tgc cgt 326  
   Cys Ser Ser Val Cys Gln Leu Cys Thr Gly Arg Gln Ile Asn Cys Arg  
   35           40           45  
  
 30 aac tta ggc ctt tcg agt att cct aag aat ttt cct gaa agt aca gtt 374  
   Asn Leu Gly Leu Ser Ser Ile Pro Lys Asn Phe Pro Glu Ser Thr Val  
   50           55           60  
  
 35 ttt ctg tat ctg act ggg aat aat ata tct tat ata aat gaa agt gaa 422  
   Phe Leu Tyr Leu Thr Gly Asn Asn Ile Ser Tyr Ile Asn Glu Ser Glu  
   65           70           75  
  
 40 tta aca gga ctt cat tct ctt gta gca ttg tat ttg gat aat tct aac 470  
   Leu Thr Gly Leu His Ser Leu Val Ala Leu Tyr Leu Asp Asn Ser Asn  
   80           85           90           95  
  
 45 att ctg tat gta tat cca aaa gcc ttt gtt caa ttg agg cat cta tat 518  
   Ile Leu Tyr Val Tyr Pro Lys Ala Phe Val Gln Leu Arg His Leu Tyr  
   100           105           110  
  
 50 ttt cta ttt cta aat aat aat ttc atc aaa cgc tta gat cct gga ata 566  
   Phe Leu Phe Leu Asn Asn Phe Ile Lys Arg Leu Asp Pro Gly Ile  
   115           120           125  
  
 55 ttt aag gga ctt tta aat ctt cgt aat tta tat tta cag tat aat cag 614  
   Phe Lys Gly Leu Leu Asn Leu Arg Asn Leu Tyr Leu Gln Tyr Asn Gln  
   130           135           140  
  
 60 gta tct ttt gtt ccg aga gga gta ttt aat gat cta gtt tca gtt cag 662  
   Val Ser Phe Val Pro Arg Gly Val Phe Asn Asp Leu Val Ser Val Gln  
   145           150           155  
  
 65 tac tta aat cta caa agg aat cgc ctc act gtc ctt ggg agt ggt acc 710  
   Tyr Leu Asn Leu Gln Arg Asn Arg Leu Thr Val Leu Gly Ser Gly Thr  
   160           165           170           175  
  
 70 ttt gtt ggt atg gtt gct ctt ccg ata ctt gat tta tca aac aat aac 758  
   Phe Val Gly Met Val Ala Leu Arg Ile Leu Asp Leu Ser Asn Asn Asn  
   180           185           190

## EP 1 574 520 A2

	att ttg agg ata tca gaa tca ggc ttt caa cat ctt gaa aac ctt gct Ile Leu Arg Ile Ser Glu Ser Gly Phe Gln His Leu Glu Asn Leu Ala 195 200 205	806
5	tgt ttg tat tta gga agt aat aat tta aca aaa gta cca tca aat gcc Cys Leu Tyr Leu Gly Ser Asn Asn Leu Thr Lys Val Pro Ser Asn Ala 210 215 220	854
10	ttt gaa gta ctt aaa agt ctt aga aga ctt tct ttg tct cat aat cct Phe Glu Val Leu Lys Ser Leu Arg Arg Leu Ser Leu Ser His Asn Pro 225 230 235	902
15	att gaa gca ata cag ccc ttt gca ttt aaa gga ctt gcc aat ctg gaa Ile Glu Ala Ile Gln Pro Phe Ala Phe Lys Gly Leu Ala Asn Leu Glu 240 245 250 255	950
	tac ctc ctc ctg aaa aat tca aga att agg aat gtt act agg gat ggg Tyr Leu Leu Lys Asn Ser Arg Ile Arg Asn Val Thr Arg Asp Gly 260 265 270	998
20	ttt agt gga att aat aat ctt aaa cat ttg atc tta agt cat aat gat Phe Ser Gly Ile Asn Asn Leu Lys His Leu Ile Leu Ser His Asn Asp 275 280 285	1046
25	tta gag aat tta aat tct gac aca ttc agt ttg tta aag aat tta att Leu Glu Asn Leu Asn Ser Asp Thr Phe Ser Leu Leu Lys Asn Leu Ile 290 295 300	1094
	tac ctt aag tta gat aga aac aga ata att agc att gat aat gat aca Tyr Leu Lys Leu Asp Arg Asn Arg Ile Ile Ser Ile Asp Asn Asp Thr 305 310 315	1142
30	ttt gaa aat atg gga gca tct ttg aag atc ctt aat ctg tca ttt aat Phe Glu Asn Met Gly Ala Ser Leu Lys Ile Leu Asn Leu Ser Phe Asn 320 325 330 335	1190
35	aat ctt aca gcc ttg cat cca agg gtc ctt aag ccg ttg tct tca ttg Asn Leu Thr Ala Leu His Pro Arg Val Leu Lys Pro Leu Ser Ser Leu 340 345 350	1238
	att cat ctt cag gca aat tct aat cct tgg gaa tgt aac tgc aaa ctt Ile His Leu Gln Ala Asn Ser Asn Pro Trp Glu Cys Asn Cys Lys Leu 355 360 365	1286
40	ttg ggc ctt cga gac tgg cta gca tct tca gcc att act cta aac atc Leu Gly Leu Arg Asp Trp Leu Ala Ser Ser Ala Ile Thr Leu Asn Ile 370 375 380	1334
45	tat tgt cag aat ccc cca tcc atg cgt ggc aga gca tta cgt tat att Tyr Cys Gln Asn Pro Pro Ser Met Arg Gly Arg Ala Leu Arg Tyr Ile 385 390 395	1382
	aac att aca aat tgt gtt aca tct tca ata aat gta tcc aga gct tgg Asn Ile Thr Asn Cys Val Thr Ser Ser Ile Asn Val Ser Arg Ala Trp 400 405 410 415	1430
50	gct gtt gta aaa tct cct cat att cat cac aag act act gcg cta atg Ala Val Val Lys Ser Pro His Ile His His Lys Thr Thr Ala Leu Met 420 425 430	1478
55	atg gcc tgg cat aaa gta acc aca aat ggc agt cct ctg gaa aat act Met Ala Trp His Lys Val Thr Thr Asn Gly Ser Pro Leu Glu Asn Thr 435 440 445	1526

## EP 1 574 520 A2

5	gag act gag aac att act ttc tgg gaa cga att cct act tca cct gct Glu Thr Glu Asn Ile Thr Phe Trp Glu Arg Ile Pro Thr Ser Pro Ala 450 455 460	1574
10	ggt aga ttt ttt caa gag aat gcc ttt ggt aat cca tta gag act aca Gly Arg Phe Phe Gln Glu Asn Ala Phe Gly Asn Pro Leu Glu Thr Thr 465 470 475	1622
15	gca gtg tta cct gtg caa ata caa ctt act act tct gtt acc ttg aac Ala Val Leu Pro Val Gln Ile Gln Leu Thr Thr Ser Val Thr Leu Asn 480 485 490 495	1670
20	ttg gaa aaa aac agt gct cta ccg aat gat gct gct tca atg tca ggg Leu Glu Lys Asn Ser Ala Leu Pro Asn Asp Ala Ala Ser Met Ser Gly 500 505 510	1718
25	aaa aca tct cta att tgt aca caa gaa gtt gag aag ttg aat gag gct Lys Thr Ser Leu Ile Cys Thr Gln Glu Val Glu Lys Leu Asn Glu Ala 515 520 525	1766
30	ttt gac att ttg cta gct ttt ttc atc tta gct tgt gtt tta atc att Phe Asp Ile Leu Leu Ala Phe Phe Ile Leu Ala Cys Val Leu Ile Ile 530 535 540	1814
35	ttt ttg atc tac aaa gtt gtt cag ttt aaa caa aaa cta aag gca tca Phe Leu Ile Tyr Lys Val Val Gln Phe Lys Gln Lys Leu Lys Ala Ser 545 550 555	1862
40	gaa aac tca agg gaa aat aga ctt gaa tac tac agc ttt tat cag tca Glu Asn Ser Arg Glu Asn Arg Leu Glu Tyr Tyr Ser Phe Tyr Gln Ser 560 565 570 575	1910
45	gca agg tat aat gta act gcc tca att tgt aac act tcc cca aat tct Ala Arg Tyr Asn Val Thr Ala Ser Ile Cys Asn Thr Ser Pro Asn Ser 580 585 590	1958
50	cta gaa agt cct ggc ttg gag cag att cga ctt cat aaa caa att gtt Leu Glu Ser Pro Gly Leu Glu Gln Ile Arg Leu His Lys Gln Ile Val 595 600 605	2006
55	cct gaa aat gag gca cag gtc att ctt ttt gaa cat tct gct tta taa Pro Glu Asn Glu Ala Gln Val Ile Leu Phe Glu His Ser Ala Leu 610 615 620	2054
	ctcaactaaa tattgtctat aagaaacttc agtgcctatgg acatgattta aactgaaacc	2114
	tccttatata attataact ttagttgaa atataatgaa ttatatgagg ttagcattat	2174
	taaaatatgt tttataaaa aaaaaaaaaa	2204
	<210> 3	
	<211> 622	
	<212> PRT	
	<213> Homo sapiens	
	<400> 3	
	Met Cys Gly Leu Gln Phe Ser Leu Pro Cys Leu Arg Leu Phe Leu Val 1 5 10 15	
	Val Thr Cys Tyr Leu Leu Leu Leu His Lys Glu Ile Leu Gly Cys	

EP 1 574 520 A2

20 25 30

Leu Gly Leu Ser Ser Ile Pro Lys Asn Phe Pro Glu Ser Thr Val Phe  
50 55 60

10 Leu Tyr Leu Thr Gly Asn Asn Ile Ser Tyr Ile Asn Glu Ser Glu Leu  
65 70 . 75 80

15 Thr Gly Leu His Ser Leu Val Ala Leu Tyr Leu Asp Asn Ser Asn Ile  
                   85                   90                   95

Leu Tyr Val Tyr Pro Lys Ala Phe Val Gln Leu Arg His Leu Tyr Phe  
100 105 110

20 Leu Phe Leu Asn Asn Asn Phe Ile Lys Arg Leu Asp Pro Gly Ile Phe  
115 120 125

25 Lys Gly Leu Leu Asn Leu Arg Asn Leu Tyr Leu Gln Tyr Ash Gln Val  
130 135 140

Ser Phe Val Pro Arg Gly Val Phe Asn Asp Leu Val Ser Val Gln Tyr  
 145 150 155 160

Leu Asn Leu Gln Arg Asn Arg Leu Thr Val Leu Gly Ser Gly Thr Phe  
165 166 167 168 169 170 171 172 173 174 175

35 Val Gly Met Val Ala Leu Arg Ile Leu Asp Leu Ser Asn Asn Asn Ile  
180 185 190

210                    215                    220

225                    230                    235                    240

50 245 250 255

Leu Leu Leu Lys Asn Ser Arg Ile Arg Asn Val Thr Arg Asp Gly Phe  
260 265 270

Ser Gly Ile Asn Asn Leu Lys His Leu Ile Leu Ser His Asn Asp Leu

EP 1 574 520 A2

275                    280                    285

5	Glu	Asn	Leu	Asn	Ser	Asp	Thr	Phe	Ser	Leu	Leu	Lys	Asn	Leu	Ile	Tyr
	290						295					300				

Leu Lys Leu Asp Arg Asn Arg Ile Ile Ser Ile Asp Asn Asp Thr Phe  
305 310 315 320

10 Glu Asn Met Gly Ala Ser Leu Lys Ile Leu Asn Leu Ser Phe Asn Asn  
325 330 335

15 Leu Thr Ala Leu His Pro Arg Val Leu Lys Pro Leu Ser Ser Leu Ile  
340 345 350

His Leu Gln Ala Asn Ser Asn Pro Trp Glu Cys Asn Cys Lys Leu Leu  
355 360 365

20 Gly Leu Arg Asp Trp Leu Ala Ser Ser Ala Ile Thr Leu Asn Ile Tyr  
370 375 380

25 Cys Gln Asn Pro Pro Ser Met Arg Gly Arg Ala Leu Arg Tyr Ile Asn  
385 390 395 400

405 410 415  
30

Val Val Lys Ser Pro His Ile His His Lys Thr Thr Ala Ieu Met Met  
420 425 430

35 Ala Trp His Lys Val Thr Thr Asn Gly Ser Pro Leu Glu Asn Thr Glu  
435 440 445

Thr Glu Asn Ile Thr Phe Trp Glu Arg Ile Pro Thr Ser Pro Ala Gly  
450 455 460

Arg Phe Phe Gln Glu Asn Ala Phe Gly Asn Pro Leu Glu Thr Thr Ala  
465 470 475 480

49 Val Leu Pro Val Gln Ile Gln Leu Thr Thr Ser Val Thr Leu Asn Leu  
495 485 490 495

50 Glu Lys Asn Ser Ala Leu Pro Asn Asp Ala Ala Ser Met Ser Gly Lys  
500 505 510

Thr Ser Leu Ile Cys Thr Gln Glu Val Glu Lys Leu Asn Glu Ala Phe  
515 520 525

55 Asp Ile Leu Leu Ala Phe Phe Ile Leu Ala Cys Val Leu Ile Ile Phe

## EP 1 574 520 A2

530

535

540

5 Leu Ile Tyr Lys Val Val Gln Phe Lys Gln Lys Leu Lys Ala Ser Glu  
 545 550 555 560

10 Asn Ser Arg Glu Asn Arg Leu Glu Tyr Tyr Ser Phe Tyr Gln Ser Ala  
 565 570 575

15 Arg Tyr Asn Val Thr Ala Ser Ile Cys Asn Thr Ser Pro Asn Ser Leu  
 580 585 590

20 Glu Ser Pro Gly Leu Glu Gln Ile Arg Leu His Lys Gln Ile Val Pro  
 595 600 605

25 Glu Asn Glu Ala Gln Val Ile Leu Phe Glu His Ser Ala Leu  
 610 615 620

30 <210> 4  
 <211> 1869  
 <212> DNA  
 <213> Homo sapiens

35 <400> 4  
 atgtgtggat tacagtttc tctgccttgc ctacgactgt ttctgggtgt tacctgttat 60  
 cttttattat tactccacaa agaaaatactt ggatgttctgt ctgtttgtca gctctgcact 120  
 gggagacaaa ttaactgccc taacttaggc ctttcgagta ttccctaagaa ttttcctgaa 180  
 agtacagttt ttctgtatct gactggaaat aatatatctt atataaatga aagtgaatta 240  
 acaggacttc attctcttgc agcattgtat ttggataatt ctaacattctt gtatgtatata 300  
 35 cccaaagcct ttgttcaatt gaggcatcta tattttctat ttctaaataa taatttcatac 360  
 aaacgcttag atcctggaaat atttaaggga cttttaaatac ttctgtatattt atatttacag 420  
 tataatcagg tatctttgtt tccgagagga gtatataatg atcttagttt acgttcagttac 480  
 40 ttaaatctac aaaggaatcg cctcaactgtc cttggggatgt gtacctttgtt tggtatggtt 540  
 gctcttcgga tacttgattt atcaaacaat aacattttga ggatatcaga atcaggcttt 600  
 caacatcttgc aaaaccttgc ttgtttgtat ttaggaagta ataatttaac aaaagtacca 660  
 45 tcaaattgcct ttgaagtact taaaagtctt agaagactttt ctttgtctca taatcctatt 720  
 gaagcaatac agccctttgc atttaaaggaa cttgccaatc tggaaatactt ctcctgaaa 780  
 aattcaagaa ttaggaatgt tactaggat gggtttagtg gaattaataa ttctaaacat 840  
 50 ttgatcttaa gtcataatga ttttagagaat tttaattctg acacattcag ttgtttaaag 900  
 aatttaattt accttaaggat agatagaaaac agaataatta gcattgataa tgatacattt 960  
 gaaaatatgg gagcatcttgc gaagatcctt aatctgtcat ttataatct tacagccttgc 1020  
 55 catccaagggg ttcttaagcc gttgtttca ttgattcatac ttctaggcaaa ttctaaatcct 1080

5	tggaaatgt aactgcaaact tttgggcctt cgagactggc tagcatcttc agccattact	1140
	ctaaacatct attgtcagaa tccccatcc atgcgtggca gaggcattacg ttatattaac	1200
	attacaaatt gtgttacatc ttcaataat gtatccagag ctgggctgt tgtaaaatct	1260
10	cctcataatc atcacaagac tactgcgcta atgatggct ggcataaaagt aaccacaaat	1320
	ggcagtcctc tggaaaatac tgagactgag aacattactt tctggaaacg aattctact	1380
	tcacctgctg gtagatttt tcaagagaat gcctttgta atccattaga gactacagca	1440
	gtgttacctg tgcaaataca acttactact tctgttacct tgaacttggaa aaaaaacagt	1500
15	gctctaccga atgatgctgc ttcaatgtca gggaaaacat ctctaattt tacacaagaa	1560
	gttgagaagt tgaatgaggc ttttgacatt ttgctagctt ttttcatctt agcttgtgtt	1620
	ttaatcattt ttttgatcta caaagttgtt cagttaaac aaaaactaaa ggcatcagaa	1680
20	aactcaaggg aaaatagact tgaatactac agcttttac agtcagcaag gtataatgt	1740
	actgcctcaa tttgtAACAC ttccccaaat tctctagaaa gtcctggctt ggagcagatt	1800
	cgacttcata aacaaattgt tcctgaaaat gaggcacagg tcattcttt tgaacattct	1860
25	gctttataa	1869

30	<210> 5
	<211> 14
	<212> PRT
	<213> Homo sapiens
	<400> 5

35	Leu Lys Ile Leu Asn Leu Ser Phe Asn Asn Leu Thr Ala Leu
	1 5 10

	<210> 6
	<211> 14
	<212> PRT
	<213> Homo sapiens
40	<400> 6

	Leu Arg Ile Leu Asp Leu Ser Asn Asn Ile Leu Arg Ile
	1 5 10

45	<210> 7
	<211> 14
	<212> PRT
	<213> Homo sapiens
	<400> 7

50	Leu Lys His Leu Ile Leu Ser His Asn Asp Leu Glu Asn Leu
	1 5 10

55	<210> 8
	<211> 14
	<212> PRT
	<213> Homo sapiens

5                   <400> 8  
 Leu Lys Ser Leu Arg Arg Leu Ser Leu Ser His Asn Pro Ile  
 1                   5                   10  
  
 10                <210> 9  
 <211> 14  
 <212> PRT  
 <213> Homo sapiens  
  
 15                <400> 9  
  
 Leu Lys Asn Leu Ile Tyr Leu Lys Leu Asp Arg Asn Arg Ile  
 1                   5                   10  
  
 20                <210> 10  
 <211> 25  
 <212> PRT  
 <213> Homo sapiens  
  
 25                <400> 10  
  
 Met Cys Gly Leu Gln Phe Ser Leu Pro Cys Leu Arg Leu Phe Leu Val  
 1                   5                   10                   15  
  
 30                Val Thr Cys Tyr Leu Leu Leu Leu  
 25                   20                   25  
  
 <210> 11  
 <211> 20  
 <212> PRT  
 <213> Homo sapiens  
  
 35                <400> 11  
  
 Leu Thr Val Leu Gly Ser Gly Thr Phe Val Gly Met Val Ala Leu Arg  
 1                   5                   10                   15  
  
 40                Ile Leu Asp Leu  
 20  
  
 <210> 12  
 <211> 24  
 <212> PRT  
 <213> Homo sapiens  
  
 45                <400> 12  
  
 Ala Phe Asp Ile Leu Leu Ala Phe Phe Ile Leu Ala Cys Val Leu Ile  
 1                   5                   10                   15  
  
 50                Ile Phe Leu Ile Tyr Lys Val Val  
 20  
  
 <210> 13  
 <211> 597  
 <212> PRT  
 <213> Homo sapiens  
  
 55                <400> 13  
  
 His Lys Glu Ile Leu Gly Cys Ser Ser Val Cys Gln Leu Cys Thr Gly  
 1                   5                   10                   15

Arg Gln Ile Asn Cys Arg Asn Leu Gly Leu Ser Ser Ile Pro Lys Asn  
 20 25 30

5 Phe Pro Glu Ser Thr Val Phe Leu Tyr Leu Thr Gly Asn Asn Ile Ser  
 35 40 45

Tyr Ile Asn Glu Ser Glu Leu Thr Gly Leu His Ser Leu Val Ala Leu  
 50 55 60

10 Tyr Leu Asp Asn Ser Asn Ile Leu Tyr Val Tyr Pro Lys Ala Phe Val  
 65 70 75 80

Gln Leu Arg His Leu Tyr Phe Leu Phe Leu Asn Asn Asn Phe Ile Lys  
 85 90 95

15 Arg Leu Asp Pro Gly Ile Phe Lys Gly Leu Leu Asn Leu Arg Asn Leu  
 100 105 110

Tyr Leu Gln Tyr Asn Gln Val Ser Phe Val Pro Arg Gly Val Phe Asn  
 115 120 125

20 Asp Leu Val Ser Val Gln Tyr Leu Asn Leu Gln Arg Asn Arg Leu Thr  
 130 135 140

Val Leu Gly Ser Gly Thr Phe Val Gly Met Val Ala Leu Arg Ile Leu  
 145 150 155 160

25 Asp Leu Ser Asn Asn Ile Leu Arg Ile Ser Glu Ser Gly Phe Gln  
 165 170 175

His Leu Glu Asn Leu Ala Cys Leu Tyr Leu Gly Ser Asn Asn Leu Thr  
 180 185 190

30 Lys Val Pro Ser Asn Ala Phe Glu Val Leu Lys Ser Leu Arg Arg Leu  
 195 200 205

Ser Leu Ser His Asn Pro Ile Glu Ala Ile Gln Pro Phe Ala Phe Lys  
 210 215 220

35 Gly Leu Ala Asn Leu Glu Tyr Leu Leu Lys Asn Ser Arg Ile Arg  
 225 230 235 240

Asn Val Thr Arg Asp Gly Phe Ser Gly Ile Asn Asn Leu Lys His Leu  
 245 250 255

40 Ile Leu Ser His Asn Asp Leu Glu Asn Leu Asn Ser Asp Thr Phe Ser  
 260 265 270

Leu Leu Lys Asn Leu Ile Tyr Leu Lys Leu Asp Arg Asn Arg Ile Ile  
 275 280 285

45 Ser Ile Asp Asn Asp Thr Phe Glu Asn Met Gly Ala Ser Leu Lys Ile  
 290 295 300

Leu Asn Leu Ser Phe Asn Asn Leu Thr Ala Leu His Pro Arg Val Leu  
 305 310 315 320

50 Lys Pro Leu Ser Ser Leu Ile His Leu Gln Ala Asn Ser Asn Pro Trp  
 325 330 335

55 Glu Cys Asn Cys Lys Leu Leu Gly Leu Arg Asp Trp Leu Ala Ser Ser  
 340 345 350

## EP 1 574 520 A2

Ala Ile Thr Leu Asn Ile Tyr Cys Gln Asn Pro Pro Ser Met Arg Gly  
 355 360 365  
 Arg Ala Leu Arg Tyr Ile Asn Ile Thr Asn Cys Val Thr Ser Ser Ile  
 5 370 375 380  
 Asn Val Ser Arg Ala Trp Ala Val Val Lys Ser Pro His Ile His His  
 385 390 395 400  
 Lys Thr Thr Ala Leu Met Met Ala Trp His Lys Val Thr Thr Asn Gly  
 10 405 410 415  
 Ser Pro Leu Glu Asn Thr Glu Thr Glu Asn Ile Thr Phe Trp Glu Arg  
 420 425 430  
 Ile Pro Thr Ser Pro Ala Gly Arg Phe Phe Gln Glu Asn Ala Phe Gly  
 15 435 440 445  
 Asn Pro Leu Glu Thr Thr Ala Val Leu Pro Val Gln Ile Gln Leu Thr  
 450 455 460  
 Thr Ser Val Thr Leu Asn Leu Glu Lys Asn Ser Ala Leu Pro Asn Asp  
 20 465 470 475 480  
 Ala Ala Ser Met Ser Gly Lys Thr Ser Leu Ile Cys Thr Gln Glu Val  
 485 490 495  
 Glu Lys Leu Asn Glu Ala Phe Asp Ile Leu Leu Ala Phe Phe Ile Leu  
 25 500 505 510  
 Ala Cys Val Leu Ile Ile Phe Leu Ile Tyr Lys Val Val Gln Phe Lys  
 515 520 525  
 Gln Lys Leu Lys Ala Ser Glu Asn Ser Arg Glu Asn Arg Leu Glu Tyr  
 30 530 535 540  
 Tyr Ser Phe Tyr Gln Ser Ala Arg Tyr Asn Val Thr Ala Ser Ile Cys  
 545 550 555 560  
 Asn Thr Ser Pro Asn Ser Leu Glu Ser Pro Gly Leu Glu Gln Ile Arg  
 35 565 570 575  
 Leu His Lys Gln Ile Val Pro Glu Asn Glu Ala Gln Val Ile Leu Phe  
 580 585 590  
 Glu His Ser Ala Leu  
 40 595  
 <210> 14  
 <211> 184  
 <212> PRT  
 45 <213> Rattus norvegicus  
 <400> 14  
 Cys Pro Ala Leu Cys Thr Cys Thr Gly Thr Thr Val Asp Cys His Gly  
 50 1 5 10 15  
 Thr Gly Leu Gln Ala Ile Pro Lys Asn Ile Pro Arg Asn Thr Glu Arg  
 20 25 30  
 Leu Glu Leu Asn Gly Asn Asn Ile Thr Trp Ile His Lys Asn Asp Phe  
 55 35 40 45

EP 1 574 520 A2

Ala Gly Leu Lys Gln Leu Arg Val Leu Gln Leu Met Glu Asn Pro Ile  
 50 55 60  
 Gly Ala Val Glu Pro Gly Ala Phe Asp Asp Met Lys Glu Leu Glu Pro  
 5 65 70 75 80  
 Phe Gln Leu Asn Arg Asn Gln Leu Gln Met Leu Pro Glu Leu Leu Phe  
 85 90 95  
 Gln Asn Asn Gln Ala Leu Ser Arg Leu Asp Leu Ser Glu Asn Ser Leu  
 10 100 105 110  
 Gln Ala Val Pro Arg Lys Ala Phe Arg Gly Ala Thr Asp Leu Lys Asn  
 115 120 125  
 Leu Gln Leu Asp Lys Asn Gln Ile Ser Cys Ile Glu Glu Gly Ala Phe  
 15 130 135 140  
 Arg Ala Leu Arg Gly Leu Glu Val Leu Thr Leu Asn Asn Asn Asn Ile  
 145 150 155 160  
 Thr Thr Ile Pro Val Ser Ser Phe Asn His Met Pro Lys Leu Arg Thr  
 20 165 170 175  
 Phe Arg Leu His Ser Asn His Leu  
 180  
 25 <210> 15  
 <211> 175  
 <212> PRT  
 <213> Rattus norvegicus  
 30 <400> 15  
 Leu Ser Lys Ile Pro Glu Arg Ile Pro Gln Ser Thr Thr Glu Leu Arg  
 1 5 10 15  
 Leu Asn Asn Asn Glu Ile Ser Ile Leu Glu Ala Thr Gly Leu Phe Lys  
 35 20 25 30  
 Lys Leu Ser His Leu Lys Ile Asn Leu Ser Asn Asn Lys Val Ser  
 35 40 45  
 Glu Ile Glu Asp Gly Thr Phe Glu Gly Ala Thr Ser Val Ser Glu Leu  
 40 50 55 60  
 His Leu Thr Ala Asn Gln Leu Glu Ser Val Arg Ser Gly Met Phe Arg  
 65 70 75 80  
 Gly Leu Asp Gly Leu Trp Ser Leu Met Leu Arg Asn Asn Arg Ile Ser  
 45 85 90 95  
 Cys Ile His Asn Asp Ser Phe Thr Gly Leu Arg Asn Val Arg Leu Leu  
 100 105 110  
 Ser Leu Tyr Asp Asn His Ile Thr Thr Ile Ser Pro Gly Ala Phe Asp  
 50 115 120 125  
 Thr Leu Gln Ala Leu Ser Thr Leu Asn Leu Leu Ala Asn Pro Phe Asn  
 130 135 140  
 Cys Asn Cys Gln Leu Ala Trp Leu Gly Asp Trp Leu Arg Lys Arg Lys  
 55 145 150 155 160

## EP 1 574 520 A2

Ile Val Thr Gly Asn Pro Arg Cys Gln Asn Pro Asp Phe Leu Arg  
 165 170 175  
 5 <210> 16  
 <211> 211  
 <212> PRT  
 <213> Rattus sp.  
 10 <400> 16  
 Met Ser Gly Ile Gly Trp Gln Thr Leu Ser Leu Ser Leu Ala Leu Val  
 1 5 10 15  
 Leu Ser Ile Leu Asn Lys Val Ala Pro His Ala Cys Pro Ala Gln Cys  
 20 25 30  
 15 Ser Cys Ser Gly Ser Thr Val Asp Cys His Gly Leu Ala Leu Arg Ser  
 35 40 45  
 Val Pro Arg Asn Ile Pro Arg Asn Thr Glu Arg Leu Asp Leu Asn Gly  
 50 55 60  
 20 Asn Asn Ile Thr Arg Ile Thr Lys Thr Asp Phe Ala Gly Leu Arg His  
 65 70 75 80  
 Leu Arg Val Leu Gln Leu Met Glu Asn Lys Ile Ser Thr Ile Glu Arg  
 85 90 95  
 25 Gly Ala Phe Gln Asp Leu Lys Glu Leu Glu Arg Leu Arg Leu Asn Arg  
 100 105 110  
 Asn Asn Leu Gln Leu Phe Pro Glu Leu Leu Phe Leu Gly Thr Ala Lys  
 115 120 125  
 30 Leu Tyr Arg Leu Asp Leu Ser Glu Asn Gln Ile Gln Ala Ile Pro Arg  
 130 135 140  
 Lys Ala Phe Arg Gly Ala Val Asp Ile Lys Asn Leu Gln Leu Asp Tyr  
 145 150 155 160  
 35 Asn Gln Ile Ser Cys Ile Glu Asp Gly Ala Phe Arg Ala Leu Arg Asp  
 165 170 175  
 Leu Glu Val Leu Thr Leu Asn Asn Asn Ile Thr Arg Leu Ser Val  
 180 185 190  
 40 Ala Ser Phe Asn His Met Pro Lys Leu Arg Thr Phe Arg Leu His Ser  
 195 200 205  
 Asn Asn Leu  
 210  
 45 <210> 17  
 <211> 174  
 <212> PRT  
 <213> Rattus sp.  
 50 <400> 17  
 Asn Gln Lys Leu Asn Lys Ile Pro Asp His Ile Pro Gln Tyr Thr Ala  
 1 5 10 15  
 55 Glu Leu Arg Leu Asn Asn Asn Glu Phe Thr Val Leu Glu Ala Thr Gly  
 20 25 30

Ile Phe Lys Lys Leu Pro Gln Leu Arg Lys Ile Asn Leu Ser Asn Asn  
 35 40 45

5 Lys Ile Thr Asp Ile Glu Glu Gly Ala Phe Glu Gly Ala Ser Gly Val  
 50 55 60

Asn Glu Ile Leu Leu Thr Ser Asn Arg Leu Glu Asn Val Gln His Lys  
 65 70 75 80

10 Met Phe Lys Gly Leu Glu Ser Leu Lys Thr Leu Met Leu Arg Ser Asn  
 85 90 95

Arg Ile Ser Cys Val Gly Asn Asp Ser Phe Thr Gly Leu Gly Ser Val  
 100 105 110

15 Arg Leu Leu Ser Leu Tyr Asp Asn Gln Ile Thr Thr Val Ala Pro Gly  
 115 120 125

Ala Phe Gly Thr Leu His Ser Leu Ser Thr Leu Asn Leu Leu Ala Asn  
 130 135 140

20 Pro Phe Asn Cys Asn Cys His Leu Ala Trp Leu Gly Glu Trp Leu Arg  
 145 150 155 160

Arg Lys Arg Ile Val Thr Gly Asn Pro Arg Cys Gln Lys Pro  
 165 170

25 <210> 18  
 <211> 489  
 <212> DNA  
 <213> Homo sapiens

30 <220>  
 <221> misc\_feature  
 <222> (1)..(489)  
 <223> n = A, T, G, or C

35 <400> 18  
 aggccctggm tttganaccg attgaacacc gtcttgacca tgcttagcgc caagcttggc 60  
 acgagggcgg aggtgggaga gggcttctgt tggtaactgtgt gttaagttgc atttctccag 120  
 40 ggtgagctgc tccaaagctaa gaagcccact gaatgcctg tggatataat aaaccaaatac 180  
 attgtcccccc acttcttagag acttcaggtt atgttagatct tggAACATGT agtcttagtaa 240  
 aatgacaatc ttattctcac taatgtcaag cttagtgaga ttggacagcc cctgtaaatac 300  
 45 tcccaaaggaccagttta gacgattgc ttttagggcg aggAACGCA gttaaagag 360  
 atgttgaat gtcctgggtt ccacattggc aatgtatgtt tcactcaagt ctatctttc 420  
 cagcagagga tatgtatgtt attttcagg gttgacgctt tttggctgt tttactgag 480  
 50 gtcctaaat 489

<210> 19  
 <211> 489  
 <212> DNA  
 <213> Homo sapiens

```

<220>
<221> misc_feature
<222> (1)..(489)
<223> n = A, T, G, or C
5

<400> 19
aggccctggm tttganaccc attgaacacc gtcttgacca tgcttagcgc caagcttggc 60
acgagggcgg aggtgggaga gggcttctgt tggtaactgtc gttaagttgc atttctccag 120
10 ggtgagctgc tccaagctaa gaagccact gaatgccctg tggatataat aaaccaaatac 180
attgtccccc acttcttagag acttcagggtt atgtatgtc tggaaacatgt agtctagtaa 240
15 aatgacaatac ttattctcac taatgtcaag ctttgtgaga ttggacagcc ccgtgaatac 300
tcccaaaggg accagctta gacgattgcc tttaggogg agggAACGCA ggttaaagag 360
atgttgaat gtcctgggtt ccacattggc aatgtatgtc tcaactcaagt ctatctttc 420
20 cagcagagga tatgatatac atttttcagg gttgaegttt tttagcctgt tttactgag 480
gtccaaagat 489

<210> 20
25 <211> 1821
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
30 <222> (1)..(1821)

<400> 20
atg ctt cac acg gcc ata tca tgc tgg cag cca ttc ctg ggt ctg gct 48
Met Leu His Thr Ala Ile Ser Cys Trp Gln Pro Phe Leu Gly Leu Ala
1 5 10 15
35 gtg gtg tta atc ttc atg gga tcc acc att ggc tgc ccc gct cgc tgt 96
Val Val Leu Ile Phe Met Gly Ser Thr Ile Gly Cys Pro Ala Arg Cys
20 25 30

40 gag tgc tct gcc cag aac aaa tct gtt agc tgt cac aga agg cga ttg 144
Glu Cys Ser Ala Gln Asn Lys Ser Val Ser Cys His Arg Arg Arg Leu
35 40 45

45 atc gcc atc cca gag ggc att ccc atc gaa acc aaa atc ttg gac ctc 192
Ile Ala Ile Pro Glu Gly Ile Pro Ile Glu Thr Lys Ile Leu Asp Leu
50 55 60

50 agt aaa aac agg cta aaa agc gtc aac cct gaa gaa ttc ata tca tat 240
Ser Lys Asn Arg Leu Lys Ser Val Asn Pro Glu Glu Phe Ile Ser Tyr
65 70 75 80

55 cct ctg ctg gaa gag ata gac ttg agt gac aac atc att gcc aat gtg 288
Pro Leu Leu Glu Glu Ile Asp Leu Ser Asp Asn Ile Ile Ala Asn Val
85 90 95

55 gaa cca gga gca ttc aac aat ctc ttt aac ctg cgt tcc ctc cgc cta 336
Glu Pro Gly Ala Phe Asn Asn Leu Phe Asn Leu Arg Ser Leu Arg Leu
100 105 110

```

## EP 1 574 520 A2

	aaa ggc aat cgt cta aag ctg gtc cct ttg gga gta ttc acg ggg ctg Lys Gly Asn Arg Leu Lys Leu Val Pro Leu Gly Val Phe Thr Gly Leu 115 120 125	384
5	tcc aat ctc act aag ctt gac att agt gag aat aag att gtc att tta Ser Asn Leu Thr Lys Leu Asp Ile Ser Glu Asn Lys Ile Val Ile Leu 130 135 140	432
10	cta gac tac atg ttc caa gat cta cat aac ctg aag tct cta gaa gtg Leu Asp Tyr Met Phe Gln Asp Leu His Asn Leu Lys Ser Leu Glu Val 145 150 155 160	480
	ggg gac aat gat ttg gtt tat ata tca cac agg gca ttc agt ggg ctt Gly Asp Asn Asp Leu Val Tyr Ile Ser His Arg Ala Phe Ser Gly Leu 165 170 175	528
15	ctt agc ttg gag cag ctc acc ctg gag aaa tgc aac tta aca gca gta Leu Ser Leu Glu Gln Leu Thr Leu Glu Lys Cys Asn Leu Thr Ala Val 180 185 190	576
20	cca aca gaa gcc ctc tcc cac ctc cgc agc ctc atc agc ctg cat ctg Pro Thr Glu Ala Leu Ser His Leu Arg Ser Leu Ile Ser Leu His Leu 195 200 205	624
	aag cat ctc aat atc aac aat atg cct gtg tat gcc ttt aaa aga ttg Lys His Leu Asn Ile Asn Asn Met Pro Val Tyr Ala Phe Lys Arg Leu 210 215 220	672
25	ttc cac ctg aaa cac cta gag att gac tat tgg cct tta ctg gat atg Phe His Leu Lys His Leu Glu Ile Asp Tyr Trp Pro Leu Leu Asp Met 225 230 235 240	720
30	atg cct gcc aat agc ctc tac ggt ctc aac ctc aca tcc ctt tca gtc Met Pro Ala Asn Ser Leu Tyr Gly Leu Asn Leu Thr Ser Leu Ser Val 245 250 255	768
	acc aac acc aat ctg tct act gta ccc ttc ctt gcc ttt aaa cac ctg Thr Asn Thr Asn Leu Ser Thr Val Pro Phe Leu Ala Phe Lys His Leu 260 265 270	816
35	gta tac ctg act cac ctt aac ctc tcc tac aat ccc atc agc act att Val Tyr Leu Thr His Leu Asn Leu Ser Tyr Asn Pro Ile Ser Thr Ile 275 280 285	864
40	gaa gca ggc atg ttc tct gac ctg atc cgc ctt cag gag ctt cat ata Glu Ala Gly Met Phe Ser Asp Leu Ile Arg Leu Gln Glu Leu His Ile 290 295 300	912
	gtg ggg gcc cag ctt cgc acc att gag cct cac tcc ttc caa ggg ctc Val Gly Ala Gln Leu Arg Thr Ile Glu Pro His Ser Phe Gln Gly Leu	960
45	305 310 315 320	
	cgc ttc cta cgc gtg ctc aat gtg tct cag aac ctg ctg gaa act ttg Arg Phe Leu Arg Val Leu Asn Val Ser Gln Asn Leu Leu Glu Thr Leu 325 330 335	1008
50	gaa gag aat gtc ttc tcc cct agg gct ctg gag gtc ttg agc att Glu Glu Asn Val Phe Ser Ser Pro Arg Ala Leu Glu Val Leu Ser Ile 340 345 350	1056
	aac aac aac cct ctg gcc tgt gac tgc cgc ctt ctc tgg atc ttg cag Asn Asn Asn Pro Leu Ala Cys Asp Cys Arg Leu Leu Trp Ile Leu Gln 355 360 365	1104
55		

## EP 1 574 520 A2

	cga cag ccc acc ctg cag ttt ggt ggc cag caa cct atg tgt gct ggc Arg Gln Pro Thr Leu Gln Phe Gly Gly Gln Gln Pro Met Cys Ala Gly 370 375 380	1152
5	cca gac acc atc cgt gag agg tct ttc aag gat ttc cat agc act gcc Pro Asp Thr Ile Arg Glu Arg Ser Phe Lys Asp Phe His Ser Thr Ala 385 390 395 400	1200
10	ctt tct ttt tac ttt acc tgc aaa aaa ccc aaa atc cgt gaa aag aag Leu Ser Phe Tyr Phe Thr Cys Lys Lys Pro Lys Ile Arg Glu Lys Lys 405 410 415	1248
	ttg cag cat ctg cta gta gat gaa ggg cag aca gtc cag cta gaa tgc Leu Gln His Leu Leu Val Asp Glu Gly Gln Thr Val Gln Leu Glu Cys 420 425 430	1296
15	agt gca gat gga gac ccg cag cct gtg att tcc tgg gtg aca ccc cga Ser Ala Asp Gly Asp Pro Gln Pro Val Ile Ser Trp Val Thr Pro Arg 435 440 445	1344
20	agg cgt ttc atc acc acc aag tcc aat gga aga ggc acc gtg ttg ggt Arg Arg Phe Ile Thr Thr Lys Ser Asn Gly Arg Ala Thr Val Leu Gly 450 455 460	1392
	gat ggc acc ttg gaa atc cgc ttt gcc cag gat caa gac agc ggg atg Asp Gly Thr Leu Glu Ile Arg Phe Ala Gln Asp Gln Asp Ser Gly Met 465 470 475 480	1440
25	tat gtt tgc atc gct agc aat gct gct ggg aat gat acc ttc aca gcc Tyr Val Cys Ile Ala Ser Asn Ala Ala Gly Asn Asp Thr Phe Thr Ala 485 490 495	1488
30	tcc tta act gtg aaa gga ttc gct tca gat cgt ttt ctt tat gcg aac Ser Leu Thr Val Lys Gly Phe Ala Ser Asp Arg Phe Leu Tyr Ala Asn 500 505 510	1536
	agg acc cct atg tac atg acc gac tcc aat gac acc att tcc aat ggc Arg Thr Pro Met Tyr Met Thr Asp Ser Asn Asp Thr Ile Ser Asn Gly 515 520 525	1584
35	acc aat gcc aat act ttt tcc ctg gac ctt aaa aca ata ctg gtg tct Thr Asn Ala Asn Thr Phe Ser Leu Asp Leu Lys Thr Ile Leu Val Ser 530 535 540	1632
40	aca gct atg ggc tgc ttc aca ttc ctg gga gtg gtt tta ttt tgt ttt Thr Ala Met Gly Cys Phe Thr Phe Leu Gly Val Val Leu Phe Cys Phe 545 550 555 560	1680
	ctt ctc ctt ttt gtg tgg agc cga ggg aaa ggc aag cac aaa aac agc Leu Leu Leu Phe Val Trp Ser Arg Gly Lys Gly Lys His Lys Asn Ser 565 570 575	1728
45	att gag ctt gag tat gtg ccc aga aaa aac aat ggt gct gtt gtg gaa Ile Asp Leu Glu Tyr Val Pro Arg Lys Asn Asn Gly Ala Val Val Glu 580 585 590	1776
50	ggg gag gta gct gga ccc agg agg ttc aac atg aaa atg att tga Gly Glu Val Ala Gly Pro Arg Arg Phe Asn Met Lys Met Ile 595 600 605	1821
55	<210> 21 <211> 606 <212> PRT	

&lt;213&gt; Homo sapiens

&lt;400&gt; 21

5 Met Leu His Thr Ala Ile Ser Cys Trp Gln Pro Phe Leu Gly Leu Ala  
1 5 10 1510 Val Val Leu Ile Phe Met Gly Ser Thr Ile Gly Cys Pro Ala Arg Cys  
20 25 3015 Glu Cys Ser Ala Gln Asn Lys Ser Val Ser Cys His Arg Arg Arg Leu  
35 40 4520 Ile Ala Ile Pro Glu Gly Ile Pro Ile Glu Thr Lys Ile Leu Asp Leu  
50 55 6025 Ser Lys Asn Arg Leu Lys Ser Val Asn Pro Glu Glu Phe Ile Ser Tyr  
65 70 75 8030 Pro Leu Leu Glu Glu Ile Asp Leu Ser Asp Asn Ile Ile Ala Asn Val  
85 90 9535 Glu Pro Gly Ala Phe Asn Asn Leu Phe Asn Leu Arg Ser Leu Arg Leu  
100 105 11040 Lys Gly Asn Arg Leu Lys Leu Val Pro Leu Gly Val Phe Thr Gly Leu  
115 120 12545 Ser Asn Leu Thr Lys Leu Asp Ile Ser Glu Asn Lys Ile Val Ile Leu  
130 135 14050 Leu Asp Tyr Met Phe Gln Asp Leu His Asn Leu Lys Ser Leu Glu Val  
145 150 155 16055 Gly Asp Asn Asp Leu Val Tyr Ile Ser His Arg Ala Phe Ser Gly Leu  
165 170 17560 Leu Ser Leu Glu Gln Leu Thr Leu Glu Lys Cys Asn Leu Thr Ala Val  
180 185 19065 Pro Thr Glu Ala Leu Ser His Leu Arg Ser Leu Ile Ser Leu His Leu  
195 200 20570 Lys His Leu Asn Ile Asn Asn Met Pro Val Tyr Ala Phe Lys Arg Leu  
210 215 22075 Phe His Leu Lys His Leu Glu Ile Asp Tyr Trp Pro Leu Leu Asp Met  
225 230 235 240

55

## EP 1 574 520 A2

Met Pro Ala Asn Ser Leu Tyr Gly Leu Asn Leu Thr Ser Leu Ser Val  
 245 250 255

5 Thr Asn Thr Asn Leu Ser Thr Val Pro Phe Leu Ala Phe Lys His Leu  
 260 265 270

10 Val Tyr Leu Thr His Leu Asn Leu Ser Tyr Asn Pro Ile Ser Thr Ile  
 275 280 285

15 Glu Ala Gly Met Phe Ser Asp Leu Ile Arg Leu Gln Glu Leu His Ile  
 290 295 300

20 Val Gly Ala Gln Leu Arg Thr Ile Glu Pro His Ser Phe Gln Gly Leu  
 305 310 315 320

25 Arg Phe Leu Arg Val Leu Asn Val Ser Gln Asn Leu Leu Glu Thr Leu  
 325 330 335

30 Glu Glu Asn Val Phe Ser Ser Pro Arg Ala Leu Glu Val Leu Ser Ile  
 340 345 350

35 Asn Asn Asn Pro Leu Ala Cys Asp Cys Arg Leu Leu Trp Ile Leu Gln  
 355 360 365

40 Arg Gln Pro Thr Leu Gln Phe Gly Gly Gln Gln Pro Met Cys Ala Gly  
 370 375 380

45 Pro Asp Thr Ile Arg Glu Arg Ser Phe Lys Asp Phe His Ser Thr Ala  
 385 390 395 400

50 Leu Ser Phe Tyr Phe Thr Cys Lys Lys Pro Lys Ile Arg Glu Lys Lys  
 405 410 415

55 Leu Gln His Leu Leu Val Asp Glu Gly Gln Thr Val Gln Leu Glu Cys  
 420 425 430

Ser Ala Asp Gly Asp Pro Gln Pro Val Ile Ser Trp Val Thr Pro Arg  
 435 440 445

60 Arg Arg Phe Ile Thr Thr Lys Ser Asn Gly Arg Ala Thr Val Leu Gly  
 450 455 460

65 Asp Gly Thr Leu Glu Ile Arg Phe Ala Gln Asp Gln Asp Ser Gly Met  
 465 470 475 480

70 Tyr Val Cys Ile Ala Ser Asn Ala Ala Gly Asn Asp Thr Phe Thr Ala  
 485 490 495

## EP 1 574 520 A2

Ser Leu Thr Val Lys Gly Phe Ala Ser Asp Arg Phe Leu Tyr Ala Asn  
 500 505 510

5 Arg Thr Pro Met Tyr Met Thr Asp Ser Asn Asp Thr Ile Ser Asn Gly  
 515 520 525

10 Thr Asn Ala Asn Thr Phe Ser Leu Asp Leu Lys Thr Ile Leu Val Ser  
 530 535 540

Thr Ala Met Gly Cys Phe Thr Phe Leu Gly Val Val Leu Phe Cys Phe  
 545 550 555 560

15 Leu Leu Leu Phe Val Trp Ser Arg Gly Lys Gly Lys His Lys Asn Ser  
 565 570 575

20 Ile Asp Leu Glu Tyr Val Pro Arg Lys Asn Asn Gly Ala Val Val Glu  
 580 585 590

Gly Glu Val Ala Gly Pro Arg Arg Phe Asn Met Lys Met Ile  
 595 600 605

25 <210> 22  
 <211> 1821  
 <212> DNA  
 <213> Homo sapiens

30 <400> 22  
 atgcttcaca cggccatatac atgctggcag ccattectgg gtctggctgt ggtgttaatc 60  
 ttcatggat ccaccattgg ctgccccgt cgctgtgagt gctctgcccc gaacaaatct  
 35 gtagctgtc acagaaggcg attgategcc atccagagg gcatccccat cgaaacccaa 180  
 atcttggacc tcagtaaaaa caggctaaaa agcgtcaacc ctgaagaatt catatcatat  
 cctctgtgg aagagataga cttgagtgc aacatcattg ccaatgtgga accaggagca 300  
 40 ttcaacaatc tctttaacct gcgttccctc cgccctaaag gcaatcgtct aaagctggtc 360  
 cctttggag tattcacggg gctgtccat ctcactaagc ttgacattag tgagaataag 420  
 attgtcattt tactagacta catgttccaa gatctacata acctgaagtc tctagaagtg  
 45 ggggacaatg atttgggtta tatatcacac agggcattca gtgggcttct tagttggag 540  
 cagctcaccc tggagaaatg caacttaaca gcagtaccaa cagaagccct ctccccaccc  
 50 cgccgcctca tcagcctgca tctgaagcat ctcaatatca acaatatgcc tgtgtatgcc  
 tttaaaagat tgttccacct gaaacaccta gagattgact attggccttt actggatatg 720  
 atgcctgcca atagectcta cggctcaac ctcacatccc tttcagtcac caacaccaat  
 55 ctgtctactg tacccttcct tgcctttaaa cacctggat acctgactca ctttaaccc  
 tcttacaatc ccatcagcac tattgaagca ggcatgttct ctgacctgat ccgccttcag 900

## EP 1 574 520 A2

5	gagtttcata tagtgggggc ccagttcgc accattgagc ctcactcctt ccaaggcgc	960
	cgcttcctac gcgtgtcaa tgtgtctcg aacctgctgg aaactttgga agagaatgtc	1020
	ttctcctccc ctagggctct ggagggtctt agcattaaca acaaccctct ggcctgtgac	1080
	tgcgccttc tctggatctt gcagcgacag cccaccctgc agtttggtgg ccagcaacct	1140
10	atgtgtgtcg gcccagacac catccgtgag aggtcttca aggatttcca tagcactgcc	1200
	ctttctttt actttacotg caaaaaaccc aaaatccgtg aaaagaagtt gcagcatctg	1260
	ctagtagatg aagggcagac agtccagcta gaatgcagtg cagatggaga cccgcagcct	1320
	gtgatttcctt gggtgcacacc ccgaaggcgt ttcatcacca ccaagtccaa tggaaagagcc	1380
15	accgtgttgg gtgatggcac cttggaaatc cgcttgcac aggatcaaga cagcgggatg	1440
	tatgtttgca tcgcttagcaa tgctgctggg aatgatactt tcacagcctc cttaactgtg	1500
	aaaggattcg cttcagatcg ttttctttt gcgaacagga cccctatgta catgaccgac	1560
20	tccaatgaca ccatttccaa tggcaccaat gccaatactt tttccctgga ccttaaaaaca	1620
	atactggtgt ctacagctat gggctgcttc acattcctgg gagtggtttt attttgtttt	1680
	cttctccttt ttgtgtggag ccgagggaaa ggcaagcaca aaaacagcat tgaccctttag	1740
25	tatgtgccc aaaaaaacaa tggtgctgtt gtggaaagggg agtagctgg acccaggagg	1800
	ttcaacatga aaatgatttg a	1821
30	<210> 23	
	<211> 33	
	<212> PRT	
	<213> Homo sapiens	
35	<400> 23	
	Leu Glu Ile Arg Phe Ala Gln Asp Gln Asp Ser Gly Met Tyr Val Cys	
	1 5 10 15	
	Ile Ala Ser Asn Ala Ala Gly Asn Asp Thr Phe Thr Ala Ser Leu Thr	
40	20 25 30	
	Val	
45	<210> 24	
	<211> 14	
	<212> PRT	
	<213> Homo sapiens	
	<400> 24	
50	Leu Thr His Leu Asn Leu Ser Tyr Asn Pro Ile Ser Thr Ile	
	1 5 10	
	<210> 25	
	<211> 24	
	<212> PRT	
55	<213> Homo sapiens	

5                   <400> 25  
 Leu Glu Cys Ser Ala Asp Gly Asp Pro Gln Pro Val Ile Ser Trp Val  
 1                   5                   10                   15  
 5                   Thr Pro Arg Arg Arg Phe Ile Thr  
 20  
 10                   <210> 26  
 <211> 27  
 <212> PRT  
 <213> Homo sapiens  
 15                   <400> 26  
 Met Leu His Thr Ala Ile Ser Cys Trp Gln Pro Phe Leu Gly Leu Ala  
 1                   5                   10                   15  
 20                   Val Val Leu Ile Phe Met Gly Ser Thr Ile Gly  
 25                   20                   25  
 25                   <210> 27  
 <211> 579  
 <212> PRT  
 <213> Homo sapiens  
 30                   <400> 27  
 25                   Cys Pro Ala Arg Cys Glu Cys Ser Ala Gln Asn Lys Ser Val Ser Cys  
 1                   5                   10                   15  
 35                   His Arg Arg Arg Leu Ile Ala Ile Pro Glu Gly Ile Pro Ile Glu Thr  
 20                   25                   30  
 40                   Lys Ile Leu Asp Leu Ser Lys Asn Arg Leu Lys Ser Val Asn Pro Glu  
 35                   40                   45  
 45                   Glu Phe Ile Ser Tyr Pro Leu Leu Glu Glu Ile Asp Leu Ser Asp Asn  
 50                   55                   60  
 55                   Ile Ile Ala Asn Val Glu Pro Gly Ala Phe Asn Asn Leu Phe Asn Leu  
 65                   70                   75                   80  
 60                   Arg Ser Leu Arg Leu Lys Gly Asn Arg Leu Lys Leu Val Pro Leu Gly  
 85                   90                   95  
 70                   Val Phe Thr Gly Leu Ser Asn Leu Thr Lys Leu Asp Ile Ser Glu Asn  
 100                   105                   110  
 75                   Lys Ile Val Ile Leu Leu Asp Tyr Met Phe Gln Asp Leu His Asn Leu  
 115                   120                   125  
 80                   Lys Ser Leu Glu Val Gly Asp Asn Asp Leu Val Tyr Ile Ser His Arg  
 130                   135                   140  
 85                   Ala Phe Ser Gly Leu Leu Ser Leu Glu Gln Leu Thr Leu Glu Lys Cys  
 145                   150                   155                   160  
 90                   Asn Leu Thr Ala Val Pro Thr Glu Ala Leu Ser His Leu Arg Ser Leu  
 165                   170                   175  
 95                   Ile Ser Leu His Leu Lys His Leu Asn Ile Asn Asn Met Pro Val Tyr  
 180                   185                   190

## EP 1 574 520 A2

Ala Phe Lys Arg Leu Phe His Leu Lys His Leu Glu Ile Asp Tyr Trp  
 195 200 205  
 Pro Leu Leu Asp Met Met Pro Ala Asn Ser Leu Tyr Gly Leu Asn Leu  
 5 210 215 220  
 Thr Ser Leu Ser Val Thr Asn Thr Asn Leu Ser Thr Val Pro Phe Leu  
 225 230 235 240  
 Ala Phe Lys His Leu Val Tyr Leu Thr His Leu Asn Leu Ser Tyr Asn  
 10 245 250 255  
 Pro Ile Ser Thr Ile Glu Ala Gly Met Phe Ser Asp Leu Ile Arg Leu  
 260 265 270  
 Gln Glu Leu His Ile Val Gly Ala Gln Leu Arg Thr Ile Glu Pro His  
 15 275 280 285  
 Ser Phe Gln Gly Leu Arg Phe Leu Arg Val Leu Asn Val Ser Gln Asn  
 290 295 300  
 Leu Leu Glu Thr Leu Glu Glu Asn Val Phe Ser Ser Pro Arg Ala Leu  
 20 305 310 315 320  
 Glu Val Leu Ser Ile Asn Asn Asn Pro Leu Ala Cys Asp Cys Arg Leu  
 325 330 335  
 Leu Trp Ile Leu Gln Arg Gln Pro Thr Leu Gln Phe Gly Gly Gln Gln  
 25 340 345 350  
 Pro Met Cys Ala Gly Pro Asp Thr Ile Arg Glu Arg Ser Phe Lys Asp  
 355 360 365  
 Phe His Ser Thr Ala Leu Ser Phe Tyr Phe Thr Cys Lys Lys Pro Lys  
 30 370 375 380  
 Ile Arg Glu Lys Lys Leu Gln His Leu Leu Val Asp Glu Gly Gln Thr  
 385 390 395 400  
 Val Gln Leu Glu Cys Ser Ala Asp Gly Asp Pro Gln Pro Val Ile Ser  
 35 405 410 415  
 Trp Val Thr Pro Arg Arg Arg Phe Ile Thr Thr Lys Ser Asn Gly Arg  
 420 425 430  
 Ala Thr Val Leu Gly Asp Gly Thr Leu Glu Ile Arg Phe Ala Gln Asp  
 40 435 440 445  
 Gln Asp Ser Gly Met Tyr Val Cys Ile Ala Ser Asn Ala Ala Gly Asn  
 450 455 460  
 Asp Thr Phe Thr Ala Ser Leu Thr Val Lys Gly Phe Ala Ser Asp Arg  
 45 465 470 475 480  
 Phe Leu Tyr Ala Asn Arg Thr Pro Met Tyr Met Thr Asp Ser Asn Asp  
 485 490 495  
 Thr Ile Ser Asn Gly Thr Asn Ala Asn Thr Phe Ser Leu Asp Leu Lys  
 50 500 505 510  
 Thr Ile Leu Val Ser Thr Ala Met Gly Cys Phe Thr Phe Leu Gly Val  
 55 515 520 525  
 Val Leu Phe Cys Phe Leu Leu Phe Val Trp Ser Arg Gly Lys Gly

## EP 1 574 520 A2

530

535

540

5 Lys His Lys Asn Ser Ile Asp Leu Glu Tyr Val Pro Arg Lys Asn Asn  
 545 550 555 560

5 Gly Ala Val Val Glu Gly Glu Val Ala Gly Pro Arg Arg Phe Asn Met  
 565 570 575

Lys Met Ile

10

<210> 28  
 <211> 157  
 <212> PRT  
 <213> Homo sapiens

15

<400> 28

Ile Leu Asp Leu Ser Lys Asn Arg Leu Lys Ser Val Asn Pro Glu Glu  
 1 5 10 15

20

Phe Ile Ser Tyr Pro Leu Leu Glu Glu Ile Asp Leu Ser Asp Asn Ile  
 20 25 30

Ile Ala Asn Val Glu Pro Gly Ala Phe Asn Asn Leu Phe Asn Leu Arg  
 35 40 45

25

Ser Leu Arg Leu Lys Gly Asn Arg Leu Lys Leu Val Pro Leu Gly Val  
 50 55 60

Phe Thr Gly Leu Ser Asn Leu Thr Lys Leu Asp Ile Ser Glu Asn Lys  
 65 70 75 80

30

Ile Val Ile Leu Leu Asp Tyr Met Phe Gln Asp Leu His Asn Leu Lys  
 85 90 95

Ser Leu Glu Val Gly Asp Asn Asp Leu Val Tyr Ile Ser His Arg Ala  
 100 105 110

35

Phe Ser Gly Leu Leu Ser Leu Glu Gln Leu Thr Leu Glu Lys Cys Asn  
 115 120 125

Leu Thr Ala Val Pro Thr Glu Ala Leu Ser His Leu Arg Pro Arg Ala  
 130 135 140

40

Lys Leu Gly Ala Lys His Gly Gln Asp Gly Val Gln Ser  
 145 150 155

<210> 29

<211> 505

<212> PRT

45

<213> Rattus norvegicus

<400> 29

50

Leu Gly Leu Ala Ile Thr Ala Leu Val Gln Ala Gly Asp Lys Lys Val  
 1 5 10 15

Asp Cys Pro Gln Leu Cys Thr Cys Glu Ile Arg Pro Trp Phe Thr Pro  
 20 25 30

55

Arg Ser Ile Tyr Met Glu Ala Ser Thr Val Asp Cys Asn Asp Leu Gly  
 35 40 45

## EP 1 574 520 A2

Leu Leu Asn Phe Pro Ala Arg Leu Pro Ala Asp Thr Gln Ile Leu Leu  
 50 55 60

5 Leu Gln Thr Asn Asn Ile Ala Arg Ile Glu His Ser Thr Asp Phe Pro  
 65 70 75 80

Val Asn Leu Thr Gly Leu Asp Leu Ser Gln Asn Asn Leu Ser Ser Val  
 85 90 95

10 Thr Asn Ile Asn Val Gln Lys Met Ser Gln Leu Leu Ser Val Tyr Leu  
 100 105 110

Glu Glu Asn Lys Leu Thr Glu Leu Pro Glu Lys Cys Leu Tyr Gly Leu  
 115 120 125

15 Ser Asn Leu Gln Glu Leu Tyr Val Asn His Asn Leu Leu Ser Ala Ile  
 130 135 140

Ser Pro Gly Ala Phe Val Gly Leu His Asn Leu Leu Arg Leu His Leu  
 145 150 155 160

20 Asn Ser Asn Arg Leu Gln Met Ile Asn Ser Lys Trp Phe Glu Ala Leu  
 165 170 175

Pro Asn Leu Glu Ile Leu Met Leu Gly Asp Asn Pro Ile Leu Arg Ile  
 180 185 190

25 Lys Asp Met Asn Phe Gln Pro Leu Leu Lys Leu Arg Ser Leu Val Ile  
 195 200 205

Ala Gly Ile Asn Leu Thr Glu Val Pro Asp Asp Ala Leu Val Gly Leu  
 210 215 220

30 Glu Asn Leu Glu Ser Ile Ser Phe Tyr Asp Asn Arg Leu Asn Lys Val  
 225 230 235 240

Pro Gln Val Ala Leu Gln Lys Ala Val Asn Leu Lys Phe Leu Asp Leu  
 245 250 255

35 Asn Lys Asn Pro Ile Asn Arg Ile Arg Arg Gly Asp Phe Ser Asn Met  
 260 265 270

Leu His Leu Lys Glu Leu Gly Ile Asn Asn Met Pro Glu Leu Val Ser  
 275 280 285

40 Ile Asp Ser Leu Ala Val Asp Asn Leu Pro Asp Leu Arg Lys Ile Glu  
 290 295 300

Ala Thr Asn Asn Pro Arg Leu Ser Tyr Ile His Pro Asn Ala Phe Phe  
 305 310 315 320

45 Arg Leu Pro Lys Leu Glu Ser Leu Met Leu Asn Ser Asn Ala Leu Ser  
 325 330 335

Ala Leu Tyr His Gly Thr Ile Glu Ser Leu Pro Asn Leu Lys Glu Ile  
 340 345 350

50 Ser Ile His Ser Asn Pro Ile Arg Cys Asp Cys Val Ile Arg Trp Ile  
 355 360 365

Asn Met Asn Lys Thr Asn Ile Arg Phe Met Glu Pro Asp Ser Leu Phe  
 370 375 380

55 Cys Val Asp Pro Pro Glu Phe Gln Gly Gln Asn Val Arg Gln Val His

## EP 1 574 520 A2

385	390	395	400
Phe Arg Asp Met Met Glu Ile Cys Leu Pro Leu Ile Ala Pro Glu Ser			
405	410	415	
5 Phe Pro Ser Ile Leu Asp Val Glu Ala Asp Ser Tyr Val Ser Leu His			
420	425	430	
Cys Arg Ala Thr Ala Glu Pro Gln Pro Glu Ile Tyr Trp Ile Thr Pro			
435	440	445	
10 Ser Gly Lys Arg Leu Leu Pro Asn Thr Leu Arg Glu Lys Phe Tyr Val			
450	455	460	
His Ser Glu Gly Thr Leu Asp Ile Arg Gly Ile Thr Pro Lys Glu Gly			
465	470	475	480
15 Gly Leu Tyr Thr Cys Ile Ala Thr Asn Leu Val Gly Ala Asp Leu Lys			
485	490	495	
Ser Ile Met Ile Lys Val Gly Gly Phe			
20 500	505		
<210> 30			
<211> 601			
<212> PRT			
<213> Homo sapiens			
25 <400> 30			
Leu Ala Cys Trp Gln Pro Ile Leu Leu Leu Val Leu Gly Ser Val Leu			
1	5	10	15
30 Ser Gly Ser Ala Thr Gly Cys Pro Pro Arg Cys Glu Cys Ser Ala Gln			
20	25	30	
Asp Arg Ala Val Leu Cys His Arg Lys Arg Phe Val Ala Val Pro Glu			
35	40	45	
35 Gly Ile Pro Thr Glu Thr Arg Leu Leu Asp Leu Gly Lys Asn Arg Ile			
50	55	60	
40 Lys Thr Leu Asn Gln Asp Glu Phe Ala Ser Phe Pro His Leu Glu Glu			
65	70	75	80
45 Leu Glu Leu Asn Glu Asn Ile Val Ser Ala Val Glu Pro Gly Ala Phe			
85	90	95	
50 Asn Asn Leu Phe Asn Leu Arg Thr Leu Gly Leu Arg Ser Asn Arg Leu			
100	105	110	
55 Lys Leu Ile Pro Leu Gly Val Phe Thr Gly Leu Ser Asn Leu Thr Lys			
115	120	125	
60 Leu Asp Thr Arg Glu Asn Lys Ile Val Ile Leu Leu Asp Tyr Met Phe			
130	135	140	
65 Gln Asp Leu Tyr Asn Leu Lys Ser Leu Glu Val Gly Asp Asn Asp Leu			
145	150	155	160
70 Val Tyr Ile Ser His Arg Ala Phe Ser Gly Leu Asn Ser Leu Glu Gln			
165	170	175	
75 Leu Thr Leu Glu Lys Cys Asn Leu Thr Ser Ile Pro Thr Glu Ala Leu			

## EP 1 574 520 A2

	180	185	190
	Ser His Leu His Gly Leu Ile Val Leu Arg Leu Arg His Leu Asn Ile		
	195	200	205
5	Asn Ala Ile Arg Asp Tyr Ser Phe Lys Arg Leu Tyr Arg Leu Lys Val		
	210	215	220
	Leu Glu Ile Ser His Trp Pro Tyr Leu Asp Thr Met Thr Pro Asn Cys		
	225	230	235
10	Leu Tyr Gly Leu Asn Leu Thr Ser Leu Ser Ile Thr His Cys Asn Leu		
	245	250	255
	Thr Ala Val Pro Tyr Leu Ala Val Arg His Leu Val Tyr Leu Arg Phe		
	260	265	270
15	Leu Asn Leu Ser Tyr Asn Pro Ile Ser Thr Ile Glu Gly Ser Met Leu		
	275	280	285
	His Glu Leu Leu Arg Leu Gln Glu Ile Gln Leu Val Gly Gly Gln Leu		
	290	295	300
20	Ala Val Val Glu Pro Tyr Ala Phe Arg Gly Leu Asn Tyr Leu Arg Val		
	305	310	315
	Leu Asn Val Ser Gly Asn Gln Leu Thr Thr Leu Glu Glu Ser Val Phe		
25	325	330	335
	His Ser Val Gly Asn Leu Glu Thr Leu Ile Leu Asp Ser Asn Pro Leu		
	340	345	350
	Ala Cys Asp Cys Arg Leu Leu Trp Val Phe Arg Arg Arg Trp Arg Leu		
30	355	360	365
	Asn Phe Asn Arg Gln Gln Pro Thr Cys Ala Thr Pro Glu Phe Val Gln		
	370	375	380
	Gly Lys Glu Phe Lys Asp Phe Pro Asp Val Leu Leu Pro Asn Tyr Phe		
35	385	390	395
	Thr Cys Arg Arg Ala Arg Ile Arg Asp Arg Lys Ala Gln Gln Val Phe		
	405	410	415
	Val Asp Glu Gly His Thr Val Gln Phe Val Cys Arg Ala Asp Gly Asp		
40	420	425	430
	Pro Pro Pro Ala Ile Leu Trp Leu Ser Pro Arg Lys His Leu Val Ser		
	435	440	445
	Ala Lys Ser Asn Gly Arg Leu Thr Val Phe Pro Asp Gly Thr Leu Glu		
45	450	455	460
	Val Arg Tyr Ala Gln Val Gln Asp Asn Gly Thr Tyr Leu Cys Ile Ala		
	465	470	475
	480		
	Ala Asn Ala Gly Gly Asn Asp Ser Met Pro Ala His Leu His Val Arg		
50	485	490	495
	Ser Tyr Ser Pro Asp Trp Pro His Gln Pro Asn Lys Thr Phe Ala Phe		
	500	505	510
	Ile Ser Asn Gln Pro Gly Glu Gly Glu Ala Asn Ser Thr Arg Ala Thr		
55	515	520	525

5	Val Pro Phe Pro Phe Asp Ile Lys Thr Leu Ile Ile Ala Thr Thr Met			
	530	535	540	
	Gly Phe Ile Ser Phe Leu Gly Val Val Leu Phe Cys Leu Val Leu Leu			
	545	550	555	560
	Phe Leu Trp Ser Arg Gly Lys Gly Asn Thr Lys His Asn Ile Glu Ile			
	565	570	575	
10	Glu Tyr Val Pro Arg Lys Ser Asp Ala Gly Ile Ser Ser Ala Asp Ala			
	580	585	590	
	Pro Arg Lys Phe Asn Met Lys Met Ile			
	595	600		
15	<210> 31			
	<211> 3542			
	<212> DNA			
	<213> homo sapiens			
20	<220>			
	<221> misc_feature			
	<222> (1)..(3542)			
	<223> n=G, A, T, or C			
25	<400> 31			
	tcgagtcttc ttggatgtgt tccggattcc aagtaactct tatttggaaat tgatgagtgc	60		
	catcttaaag ctgttatcatg agctgcctgc acttctaaag tgtccagtgg attttttaatc	120		
30	acatgagcct ggaaataggg ttatgagaag aagctcagag cagagcacccg aaagtggcca	180		
	ctaccagcat gaagagccca acaattcaaa ctgactgtcc catttctgc cagaatcctg	240		
	acaatcacccg tctccaggtg aagtgagaaa aacagaatgc agctttcaag gttcgtttca	300		
35	agcagttggc ttgtgggact ctgagagatg ctgctgc cca tgacatgcgg gaattatcat	360		
	gatcaactac ccagcttggc tttcacccag tggccaaagag ctttgtgtgg gagacggcaa	420		
	gggttggatt tttcaaaaga gtaaaccaga cccgtgacca aggtgttagac taagaagtgg	480		
40	agtcatgctt cacacggcca tatcatgtg gcagccattc ctgggtctgg ctgtgggttt	540		
	aatcttcatg ggttccacca ttggctgccc cgtcgctgt gagtgtctg cccagaacaa	600		
	atctgttagc tgcacagaa ggcgattgtat cgcacatccca gagggcattc ccatcgaaac	660		
45	caaaatcttg gacctcagta aaaacaggct aaaaacgcgc aaccctgaag aattcatatc	720		
	atatcctctg ctgaaagaga tagacttgag tgacaaacatc attgccaatg tggaaccagg	780		
	agcattcaac aatctcttta acctgcgttc cctccgccta aaaggcaatc gtctaaagct	840		
50	ggtccctttg ggagtattca cggggctgtc caatctcaact aagcttgaca ttagtgagaa	900		
	taagattgtc attttactatc actacatgtt ccaagatcta cataacactga agtctctaga	960		
	agtgggggac aatgatttg tttatataatc acacaggca ttcagtgggc ttcttagctt	1020		
55	ggagcagctc accctggaga aatgcaactt aacagcagta ccaacagaag ccctctccca	1080		

EP 1 574 520 A2

5	cctccgcgc ctcatcagcc tgcatactgaa gcatctcaat atcaacaata tgcctgtgtaa tgcctttaaa agattgttcc acctgaaaca ccttagagatt gactattggc ctttactggaa tatgatgcct gccaataagcc tctacggctc caacctcaca tcccttcag tcaccaacac caatctgtct actgtaccct tccttgcctt taaacacccgt gtataactga ctcacccctaa cctctctac aatcccatca gcactatgtg agcaggcatg ttctctgacc tgatccgcct..	1140 1200 1260 1320 1380
10	tdaggagctt catatagtgg gggcccagct tcgcaccatt gagcctcaact ccttccaagg gctccgcttc ctacgcgtgc tcaatgtgtc tcagaacccgt ctggaaactt tggaagagaa tgtcttctcc tcccttaggg ctctggaggt cttgagcatt aacaacaacc ctctggcctg tgactgccgc cttctctgga tcttgcagcg acagccacc ctgcagttt gtggccagca	1440 1500 1560 1620
15	acctatgtgt gctggcccag acaccatccg tgagaggtct ttcaaggatt tccatagcac tgcctttctt tttacttta cctgcaaaaa accccaaatc cgtaaaaaga agttgcagca tctgttagta gatgaagggc agacagtcca gctagaatgc agtgcagatg gagacccgca gcctgtgatt tcctgggtga caccggaaag gcgtttcatc accaccaagt ccaatggaaag	1680 1740 1800 1860
20	agccacccgtg ttgggtgatg gcaccttggaa aatccgttt gcccaggatc aagacacccgg gatgtatgtt tgcatcgcta gcaatgtgc tggaaatgtat accttacag cttcttaac tgtgaaagga ttgccttcag atcgtttctt ttagtgcac accaccccta tgtacatgac cgactccaaat gacaccatcc tcaatggcac caatgcaat acttttccc tggacccctaa	1920 1980 2040 2100
25	aacaatactg gtgtctacag ctatggctg cttcacattc ctgggagtgg ttttatttttgc ttttcttc tttttgtgt ggagccgagg gaaaggcaag cacaaaaaca gcattgaccc tgagtagtgc cccagaaaaa acaatggtgc tgggtggaa ggggaggttag ctggaccccg gagggtcaac atgaaaatga tttgaaggcc cacccttac attactgtct tttgtcaat	2160 2220 2280 2340
30	gtgggtaaatc agtaagacag tatggcacag taaattacta gattaagagg cagccatgtg cagctcccc tggatcaaaa gcagggtcta tggaaagcagg aggacttca atggagactc tccatcgaaa ggcaggcagg caggcatgtg tcagagccct tcacacagtg ggatactaag tgtttgcgtt gcaaatatttgc gcttctggg gatctcagta atgaacctga atattttggct	2400 2460 2520 2580
35	cacactcactc gacaattattt cagcattttc taccactgca aaaaacaaaa gaaaaaataaa aaaagaacaa cctacagtgt aggatttaca tattaaaaag acacatttgc taaaacata ctctacagaa aaattttgtat ctatgattat cattttgttac agccttgcataccatatt	2640 2700 2760
40	tgttgggtca gtaccacaaa gagatcaata tatttttttc tccctttttt gaaacatata tgctgtacat gttttaaaggc aatatgaatg agaggttgc ttttagtta ctcaccacta	2820 2880
45	tagatccaaatg tggatccat cttccgtta cttacagatg accctgagac tagatccctg gagttatggg cggagatattt ttgagagatg tgtttgcgtt atgttagatg ccaagaaaca	2940 3000
50		
55		

5	ggacccaagg caaaaactgct caactctgtt aacttctgtt actataaata a <del>gg</del> ggcatgtg	3060
	cctagtttg ataccganna aaaaaaaaaa gaaaaaaaaa aaaaaaaaaa aaaaagaaaaa	3120
	aatggggggc cccctgtttg aggggttact atttaaggg gggggtttgt aggggaaaaa	3180
	ctttttttt gggccccaa aaaaaaattt tggggggggg ggttaaaaaa cgggggggt	3240
10	ggaaaacccc tggggAACCC ccattttaaa accggcggga caaaacaaaa nngggtttt	3300
	tggtnnnngc ggcgtttttt ccgtngcgcc gttgttgttgc nccggccccc ggagctcgcg	3360
	tgtggcgtttgc ccccggtttaa ccccggtgttgc ttttttttgc ttttttttgc acnggggggtt	3420
15	gtctcgccgc ggggggggggg nggggcgggg ggggggcgc ggcncctcgcc gggggccgc	3480
	gcgcgcgggg gggngtgcgc gcgggtgtgc cggcgtgtgn ngtgtgcgg tcccgccgc	3540
	cg	3542

20

## Claims

- 25 1. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 2, 4, 19-20, 22, and 31, the translated protein coding portion thereof, the mature protein coding portion thereof, the extracellular portion thereof, or the active domain thereof.
2. An isolated polynucleotide encoding a polypeptide with biological activity, which polynucleotide hybridizes to the complement of a polynucleotide of claim 1 under stringent hybridization conditions.
- 30 3. An isolated polynucleotide encoding a polypeptide with biological activity, said polynucleotide having greater than about 90% sequence identity with the polynucleotide of claim 1.
4. The polynucleotide of claim 1 which is a DNA sequence.
5. An isolated polynucleotide which comprises the complement of the polynucleotide of claim 1.
6. A vector comprising the polynucleotide of claim 1.
- 40 7. An expression vector comprising the polynucleotide of claim 1.
8. A host cell genetically engineered to express the polynucleotide of claim 1.
9. The host cell of claim 8 wherein the polynucleotide is in operative association with a regulatory sequence that controls expression of the polynucleotide in the host cell.
- 50 10. An isolated polypeptide comprising an amino acid sequence which is at least 80% identical to the amino acid sequence selected from the group consisting of SEQ ID NO: 3, 5-13, 21, 23-27 or 28 the translated protein coding portion thereof, the mature protein coding portion thereof, the extracellular portion thereof, or the active domain thereof.
11. A composition comprising the polypeptide of claim 10 and a carrier.
- 55 12. A polypeptide, having NGM-like biological activity, comprising at least ten consecutive amino acids from the polypeptide sequences selected from the group consisting of SEQ ID NO: 3, 5-13, 21, 23-27 or 28.
13. The polypeptide of claim 12, comprising at least five consecutive amino acids from the polypeptide sequences

selected from the group consisting of SEQ ID NO: 3, 5-13, 21, 23-27 or 28.

14. A polynucleotide encoding a polypeptide according to claim 12.

5 15. A polynucleotide encoding a polypeptide according to claim 13.

16. A polynucleotide encoding a polypeptide according to claim 10.

17. An antibody specific for the polypeptide of claim 10.

10 18. A method for detecting the polynucleotide of claim 1 in a sample, comprising:

a) contacting the sample with a compound that binds to and forms a complex with the polynucleotide of claim 1 for a period sufficient to form the complex; and

15 b) detecting the complex, so that if a complex is detected, the polynucleotide of claim 1 is detected.

19. A method for detecting the polynucleotide of claim 1 in a sample, comprising:

20 a) contacting the sample under stringent hybridization conditions with nucleic acid primers that anneal to the polynucleotide of claim 1 under such conditions;

b) amplifying a product comprising at least a portion of the polynucleotide of claim 1; and

c) detecting said product and thereby the polynucleotide of claim 1 in the sample.

25 20. The method of claim 19, wherein the polynucleotide comprises an RNA molecule and the method further comprises reverse transcribing an annealed RNA molecule into a cDNA polynucleotide.

21. A method for detecting the polypeptide of claim 10 in a sample, comprising:

30 a) contacting the sample with a compound that binds to and forms a complex with the polypeptide under conditions and for a period sufficient to form the complex; and

b) detecting formation of the complex, so that if a complex formation is detected, the polypeptide of claim 10 is detected.

22. A method for identifying a compound that binds to the polypeptide of claim 10, comprising:

35 a) contacting the compound with the polypeptide of claim 10 under conditions and for a time sufficient to form a polypeptide/compound complex; and

b) detecting the complex, so that if the polypeptide/compound complex is detected, a compound that binds to the polypeptide of claim 10 is identified.

40 23. A method for identifying a compound that binds to the polypeptide of claim 10, comprising:

a) contacting the compound with the polypeptide of claim 10, in a cell, for a time sufficient to form a polypeptide/compound complex, wherein the complex drives expression of a reporter gene sequence in the cell; and

45 b) detecting the complex by detecting reporter gene sequence expression, so that if the polypeptide/compound complex is detected, a compound that binds to the polypeptide of claim 10 is identified.

24. A method of producing an NGM-like polypeptide, comprising,

50 a) culturing the host cell of claim 8 under conditions sufficient to express the polypeptide in said cell; and

b) isolating the polypeptide from the cell culture or cells of step (a).

25. A kit comprising the polypeptide of claim 10.

55 26. A nucleic acid array comprising the polynucleotide of claim 1 or a unique segment of the polynucleotide of claim 1 attached to a surface.

27. The array of claim 26, wherein the array detects full-matches to the polynucleotide or a unique segment of the

polynucleotide of claim 1.

28. The array of claim 26, wherein the array detects mismatches to the polynucleotide or a unique segment of the polynucleotide of claim 1.

5

29. A method of treatment of a subject in need of enhanced activity or expression of NGM-like polypeptide of claim 10 comprising administering to the subject a composition selected from the group consisting of:

10 (a) a therapeutic amount of a agonist of said polypeptide;

(b) a therapeutic amount of the polypeptide; and

(c) a therapeutic amount of a polynucleotide encoding the polypeptide in a form and under conditions such that the polypeptide is produced,

15 and a pharmaceutically acceptable carrier.

15

30. A method of treatment of a subject having need to inhibit activity or expression of NGM-like polypeptide of claim 10 comprising administering to the subject a composition selected from the group consisting of:

20 (a) a therapeutic amount of an antagonist to said polypeptide;

(b) a therapeutic amount of a polynucleotide that inhibits the expression of the nucleotide sequence encoding said polypeptide; and

(c) a therapeutic amount of a polypeptide that competes with the NGM-like polypeptide for its ligand

25 and a pharmaceutically acceptable carrier.

25

30

35

40

45

50

55

**BLASTX ALIGNMENT OF SEQ ID NO: 3 NEURONAL GUIDANCE MOLECULE-LIKE ( IDENTIFIED AS NGM-LIKE ) PROTEIN WITH SLT1 PROTEIN SEQ ID NO: 14**

---

Query: Neuronal guidance molecule-like (NGM-like) polypeptide (SEQ ID NO: 3)  
 Sbjct: gb|ADD25540.1|AF133730\_1| Slt1 [Rattus norvegicus] (SEQ ID NO: 14)  
 Length = 1530

Score = 287 (106.1 bits), Expect = 9.4e-40, Sum P(2) = 9.4e-40  
 Identities = 66/185 (35%), Positives = 98/185 (52%)

Query: 279 CSSVCQLCTGROINCRNGLSSIPKNNPPESTVFLYLTGNNNISYINESELTGLHSLVALYL 458  
 Sbjct: C ++C CTG ++C GL +IPKN P +T L L GNNI++I+++ GL L L L  
 Sbjct: 34 CPACT-CCTGTTVDCHTGTGLQAIKPKNTPRTERLENGNNNTIWIKNDPAGLKQLRLVQL 92

Query: 459 DNSNITYVTEKAFVQLRHLVFLPNNNFIKRLDPGIFKGLLNRLNLYQYNNQVSFVPRGV 638  
 Sbjct: + I V P AF ++ L LN N ++ L +F+ L L L N + VPR  
 Sbjct: 93 MENPIGAVEPGAFDDMKTELEPPQLANRNLQMLPELFQNNQALSRLDSENSLQAVPRKA 152

Query: 639 FNDLIVSVOYLNQQRNLTVLGSGFTVGVYALRLLDLSNNNNLRISESGQHLENLACLYL 818  
 Sbjct: F ++ L L +N+++ + G F + L +L L+NNNI I S F H+ L L  
 Sbjct: 153 FRGATDILNLQDKNQISCTEEGAFRAORGLEVTLANNNNITRIPVSSPNHMPKLRTRFRL 212

Query: 819 GSNNL 833  
 Sbjct: SN+L

Query: 213 HSNHL 217

**FIG. 1**

**BLASTX ALIGNMENT OF SEQ ID NO: 3 NEURONAL GUIDANCE MOLECULE-LIKE ( IDENTIFIED AS NGM-LIKE ) PROTEIN WITH SLIT1 PROTEIN SEQ ID NO: 15**

---

Query: Neuronal guidance molecule-like (NGM-like) polypeptide (SEQ ID NO: 3)  
 Sbjct: gb|AAD25540.1|AF133730\_1 (AF133730\_1) Slit1 [Rattus norvegicus] (SEQ ID NO: 15)

Length = 1530

Score = 239 (89.2 bits), Expect = 9.4e-40, Sum P(2) = 9.4e-40  
 Identities = 60/179 (33%), Positives = 96/179 (53%)

Query: 831 LTKVPSNAFEVLLKSLRRLSLSHNPNPLEAIQPF-AFKGLANLEYLLKNSRIRNVTRDGFGSG 1007  
 Sbjct: L+K+P + S L L++N I ++ FK L++L + L N+++ + F G  
 531 LSKLPER---IPQSTTELRUNNEISILEATGLFKKLDSHLRKKINLSNPKVSEIEIDGTFEG 587

Query: 1008 INNLKHLILSHNDLENLNSDPPSLKKNLIVLKDNRILISIDNDTFENMGASLKLINLSF 1187  
 Sbjct: ++ L L+ N LE++ S F L L L NRI I ND+F + ++++L+L  
 588 ATSVSELHLTANQLESVRSGMERGLDGLWSMLRNRRISCIHNDSTFGL-RNVRLLSLYD 646

Query: 1188 NNLTPLHPRVULKPLSSLIHQANSNPWECNCKULGJRDWMASSAI-TLNNTYCONPPSMR 1361  
 Sbjct: N++T + P L +L L +NP+ CNC+L L DWL I T N CQNP +R  
 647 NHITITSPGAFTDLQALSTANILANPFCNCQCLAMLGDWLRKRKIVTGPNRQCNPDLR 705

**FIG. 2**

BLASTX ALIGNMENT OF SEQ ID NO: 3 NEURONAL GUIDANCE MOLECULE-LIKE (IDENTIFIED AS NGM-LIKE) PROTEIN WITH RAT SLIT HOMOLOGUE PROTEIN SEQ ID NO: 16

Query: Neuronal guidance molecule-like (NGM-like) polypeptide (SEQ ID NO: 3)  
 Sbjct: sp|Y76117|Y76117 Rat Slit homologue, SEQ ID NO:396. (SEQ ID NO: 16)

Length = 1529

Score = 297 (109.6 bits), Expect = 2.5e-40, Sum P(2) = 2.5e-40  
 Identities = 73/216 (33%), Positives = 109/216 (50%)

Query: 186 MCGLQFSLPCLRFLFLVWTCVLLLHKETLGCSVCOQLCTGRQINCRLGLSSIPKNEPE 365  
 Sbjct: M G+ + L L LV++ + H C + C C+G ++C L L S+P+N P  
 1 MSGIGMOTLSLAVLSSILNRYAPH---ACPAQCS-CSGSTDVCHGLALRSUPRNIPR 55

Query: 366 STVFVLTGNNISYNESELGPHISVALYLDNSNILVYKAFVQLRHLYFLFIMNNFI 545  
 Sbjct: +T L L GNNI+ I +++ GL L L L + I + NP L+ L L LN N +

56 NTERIDLNGNNITRITKTDAGLHRIVLQLMENKISTIERGAFQDLKELERLRLRNRLN 115

Query: 546 KRUDPEGIFKGLLNLRNLYLQINQVSFVPRGVFDNLVSVQYLNLRQRNRLTVLGSCTFVG&V 725  
 Sbjct: + F G L L L NQ+ +PR F V ++ L L N++ + G F +

116 QLFPELFLFLGTAKLYRLDSENQIQLAIPRKAFAVGDIKRNQLDYNQISCIEDGAFRALR 175

Query: 726 ARIILDLSNNNITRISESGFHLENLACLYLGSNNL 833  
 Sbjct: L +L L+NNNT R+S + P H+ L L SNNL

176 DLEVITANNNNITRLSVASFTNMEKLRTFRLHSNNL 211

FIG. 3

**BLASTX ALIGNMENT OF SEQ ID NO: 3 NEURONAL GUIDANCE MOLECULE-LIKE (IDENTIFIED AS NGM-LIKE) PROTEIN WITH RAT SLIT HOMOLOGUE PROTEIN SEQ ID NO: 17**

Query: Neuronal guidance molecule-like (NGM-like) polypeptide (SEQ ID NO: 3)  
 Sbjct: sp|Y76117|Y76117 Rat Slit homologue, SEQ ID NO:396 (SEQ ID NO: 17)

Length = 1529

Score = 231 (86.4 bits), Expect = 2.5e-40, Sum P(2) = 2.5e-40  
 Identities = 58/178 (32%), Positives = 91/178 (51%)

Query: 822 SNNLTKVPSNAFEVLSKSDRILSLSHNPPIRAIQPPA-PKGLANLEYLLKNSRIRNVTROG 998  
 + L K+P + LR L++N +  
 Sbjct: 521 NQKLNKIPDHPQYTAELR---LNNNEFTVLEATGIFKQLPQLRKINLSNNKTTDIEEGA 577

Query: 999 PSGINNLKHLILSHNDLNLNSDTSLLKRNLYLKLDRNRIISIDNDTFFMGASILKILN 1178  
 P G + + +L+ N LEN+ F L++L L L NRI + ND+P +G S++L+  
 Sbjct: 578 FEGASGVNBILLTSNRLENVQHKGMEFKGLESRKTLMRSNRISCVGNDGSPFTGLG-SVRLLS 636

Query: 1179 LSFANLTALHPRVLKPLSSLTHLQANSNPWECNCKLGRLWASSAI-TINLYCQNP 1349  
 Sbjct: 637 LYDNQITTVAPGAFGTDLHSLSTNLANPPNCNCHLAWLGEWLRRKRTVTGNPRCQKP 694

**FIG. 4**

**BLASTX ALIGNMENT OF SEQ ID NO: 21 NEURONAL GUIDANCE MOLECULE-LIKE (IDENTIFIED AS NGM-LIKE) PROTEIN WITH NEURONAL LEUCINE-RICH REPEAT PROTEIN-3 (NLRR-3) PROTEIN SEQ ID NO: 29**

Query: Neuronal guidance molecule-like (NGM-like) polypeptide (SEQ ID NO: 21)  
 Sbjct: gbaAGG0604.1|AF291437.1 (AF291437) neuronal leucine-rich repeat protein-3 (Rattus norvegicus) (SEQ ID NO:29)  
 Length = 707

Score = 432 (157.1 bits), Expect = 8.6e-38, P = 8.6e-38  
 Identities = 138/511 (27%). Positives = 237/511 (46%)

Query: 37 LGGLAVV-LIPIGST-IGCPARCECSA-----QNKSVSCHRRLIAPIRGPIET 177  
 Sbjct: 12 IGLAITALVQAGDKKVQDCQLCQTCBIRWPFPRSTINEASTVENDLGLANPAPRLADT 71

Query: 178 KILDLSKRNRLAKSVNPEEFISYPL-LREIILSDNLYIANVEGAFANLNLRSURLKGNLK 354  
 Sbjct: 72 QILQLQTQNTAVL--EHSNDEPWNLTGLDSQNLSSVTNTNIVQMSQISVYEEPKLT 129

Query: 355 LVPAGVFTGILSNLTKLDSENKTVILLDDTMFQDLHNLKMSLEVCDNDLVYISHRAFSCLLS 534  
 Sbjct: 130 ELPERKCLGQSLNQLQELVNHNLSAISPGQAFVGLHNLRLHNSNRQMINSKWFLPN 189

Query: 535 LEQTLIEKCNLTVFPTENLHRSLSLTHKHLNINDPMQAFKRLFIRKHLIEDWPLL 714  
 Sbjct: 190 LEITMLGDNDEPLRILKDNFQPLKLRSVLAGTINTEYPPDDAVGLENESISP-YDNRL 248

Query: 715 DRNPAANSLY-GLNLNFTLSLSVTNTLSTVPPFLAKHIVYLTHLNLSSYNP-ISTIEAGAFDSL 688  
 Sbjct: 249 NEFVQVALQIAVNLKPLDNLKQPLNIRNGDFSNBULHKELOINNMPPEVSDSLAVDNL 308

Query: 889 IRLOQELHTG-AQLRTPRPHSPQQLRPLRVNVSQNLTELEKNTSPRALVTSIARN 1065  
 Sbjct: 309 PDLRKIRATNVPRLSTTHPNAFPLPKLPLSMLNSNALSAYHTGTIBSLPNLKTSIHSN 368

Query: 1066 PLACDCRLWILQROPLQPGQCPM-CIGEDTINERSDPLPHSTALSFYFTCKPKIRE 1242  
 Sbjct: 369 PTCDCVTRWINEAKTNIRPREDLSLFCVDPPTQGQNVRQVAFRDMEI--CH-PLIAP 425

Query: 1243 KKLQHLL-VDEGQTVQLECBADODPQVTSWWTPL-RFIFITKNSGRATVLDGOTLIRF 1416  
 Sbjct: 426 ESEFPSTLVEDADSVSLCRVTAEPQPTXYWITPSGKRLLENTLRECPVYHSESTLDIIG 485

Query: 1417 RQDQDSRYVCIASNDAGNDYETASLTVKGP 1509  
 Sbjct: 486 RPKEGGLYTCIATNLVGAQDLSKIMKGGF 516

**FIG. 5**

## BLASTX ALIGNMENT OF SEQ ID NO: 21 NEURONAL GUIDANCE MOLECULE-LIKE ( IDENTIFIED AS NGM-LIKE ) PROTEIN WITH HUMAN TANGO-79 PROTEIN SEQ ID NO: 30

Query: Neuronal Guidance molecule-like (NGM-like) polypeptide (SEQ ID NO: 21)  
 Sbjct: >sp|W84596|W84596 Amino acid sequence of the human Tango-79 protein (SEQ ID NO: 30)

Length = 614      Score = 1940      Expect = 8.7e-200      P = 8.7e-200  
 Identities = 363/603 (60%)      Positivies = 466/603 (77%)

Query: 16 ISCRQQPFLAAVLLIFPSTSTIGCPARCECSQNKSVSCHRRRLAIPPGIPIETKILDLIS 195  
 Sbjct: 14 LACNQPIILWIGSVLSQATGCPARCECSQNKSVSCHRRRLAIPPGIPIETKILDLIS 195  
 Query: 196 KNRKVSNNPPEKTFPPEIDLSDN1LAVNVEPGAPNLNFSLRLKGKNLKLVPGQVF 375  
 Sbjct: 14 KNRKXTLNDQDFASFPDEELNLNIVSAVEGAPNLNFSLRLKGKNLKLVPGQVF 375  
 Sbjct: 74 KNRKXTLNDQDFASFPDEELNLNIVSAVEGAPNLNFSLRLKGKNLKLVPGQVF 133

Query: 376 TGLSNLTKLDSENKIVLILDFQDMLNLKSLKLEVGNNDLVTVTSHRAFSSLLSLBQTLLE 555  
 Sbjct: 134 TGLSNLTKLDSENKIVLILDFQDMLNLKSLKLEVGNNDLVTVTSHRAFSSLLSLBQTLLE 193

Query: 556 KCMLTAVPPLRSLRSLSLHUKHNNNNMPYAFKRLFHAKHLEIDYMLLDQDNPANS 735  
 Sbjct: 194 KCMLTAVPPLRSLRSLSLHUKHNNNNMPYAFKRLFHAKHLEIDYMLLDQDNPANS 735

Query: 736 LYQANLTSLSVTNTNLSLTVPPFLAKHVVVLTMLNSKPNISTEGMPSDLIRLQELHIV 915  
 Sbjct: 254 LYQANLTSLSVTNTNLSLTVPPFLAKHVVVLTMLNSKPNISTEGMPSDLIRLQELHIV 915

Query: 916 GAOQRTIEPPFSQGLRPLTVLQNSQNLLETFKENTVSSPRAJLWVLLNNPLACDRLW 1095  
 Sbjct: 314 GQQLAVVEPAPFRGLNLTVRLWVSGNQLLTKEESVTHSGNLETLILDSNPLACDRLW 373

Query: 1096 ILQROPTLQPSQQEKGASPPOTIPERSFDPHSTALSPYFCTKPKIREKLQLWDEG 1275  
 Sbjct: 374 YPFRRMWRLANPQQPCTCATPETYQKEFDFPDVLLAFNPFCTPARIIDRKAQQVFDEG 433

Query: 1276 QTYOLECSAADDQFQVISMWTPHRRFITKNSGRATVLDGTDIEIFQADQDSGMTCVLA 1455  
 Sbjct: 370 C ACDP P I W+PR+      ++ KSNGR TV      DGTLE+R+AQ QD+G Y+CLIA

Query: 434 RPTVQPVCRADQDDEPAILWSPKELVSAKSNGLTVPPGTEVRYAVQDNGTICIA 493  
 Sbjct: 494 ANAGGNDSTPAHLHVSYSQDMPHQNKTAFAPISQDGEANSTRATVPPFDIKLII 553

FIG. 6A

BLASTX ALIGNMENT OF SEQ ID NO: 21 NEURONAL GUIDANCE MOLECULE-LIKE (IDENTIFIED AS NGM-LIKE) PROTEIN WITH HUMAN TANGO-79 PROTEIN SEQ ID NO: 30

Query: 1630 STAGGPTFLGVVLFCLLWWSRCKKHNNSIDLEYPRKNGAVAVGEGVAGPRFENN 1809  
+T MG +FLGVVLF +FLGVVLF +WSRCKG K++I++EVPRK++ + PR+PRNN  
Sbjct: 554 ATTAGPISPLGVVLFCLLWWSRCKGNTUNIEETVPRKSDAGISSADA--PRCFNN 611

Query: 1810 KML 1818  
Sbjct: KML 612 KML 614

FIG. 6B



(19)

Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

EP 1 574 520 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:  
21.12.2005 Bulletin 2005/51

(51) Int Cl.7: C07K 14/47

(43) Date of publication A2:  
14.09.2005 Bulletin 2005/37

(21) Application number: 05005504.5

(22) Date of filing: 02.02.2001

(84) Designated Contracting States:  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE TR

(30) Priority: 03.02.2000 US 496914  
27.04.2000 US 560875  
22.11.2000 US 721115

(62) Document number(s) of the earlier application(s) in  
accordance with Art. 76 EPC:  
01908837.6 / 1 254 269

(71) Applicant: Nuvelo, Inc.  
Sunnyvale, CA 94085 (US)

(72) Inventors:  
• Boyle, Bryan, J.  
San Francisco CA 94116 (US)  
• Yeung, George  
Mountain View CA 94043 (US)

- Arterburn, Matthew, C.  
Pleasanton CA 94566 (US)
- Lui, Chenghua  
San Jose CA 95117 (US)
- Tang, Y., Tom  
San Jose CA 95118 (US)
- Godbole, Shubhada, D.  
Santa Clara CA 95051 (US)
- Kuo, Chiaoyun  
San Jose CA 95132 (US)
- Drmanac, Radoje, T.  
Palo Alto CA 94303 (US)
- Palencia, Sereando  
Santa Cruz CA 95060 (US)

(74) Representative: Forstmeyer, Dietmar et al  
Boeters & Lieck,  
Bereiteranger 15  
81541 München (DE)

(54) Methods and materials relating to neuronal guidance molecule-like (NGM-like) polypeptides  
and polynucleotides

(57) The invention provides novel polynucleotides  
and polypeptides encoded by such polynucleotides and  
mutants or variants thereof that correspond to novel hu-  
man secreted NGM-like polypeptides. These polynucle-  
otides comprise nucleic acid sequences isolated from  
at least cDNA libraries prepared from adult spleen mR-  
NA (GIBCO) (Hyseq clone identification numbers

3073928 (SEQ ID NO: 1), and from infant brain mRNA  
(Columbia University) (Hyseq clone identification  
number 6346549) (SEQ ID NO: 18). Other aspects of  
the invention include vectors containing processes for  
producing novel human secreted NGM-like polypep-  
tides, and antibodies specific for such polypeptides.

EP 1 574 520 A3



European Patent  
Office

## PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 05 00 5504  
shall be considered, for the purposes of subsequent  
proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)												
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim													
E	WO 02/10216 A (CURAGEN CORPORATION; PADIGARU, MURALIDHARA; MEZES, PETER; MISHRA, VISH) 7 February 2002 (2002-02-07) * pages 1-6 * * page 8, lines 10-15 * * page 42, line 18 - page 48, line 23 * * example 8 * -----	1-30	C07K14/47												
E	WO 02/24733 A (CURAGEN CORPORATION; MISHRA, VISHNU, S; SYPTEK, KIMBERLY, ANN; TAUPIER) 28 March 2002 (2002-03-28) * pages 1-5 * * page 8, lines 5-19 * * page 32, line 3 - page 40, line 17 * * page 156, line 32 - page 174, line 8 * -----	1-30													
P,X	WO 00/75358 A (MILLENNIUM PHARMACEUTICALS, INC) 14 December 2000 (2000-12-14) * pages 1-8; figure 1; examples 1-3 * -----	1-30 -/-													
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)												
			C07K												
INCOMPLETE SEARCH															
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>see sheet C</p>															
<p>2</p> <table border="1"> <tr> <td>Place of search</td> <td>Date of completion of the search</td> <td>Examiner</td> </tr> <tr> <td>Munich</td> <td>21 October 2005</td> <td>Steffen, P</td> </tr> <tr> <td colspan="2">CATEGORY OF CITED DOCUMENTS</td> <td>           T : theory or principle underlying the invention            E : earlier patent document, but published on, or            after the filing date            D : document cited in the application            L : document cited for other reasons            .....            &amp; : member of the same patent family, corresponding            document         </td> </tr> <tr> <td colspan="2">           X : particularly relevant if taken alone            Y : particularly relevant if combined with another            document of the same category            A : technological background            O : non-written disclosure            P : intermediate document         </td> <td></td> </tr> </table>				Place of search	Date of completion of the search	Examiner	Munich	21 October 2005	Steffen, P	CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ..... & : member of the same patent family, corresponding document	X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		
Place of search	Date of completion of the search	Examiner													
Munich	21 October 2005	Steffen, P													
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ..... & : member of the same patent family, corresponding document													
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document															
EPO FORM 1503/03-82 (P04C07)															



DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
P,X	<p>DATABASE EMBL [Online]  20 April 2000 (2000-04-20), "Human DNA sequence from clone RP11-438B23 on chromosome 9 Contains the 3' end of a novel gene (FLJ31810)."  XP002350508  retrieved from EBI accession no.  EM_HUM:AL353746  Database accession no. AL353746  * nucleotides 74543-76354 *  * nucleotides 75752-76174*</p> <p>-----</p>	1-9	
A,D	WO 99/06427 A (MILLENNIUM BIOTHERAPEUTICS INC) 11 February 1999 (1999-02-11) -----		
A	<p>WANG KUAN HONG ET AL: "Biochemical purification of a mammalian Slit protein as a positive regulator of sensory axon elongation and branching"  CELL,  vol. 96, no. 6,  19 March 1999 (1999-03-19), pages 771-784,  XP002273837  ISSN: 0092-8674</p> <p>-----</p>		
2			



Although claims 29 and 30 are directed to a method of treatment of the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compound/composition.

-----

Claim(s) searched incompletely:  
29 and 30 (parts (a))

Reason for the limitation of the search:

Claims 29 and 30 (parts (a)) relate to a method of treatment defined by a parameter or property, namely to employ an otherwise unspecified agonist or an antagonist of given protein. The use of these parameters in the present context is considered to lead to a lack of clarity within the meaning of Article 84 EPC. It is impossible to compare the parameters the applicant has chosen to employ with what is set out in the prior art. The lack of clarity is such as to render a meaningful complete search impossible. Consequently, no search has been carried out for claims 29 and 30 (parts (a)).

Moreover, the claims cover all methods of treatment employing the unspecified agonists or antagonists, whereas the application provides no support within the meaning of Article 84 EPC and/or disclosure within the meaning of Article 83 EPC. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search is impossible.

ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.

EP 05 00 5504

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
 The members are as contained in the European Patent Office EDP file on  
 The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

21-10-2005

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0210216	A	07-02-2002	AU CA EP JP	8308901 A 2417349 A1 1326971 A2 2004511222 T	13-02-2002 07-02-2002 16-07-2003 15-04-2004
WO 0224733	A	28-03-2002	AU CA EP JP	9273401 A 2421576 A1 1360291 A2 2004529607 T	02-04-2002 28-03-2002 12-11-2003 30-09-2004
WO 0075358	A	14-12-2000	AU EP	5320700 A 1187932 A2	28-12-2000 20-03-2002
WO 9906427	A	11-02-1999	AU CA EP JP	8768798 A 2299276 A1 1001964 A1 2001512003 T	22-02-1999 11-02-1999 24-05-2000 21-08-2001

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**